PT J
AU Haaz, S
   Fontaine, KR
   Cutter, G
   Limdi, N
   Perumean-Chaney, S
   Allison, DB
AF Haaz, S
   Fontaine, KR
   Cutter, G
   Limdi, N
   Perumean-Chaney, S
   Allison, DB
TI Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity:: an update
SO OBESITY REVIEWS
LA English
DT Review
DE bitter orange; Citrus aurantium; herbal supplements; synephrine
ID seville orange juice; spinal-anesthesia; beta(3)-adrenoceptor agonists; grapefruit juice; ephedra-free; body-weight; phenylephrine; caffeine; adults; drugs
AB Obesity is a major health problem facing the developed and developing world. Efforts by individuals, health professionals, educators, and policy makers to combat the escalating trend of growing obesity prevalence have been multifaceted and mixed in outcome. Various dietary supplements have been marketed to reduce obesity. These products have been suggested to accomplish this by decreasing energy intake and energy absorption, and/or increasing metabolic rate. Ephedra, one such supplement, was banned from sale in the US market because of concerns about adverse events. Another substance, Citrus aurantium, which contains several compounds including synephrine alkaloids, has been suggested as a safe alternative. This review examines the evidence for safety and efficacy of C. aurantium and synephrine alkaloids as examined in animal studies, clinical weight loss trials, acute physiologic studies and case reports. Although at least three reviews of C. aurantium have been published, our review expands upon these by: (i) distinguishing and evaluating the efficacy of C. aurantium and related compounds; (ii) including results from previously unreviewed research; (iii) incorporating recent case reports that serve to highlight, in an anecdotal way, potential adverse events related to the use of C. aurantium and related compounds; and (iv) offering recommendations to guide the design of future trials to evaluate the safety and efficacy of C. aurantium. While some evidence is promising, we conclude that larger and more rigorous clinical trials are necessary to draw adequate conclusions regarding the safety and efficacy of C. aurantium and synephrine alkaloids for promoting weight loss.
C1 Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Nutr Res Ctr, Birmingham, AL 35294 USA.
   Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD USA.
C3 University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University
RP Univ Alabama Birmingham, Dept Biostat, Ryals Publ Hlth Bldg,1665 Univ Blvd, Birmingham, AL 35294 USA.
EM Dallison@ms.soph.uab.edu
FU NIAMS NIH HHS [AR49720-01A1] Funding Source: Medline; NIDDK NIH HHS [P30DK056336] Funding Source: Medline
CR Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530
   Allison DB, 2005, INT J OBESITY, V29, P443, DOI 10.1038/sj.ijo.0802879
   Allison DB, 1999, AM J PUBLIC HEALTH, V89, P1194, DOI 10.2105/AJPH.89.8.1194
   Unknown -, 2004, CLARKES ANAL DRUGS P, V3rd, P0
   Unknown -, 2004, MARTINDALE: THE COMPLETE DRUG REFERENCE, V0, P0
   Unknown -, 2017, ANNEX 3-03, V0, P4
   Antipatis VJ, 2001, INTERNATIONAL TEXTBOOK OF OBESITY, V0, P3
   Arch JRS, 2002, EUR J PHARMACOL, V440, P99, DOI 10.1016/S0014-2999(02)01421-8
   Armstrong WJ, 2001, JOURNAL OF EXERCISE PHYSIOLOGY ONLINE, V4, P28
   Astrup A, 2000, ENDOCRINE, V13, P207, DOI 10.1385/ENDO:13:2:207
   ASTRUP A, 1993, INT J OBESITY, V17, P0
   ATKINSON RL, 1994, JAMA-J AM MED ASSOC, V272, P1196, DOI 10.1001/jama.272.15.1196
   Ayyad C, 2000, OBES REV, V1, P113, DOI 10.1046/j.1467-789x.2000.00019.x
   Barnes J, 2003, BRIT J CLIN PHARMACO, V55, P331, DOI 10.1046/j.1365-2125.2003.01811.x
   Billington C J, 2000, J AM BOARD FAM PRACT, V13, P222
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   BRADLEY JG, 1991, POSTGRAD MED, V89, P195
   Bray GA, 1999, ENDOCR REV, V20, P805, DOI 10.1210/er.20.6.805
   BROWN CM, 1988, BRIT J PHARMACOL, V93, P417, DOI 10.1111/j.1476-5381.1988.tb11449.x
   Calapai G, 1999, FITOTERAPIA, V70, P586, DOI 10.1016/S0367-326X(99)00093-3
   *CANT HLTH SCI INT, 2000, SAF ASS DET TOL LIM, V0, P0
   Cantu C, 2003, STROKE, V34, P1667, DOI 10.1161/01.STR.0000075293.45936.FA
   COLDITZ GA, 1992, AM J CLIN NUTR, V55, P503
   Colker CM, 1999, CURR THER RES CLIN E, V60, P145, DOI 10.1016/S0011-393X(00)88523-9
   Cooper DW, 2002, ANESTHESIOLOGY, V97, P1582, DOI 10.1097/00000542-200212000-00034
   DESFAITS AC, 1995, LIFE SCI, V57, P705, DOI 10.1016/0024-3205(95)00322-W
   Di Marco MP, 2002, LIFE SCI, V71, P1149, DOI 10.1016/S0024-3205(02)01799-X
   DITTRICH A, 1991, J UROLOGY, V146, P323, DOI 10.1016/S0022-5347(17)37781-9
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Eyeson-Annan ML, 1998, OPHTHALMOLOGY, V105, P726, DOI 10.1016/S0161-6420(98)94030-1
   *FDA, 2001, OV DIET SUPPL, V0, P0
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187
   Fontaine KR, 2000, INT J EAT DISORDER, V27, P101, DOI 10.1002/(SICI)1098-108X(200001)27:1<101::AID-EAT12>3.0.CO;2-D
   Food and Drug Administration HHS, 2004, FED REGIST, V69, P6787
   Freedman MR, 2001, OBES RES, V9, P1S, DOI 10.1038/oby.2001.113
   Fugh-Berman A, 2004, EXP BIOL MED, V229, P698, DOI 10.1177/153537020422900802
   Geyer H, 2004, INT J SPORTS MED, V25, P124, DOI 10.1055/s-2004-819955
   Gurley BJ, 2000, AM J HEALTH-SYST PH, V57, P963, DOI 10.1093/ajhp/57.10.963
   Halpern A, 2003, OBES REV, V4, P25, DOI 10.1046/j.1467-789X.2003.00083.x
   Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847
   HEDREI P, 1997, THERMOGENIC EFFECT B, V0, P0
   HELLMICH N, 2002, USA TODAY 0120, V0, P0
   Heo M, 1998, MECH AGEING DEV, V102, P45, DOI 10.1016/S0047-6374(98)00010-4
   Iaccarino G, 1998, AM J PHYSIOL-HEART C, V275, PH1298, DOI 10.1152/ajpheart.1998.275.4.H1298
   IBRAHIM KE, 1984, ANAL CHEM, V56, P1695, DOI 10.1021/ac00273a037
   JONES D, 2001, PATENT NO. 6224873, V0, P0
   JORDAN R, 1987, J PHARM PHARMACOL, V39, P752, DOI 10.1111/j.2042-7158.1987.tb06986.x
   Kalman D, 2002, INT J OBESITY, V26, P1363, DOI 10.1038/sj.ijo.0802061
   Kalman DS, 2000, CURR THER RES CLIN E, V61, P199, DOI 10.1016/S0011-393X(00)89034-7
   Kim KW, 2001, N-S ARCH PHARMACOL, V364, P21, DOI 10.1007/s002100100416
   Lee A, 2002, ANESTH ANALG, V94, P920, DOI 10.1097/00000539-200204000-00028
   Malhotra S, 2001, CLIN PHARMACOL THER, V69, P14, DOI 10.1067/mcp.2001.113185
   Marcus DM, 2003, SCIENCE, V301, P1669
   Markus CR, 2003, PHARMACOL BIOCHEM BE, V76, P487, DOI 10.1016/j.pbb.2003.09.002
   Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195
   MOONEY RA, 1984, INT J BIOCHEM, V16, P55, DOI 10.1016/0020-711X(84)90050-8
   MORO CO, 2002, FITOTERAPIA S1, V71, P0
   Nasir JM, 2004, MAYO CLIN PROC, V79, P1059, DOI 10.4065/79.8.1059
   *NAT TOX PROGR, 1987, NATL TOX PROGR TECH, V322, P1
   National Taxicology Program, 1986, NATL. TOXICOL. PROGR. TECH. REP, V307, P1
   Newton Gail D, 2004, J AM PHARM ASSOC (2003), V44, P211, DOI 10.1331/154434504773062636
   Nykamp DL, 2004, ANN PHARMACOTHER, V38, P812, DOI 10.1345/aph.1D473
   PATHAK B, 1999, CURRENT THERAPEUTIC, V60, P145
   Pellati F, 2002, J PHARMACEUT BIOMED, V29, P1113, DOI 10.1016/S0731-7085(02)00153-X
   Penzak SR, 2001, J CLIN PHARMACOL, V41, P1059, DOI 10.1177/00912700122012652
   Preuss Harry G, 2002, JOURNAL OF MEDICINE (WESTBURY), V33, P247
   RADACK K, 1986, ANN ALLERGY, V56, P396
   Rados C, 2004, FDA CONSUMER MAG MAR, V0, P0
   REDFEARN S, 2003, WASHINGTON POST 0113, V0, P0
   Sahu D, 2003, INDIAN J ANAESTH, V47, P125
   SCHUMER C, 2004, NEW US EPHEDRA BAN D, V0, P0
   SHUGARMAN AE, 2004, MED SCI SPORTS EXERC, V31, P0
   Spurlock ME, 1996, PHYSIOL BEHAV, V60, P1217, DOI 10.1016/S0031-9384(96)00219-3
   Starke K, 1998, N-S ARCH PHARMACOL, V358, P1, DOI 10.1007/PL00005229
   STRICKER EM, 1991, BRAIN RES BULL, V27, P299, DOI 10.1016/0361-9230(91)90115-Z
   Thomas DG, 1996, BRIT J ANAESTH, V76, P61, DOI 10.1093/bja/76.1.61
   THOMAS SHL, 1991, BRIT J CLIN PHARMACO, V32, P705
   *US FDA, 2003, WHIT PAP EV SAF EFF, V0, P0
   Weyer C, 1999, DIABETES METAB, V25, P11
   WHO, 1997, WHO CONS OB, V0, P0
   Xie JT, 2002, PHYTOMEDICINE, V9, P254, DOI 10.1078/0944-7113-00106
   Yeh SY, 1999, PHYSIOL BEHAV, V68, P227, DOI 10.1016/S0031-9384(99)00180-8
   YOSHIDA T, 1994, INT J OBESITY, V18, P345
NR 85
TC 156
Z9 170
U1 0
U2 66
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1467-7881
EI 1467-789X
J9 OBES REV
JI Obes. Rev.
PD FEB 15
PY 2006
VL 7
IS 1
BP 79
EP 88
DI 10.1111/j.1467-789X.2006.00195.x
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 007QC
UT WOS:000234983400008
PM 16436104
DA 2025-04-28
ER

PT J
AU Kovacs, EMR
   Mela, DJ
AF Kovacs, EMR
   Mela, DJ
TI Metabolically active functional food ingredients for weight control
SO OBESITY REVIEWS
LA English
DT Review
DE energy expenditure; fat oxidation; metabolism; thermogenesis
ID conjugated linoleic-acid; medium-chain triglycerides; reduces body-fat; 24-h energy-expenditure; ephedrine methylxanthine mixtures; long-chain; double-blind; red-pepper; green tea; dietary diacylglycerol
AB The scale of the obesity epidemic creates a pressing consumer need as well as an enormous business opportunity for successful development and marketing of food products with added benefits for weight control. A number of proposed functional food ingredients have been shown to act post-absorptively to influence substrate utilization or thermogenesis. Characteristics and supporting data on conjugated linoleic acid, diglycerides, medium-chain triglycerides, green tea, ephedrine, caffeine, capsaicin and calcium, are reviewed here, giving examples of how these could act to alter energy expenditure or appetite control. Consideration is also given to other factors, in addition to efficacy, which must be satisfied to get such ingredients into foods. We conclude that, for each of the safe, putatively metabolically active agents, there remain gaps in clinical evidence or knowledge of mechanisms, which need to be addressed in order to specify the dietary conditions and food product compositions where these ingredients could be of most benefit for weight control.
C1 Unilever Res Labs, Unilever Hlth Inst, NL-3130 AC Vlaardingen, Netherlands.
C3 Unilever
RP Unilever Res Labs, Unilever Hlth Inst, POB 114, NL-3130 AC Vlaardingen, Netherlands.
EM eva.kovacs@unilever.com
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   AMELSVOORT JM, 2001, XENOBIOTICA, V31, P891
   Unknown -, 2001, J OLEO SCI, V0, P0, DOI DOI 10.5650/JOS.50.677
   ASTRUP A, 1991, METABOLISM, V40, P323, DOI 10.1016/0026-0495(91)90117-F
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   ASTRUP A, 1992, METABOLISM, V41, P686, DOI 10.1016/0026-0495(92)90304-S
   ASTRUP A, 1985, AM J CLIN NUTR, V42, P83, DOI 10.1093/ajcn/42.1.83
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Astrup A, 1999, AM J CLIN NUTR, V69, P1117
   BABA N, 1982, AM J CLIN NUTR, V35, P678, DOI 10.1093/ajcn/35.4.678
   BABAYAN VK, 1987, LIPIDS, V22, P417, DOI 10.1007/BF02537271
   Bach AC, 1996, J LIPID RES, V37, P708
   Barbera R, 2000, GUT, V46, P32, DOI 10.1136/gut.46.1.32
   Barr SI, 2003, J NUTR, V133, P0
   BELL DG, 1900, V93, V0, P1227
   Berven G, 2000, EUR J LIPID SCI TECH, V102, P455, DOI 10.1002/1438-9312(200008)102:7<455::AID-EJLT455>3.0.CO;2-V
   BIERBACH H, 1983, DIGESTION, V28, P138, DOI 10.1159/000198977
   Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943
   BLUMENTHAL M, 1998, MONOGRAPHS THERAPEUT, V0, P125
   Boon N, 2005, AM J CLIN NUTR, V82, P1244, DOI 10.1093/ajcn/82.6.1244
   Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   Bowen J, 2005, INT J OBESITY, V29, P957, DOI 10.1038/sj.ijo.0802895
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   BRAY GA, 1995, OBES RES, V3, P491, DOI 10.1002/j.1550-8528.1995.tb00180.x
   BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420
   BREUM L, 1994, INT J OBESITY, V18, P99
   Brodie AE, 1999, J NUTR, V129, P602
   BUIATTI E, 1989, INT J CANCER, V44, P611, DOI 10.1002/ijc.2910440409
   Bursey R, 1989, THE JOURNAL OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, V3, P0
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Cheng S, 2005, AM J CLIN NUTR, V82, P1115, DOI 10.1093/ajcn/82.5.1115
   Clément L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200
   CROZIER G, 1987, METABOLISM, V36, P807, DOI 10.1016/0026-0495(87)90122-3
   DALY PA, 1993, INT J OBESITY, V17, P0
   Davies KM, 2000, J CLIN ENDOCR METAB, V85, P4635, DOI 10.1210/jc.85.12.4635
   Delany JP, 1999, AM J PHYSIOL-REG I, V276, PR1172, DOI 10.1152/ajpregu.1999.276.4.R1172
   DENKE MA, 1993, J NUTR, V123, P1047
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   DULLOO AG, 1986, INT J OBESITY, V10, P467
   Dulloo AG, 1996, EUR J CLIN NUTR, V50, P152
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   DULLOO AG, 1987, AM J PHYSIOL, V252, PR507, DOI 10.1152/ajpregu.1987.252.3.R507
   DULLOO AG, 1987, J NUTR, V117, P383, DOI 10.1093/jn/117.2.383
   DULLOO AG, 1986, AM J CLIN NUTR, V43, P388, DOI 10.1093/ajcn/43.3.388
   DULLOO AG, 1989, NUTRITION, V5, P7
   ELDERSHAW TPD, 1992, INT J OBESITY, V16, P755
   FLATT JP, 1995, AM J CLIN NUTR, V62, P820, DOI 10.1093/ajcn/62.4.820
   Flickinger BD, 2003, LIPIDS, V38, P129, DOI 10.1007/s11745-003-1042-8
   FREED WJ, 1979, SCIENCE, V206, P850, DOI 10.1126/science.493987
   FRIRTSCHE J, 1998, Z LEBENSM UNTERS F A, V206, P77
   FURUSE M, 1992, PHYSIOL BEHAV, V52, P815, DOI 10.1016/0031-9384(92)90419-3
   Gaullier JM, 2004, AM J CLIN NUTR, V79, P1118
   GELIEBTER A, 1983, AM J CLIN NUTR, V37, P1
   Graham TE, 2000, J PHYSIOL-LONDON, V529, P837, DOI 10.1111/j.1469-7793.2000.00837.x
   Gunther CW, 2005, AM J CLIN NUTR, V81, P751, DOI 10.1093/ajcn/81.4.751
   Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502
   Han LK, 1999, INT J OBESITY, V23, P98, DOI 10.1038/sj.ijo.0800766
   HARA K, 1993, ANN NUTR METAB, V37, P185, DOI 10.1159/000177767
   Harvey-Berino J, 2005, OBES RES, V13, P1720, DOI 10.1038/oby.2005.210
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   HASHIM SA, 1960, LANCET, V1, P1105
   Heaney RP, 2002, FOOD CHEM TOXICOL, V40, P1263, DOI 10.1016/S0278-6915(02)00094-7
   HENRY CJK, 1986, HUM NUTR-CLIN NUTR, V40C, P165
   HETZLER RK, 1990, J APPL PHYSIOL, V68, P44, DOI 10.1152/jappl.1990.68.1.44
   HILL JO, 1990, J LIPID RES, V31, P407
   HILL JO, 1989, METABOLISM, V38, P641, DOI 10.1016/0026-0495(89)90101-7
   HOLLANDS MA, 1981, AM J CLIN NUTR, V34, P2291, DOI 10.1093/ajcn/34.10.2291
   HOLT PR, 1967, GASTROENTEROLOGY, V53, P961
   Ivy JL, 1980, INT J SPORTS MED, V1, P15, DOI 10.1055/s-2008-1034624
   Jacqmain M, 2003, AM J CLIN NUTR, V77, P1448, DOI 10.1093/ajcn/77.6.1448
   JEBB SA, 1995, WEIGHT CONTROL CURRE, V0, P0
   JONDERKO K, 1991, ALIMENT PHARM THERAP, V5, P413
   JUNG RT, 1981, CLIN SCI, V60, P527, DOI 10.1042/cs0600527
   Kamphuis MMJW, 2003, INT J OBESITY, V27, P840, DOI 10.1038/sj.ijo.0802304
   Kamphuis MMJW, 2003, AM J CLIN NUTR, V77, P1133, DOI 10.1093/ajcn/77.5.1133
   Kang WS, 1999, THROMB RES, V96, P229, DOI 10.1016/S0049-3848(99)00104-8
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   KAWADA T, 1988, P SOC EXP BIOL MED, V188, P229, DOI 10.3181/00379727-188-2-RC1
   KAWADA T, 1986, J NUTR, V116, P1272, DOI 10.1093/jn/116.7.1272
   KAWADA T, 1986, P SOC EXP BIOL MED, V183, P250
   Kim KM, 1998, J NUTR, V128, P1978, DOI 10.1093/jn/128.11.1978
   Kim SJ, 2000, J AGR FOOD CHEM, V48, P3922, DOI 10.1021/jf991215z
   KOBAYASHI A, 2001, AM J PHYSIOL, V275, P0
   KONO S, 1992, PREV MED, V21, P526, DOI 10.1016/0091-7435(92)90060-U
   KOOT P, 1995, ANN NUTR METAB, V39, P135, DOI 10.1159/000177854
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Kreider RB, 2002, J STRENGTH COND RES, V16, P325
   Krotkiewski M, 2001, INT J OBESITY, V25, P1393, DOI 10.1038/sj.ijo.0801682
   LASEKAN JB, 1992, J NUTR, V122, P1483, DOI 10.1093/jn/122.7.1483
   LAVAU MM, 1978, J NUTR, V108, P613, DOI 10.1093/jn/108.4.613
   LEBLANC J, 1985, J APPL PHYSIOL, V59, P832, DOI 10.1152/jappl.1985.59.3.832
   Ledeboer M, 1999, JPEN-PARENTER ENTER, V23, P203, DOI 10.1177/0148607199023004203
   Lejeune MPGM, 2003, BRIT J NUTR, V90, P651, DOI 10.1079/BJN2003938
   Lim K, 1997, MED SCI SPORT EXER, V29, P355, DOI 10.1097/00005768-199703000-00010
   Lin YC, 2000, J AM COLL NUTR, V19, P754, DOI 10.1080/07315724.2000.10718075
   Lin YG, 2001, J NUTR BIOCHEM, V12, P183, DOI 10.1016/S0955-2863(00)00155-8
   LIU YL, 1995, INT J OBESITY, V19, P678
   LOPEZCARRILLO L, 1994, AM J EPIDEMIOL, V139, P263, DOI 10.1093/oxfordjournals.aje.a116993
   Lorenzen JK, 2004, INT J OBESITY, V28, P0
   LOWERY LM, 1998, MED SCI SPORTS EXERC, V30, P182
   Maas MIM, 1998, EUR J CLIN INVEST, V28, P123, DOI 10.1046/j.1365-2362.1998.00255.x
   Maki KC, 2002, AM J CLIN NUTR, V76, P1230, DOI 10.1093/ajcn/76.6.1230
   Malpuech-Brugère C, 2004, OBES RES, V12, P591, DOI 10.1038/oby.2004.68
   MASSOUDI M, 1983, ANN NUTR METAB, V27, P26, DOI 10.1159/000176621
   Matsuo T, 1996, J NUTR SCI VITAMINOL, V42, P249, DOI 10.3177/jnsv.42.249
   MCCARRON DA, 1984, SCIENCE, V224, P1392, DOI 10.1126/science.6729459
   McLaughlin J, 1999, GASTROENTEROLOGY, V116, P46, DOI 10.1016/S0016-5085(99)70227-1
   Meguro S, 2001, J OLEO SCI, V50, P593, DOI 10.5650/JOS.50.593
   Melanson EL, 2004, FASEB J, V18, P0
   Melanson EL, 2003, INT J OBESITY, V27, P196, DOI 10.1038/sj.ijo.802202
   Meng XH, 2004, LIPIDS, V39, P37, DOI 10.1007/s11745-004-1199-1
   METZ JA, 1988, AM J HYPERTENS, V1, P58, DOI 10.1093/ajh/1.1.58
   Mougios V, 2001, J NUTR BIOCHEM, V12, P585, DOI 10.1016/S0955-2863(01)00177-2
   Moya-Camarena SY, 1999, J LIPID RES, V40, P1426
   Mukhtar H, 1999, TOXICOL SCI, V52, P111, DOI 10.1093/toxsci/52.suppl_1.111
   Murase T, 2002, J LIPID RES, V43, P1312, DOI 10.1194/jlr.M200094-JLR200
   Murase T, 2002, J NUTR, V132, P3018, DOI 10.1093/jn/131.10.3018
   Murase T, 2001, J LIPID RES, V42, P372
   MURATA M, 1994, BIOSCI BIOTECH BIOCH, V58, P1416, DOI 10.1271/bbb.58.1416
   Murata M, 1997, BRIT J NUTR, V77, P107, DOI 10.1079/BJN19970013
   Nagao T, 2000, J NUTR, V130, P792, DOI 10.1093/jn/130.4.792
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Nagasawa A, 2001, J OLEO SCI, V50, P711, DOI 10.5650/jos.50.711
   Noone EJ, 2002, BRIT J NUTR, V88, P243, DOI 10.1079/BJN2002615
   Ohnuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P2033, DOI 10.1271/bbb.65.2033
   Ohnuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P2735, DOI 10.1271/bbb.65.2735
   Papakonstantinou E, 2003, OBES RES, V11, P387, DOI 10.1038/oby.2003.52
   Parikh SJ, 2004, J CLIN ENDOCR METAB, V89, P1196, DOI 10.1210/jc.2003-031398
   Pariza M, 1997, FASEB J, V11, P813
   Park Y, 1999, LIPIDS, V34, P243, DOI 10.1007/s11745-999-0359-7
   Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x
   Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8
   PASQUALI R, 1985, INT J OBESITY, V9, P93
   PASQUALI R, 1987, INT J OBESITY, V11, P163
   PASQUALI R, 1992, CLIN SCI, V82, P85, DOI 10.1042/cs0820085
   PERLOW MJ, 1980, PHARMACOL BIOCHEM BE, V12, P609, DOI 10.1016/0091-3057(80)90196-3
   POEHLMAN ET, 1985, MED SCI SPORT EXER, V17, P689, DOI 10.1249/00005768-198512000-00012
   Rados Carol, 2004, FDA CONSUM, V38, P6
   Ramsey JJ, 1998, AM J CLIN NUTR, V68, P42, DOI 10.1093/ajcn/68.1.42
   Rasheed A, 1998, ARCH PHARM RES, V21, P348, DOI 10.1007/BF02975300
   RAVUSSIN E, 1985, AM J PHYSIOL, V249, PE470, DOI 10.1152/ajpendo.1985.249.5.E470
   RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802
   Reid IR, 2005, J CLIN ENDOCR METAB, V90, P3824, DOI 10.1210/jc.2004-2205
   Risérus U, 2002, DIABETES CARE, V25, P1516, DOI 10.2337/diacare.25.9.1516
   Risérus U, 2002, CIRCULATION, V106, P1925, DOI 10.1161/01.CIR.0000033589.15413.48
   Risérus U, 2001, INT J OBESITY, V25, P1129, DOI 10.1038/sj.ijo.0801659
   ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403
   ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124
   Roche HM, 2002, DIABETES, V51, P2037, DOI 10.2337/diabetes.51.7.2037
   ROLLS BJ, 1988, AM J CLIN NUTR, V48, P66, DOI 10.1093/ajcn/48.1.66
   ROTHWELL NJ, 1987, METABOLISM, V36, P128, DOI 10.1016/0026-0495(87)90005-9
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Satory DL, 1999, J NUTR, V129, P92, DOI 10.1093/jn/129.1.92
   SCALFI L, 1991, AM J CLIN NUTR, V53, P1130, DOI 10.1093/ajcn/53.5.1130
   SEATON TB, 1986, AM J CLIN NUTR, V44, P630, DOI 10.1093/ajcn/44.5.630
   Serafini M, 1996, EUR J CLIN NUTR, V50, P28
   Shannon JR, 1999, CLIN SCI, V96, P483, DOI 10.1042/CS19980206
   Shapses SA, 2004, J CLIN ENDOCR METAB, V89, P632, DOI 10.1210/jc.2002-021136
   Skinner JD, 2003, J AM DIET ASSOC, V103, P1626, DOI 10.1016/j.jada.2003.09.018
   Smedman A, 2001, LIPIDS, V36, P773, DOI 10.1007/s11745-001-0784-7
   St-Onge MP, 2003, INT J OBESITY, V27, P1565, DOI 10.1038/sj.ijo.0802467
   St-Onge MP, 2003, OBES RES, V11, P395, DOI 10.1038/oby.2003.53
   St-Onge MP, 2003, INT J OBESITY, V27, P95, DOI 10.1038/sj.ijo.0802169
   Stubbs RJ, 1996, INT J OBESITY, V20, P435
   Summerbell CD, 1998, BRIT MED J, V317, P1487, DOI 10.1136/bmj.317.7171.1487
   Sung H, 2000, EUR J CLIN NUTR, V54, P527, DOI 10.1038/sj.ejcn.1600994
   Surh YJ, 1996, FOOD CHEM TOXICOL, V34, P313, DOI 10.1016/0278-6915(95)00108-5
   Taguchi H, 2000, J AM COLL NUTR, V19, P789, DOI 10.1080/07315724.2000.10718079
   Taguchi H, 2001, LIPIDS, V36, P379, DOI 10.1007/s11745-001-0731-7
   Terpstra AHM, 2003, J NUTR, V133, P3181, DOI 10.1093/jn/133.10.3181
   Thom E, 2001, J INT MED RES, V29, P392, DOI 10.1177/147323000102900503
   Thompson WG, 2005, OBES RES, V13, P1344, DOI 10.1038/oby.2005.163
   TOUBRO S, 1993, INT J OBESITY, V17, P0
   Toubro S, 2003, INTERNATIONAL JOURNAL OF OBESITY, V27, P0
   TREMBLAY A, 1988, NUTR RES, V8, P553, DOI 10.1016/S0271-5317(88)80077-0
   TSCHIDA T, 2002, PROG MED, V22, P2189
   Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534
   Tsuji H, 2001, J NUTR, V131, P2853, DOI 10.1093/jn/131.11.2853
   TULP OL, 1986, COMP BIOCHEM PHYS C, V85, P17
   TURKENKOPF IJ, 1982, J NUTR, V112, P1254, DOI 10.1093/jn/112.7.1254
   Van Wymelbeke V, 1998, AM J CLIN NUTR, V68, P226, DOI 10.1093/ajcn/68.2.226
   Van Wymelbeke V, 2001, AM J CLIN NUTR, V74, P620
   Warden BA, 2001, J NUTR, V131, P1731, DOI 10.1093/jn/131.6.1731
   Watanabe H, 1997, JOURNAL OF THE JAPAN OIL CHEMISTS SOCIETY, V46, P309
   Watanabe H, 1997, J JPN OIL CHEM SOC, V46, P301
   WATANABE T, 1987, BIOCHEM BIOPH RES CO, V142, P259, DOI 10.1016/0006-291X(87)90479-7
   WATANABE T, 1988, P SOC EXP BIOL MED, V187, P370
   WATANABE T, 1988, AM J PHYSIOL, V255, PE23, DOI 10.1152/ajpendo.1988.255.1.E23
   WATANABE T, 1994, LIFE SCI, V54, P369, DOI 10.1016/0024-3205(94)00793-4
   WELBERG JWM, 1994, ANN NUTR METAB, V38, P185, DOI 10.1159/000177810
   West DB, 1998, AM J PHYSIOL-REG I, V275, P0
   West DB, 2000, J NUTR, V130, P2471, DOI 10.1093/jn/130.10.2471
   Westerterp-Plantenga MS, 2004, INT J OBESITY, V28, P0
   White MD, 1999, AM J CLIN NUTR, V69, P883
   Yang L, 2000, J AGR FOOD CHEM, V48, P3072, DOI 10.1021/jf0003404
   Yang YC, 2004, ARCH INTERN MED, V164, P1534, DOI 10.1001/archinte.164.14.1534
   Yoshioka M, 1995, J NUTR SCI VITAMINOL, V41, P647, DOI 10.3177/jnsv.41.647
   Yoshioka M, 1999, BRIT J NUTR, V82, P115, DOI 10.1017/S0007114599001269
   Yoshioka M, 1998, BRIT J NUTR, V80, P503, DOI 10.1017/S0007114598001597
   Yoshioka M, 2004, BRIT J NUTR, V91, P991, DOI 10.1079/BJN20041148
   Yoshioka M, 2001, BRIT J NUTR, V85, P203, DOI 10.1079/BJN2000224
   YOST TJ, 1989, AM J CLIN NUTR, V49, P326, DOI 10.1093/ajcn/49.2.326
   Zambell KL, 2000, LIPIDS, V35, P777, DOI 10.1007/s11745-000-0585-z
   Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132
   Zemel MB, 2004, OBES RES, V12, P582, DOI 10.1038/oby.2004.67
   Zemel MB, 2001, J AM COLL NUTR, V20, P428S, DOI 10.1080/07315724.2001.10719180
   Zemel MB, 2002, J AM COLL NUTR, V21, P146S, DOI 10.1080/07315724.2002.10719212
   Zhang QM, 2004, AM J PHYSIOL-REG I, V286, PR669, DOI 10.1152/ajpregu.00655.2003
NR 212
TC 84
Z9 96
U1 0
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1467-7881
EI 1467-789X
J9 OBES REV
JI Obes. Rev.
PD FEB 15
PY 2006
VL 7
IS 1
BP 59
EP 78
DI 10.1111/j.1467-789X.2006.00203.x
PG 20
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 007QC
UT WOS:000234983400007
PM 16436103
DA 2025-04-28
ER

PT J
AU Iso, H
   Date, C
   Wakai, K
   Fukui, M
   Tamakoshi, A
AF Iso, H
   Date, C
   Wakai, K
   Fukui, M
   Tamakoshi, A
TI The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID coffee consumption; epigallocatechin gallate; mellitus; prevalence; tolerance
AB Background: in western populations, coffee consumption is associated with a reduced risk for type 2 diabetes; however, the effect of green, black, and oolong teas is unclear. Objective: To examine the relationship between consumption of these beverages and risk for diabetes. Design: Retrospective cohort study. Setting: 25 communities across Japan. Participants: A total of 17 413 persons (6727 men and 10 686 women; 49% of the original study population) who were 40 to 65 years of age; had no history of type 2 diabetes, cardiovascular disease, or cancer at the baseline lifestyle survey; and completed the 5-year follow-up questionnaire. There was no difference in body mass index levels at baseline between respondents and non-respondents. Measurements: Questionnaire on consumption of coffee; black, green, and oolong teas; and physician-diagnosed diabetes. Results: During the 5-year follow-up, there were 444 self-reported new cases of diabetes in 231 men and 213 women (5-year event rates, 3.4% and 2.0%, respectively). Consumption of green tea and coffee was inversely associated with risk for diabetes after adjustment for age, sex, body mass index, and other risk factors. Multivariable odds ratios for diabetes among participants who frequently drank green tea and coffee ( :6 cups of green tea per day and 3 cups of coffee per day) were 0.67 (95% Cl, 0.47 to 0.94) and 0.58 (Cl, 0.37 to 0.90), respectively, compared with those who drank less than I cup per week. No association was found between consumption of black or oolong teas and the risk for diabetes. Total caffeine intake from these beverages was associated with a 33% reduced risk for diabetes. These inverse associations were more pronounced in women and in overweight men. Limitations: Diabetes was self-reported, no data were available on consumption of soda, and the follow-up rate was low. Conclusions: Consumption of green tea, coffee, and total caffeine was associated with a reduced risk for type 2 diabetes.
C1 Osaka Univ, Grad Sch Med, Dept Social & Environm Hlth, Suita, Osaka 5650871, Japan.
   Osaka City Univ, Osaka 558, Japan.
   Nara Womens Univ, Nara 630, Japan.
   Aichi Canc Ctr, Nagoya, Aichi 464, Japan.
   Nagoya Univ, Nagoya, Aichi, Japan.
C3 The University of Osaka; Osaka Metropolitan University; Nara Womens University; Aichi Cancer Center; Nagoya University
RP Osaka Univ, Grad Sch Med, Dept Social & Environm Hlth, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM iso@pbhei.med.osaka-u-ac.jp
CR ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Carlsson S, 2004, INT J EPIDEMIOL, V33, P616, DOI 10.1093/ije/dyh185
   Date C, 2005, J EPIDEMIOL, V15, PS9, DOI 10.2188/jea.15.S9
   Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360
   Kao WHL, 1999, ARCH INTERN MED, V159, P2151, DOI 10.1001/archinte.159.18.2151
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   OHMURA T, 1993, DIABETOLOGIA, V36, P1198, DOI 10.1007/BF00401066
   Ohno Y, 2001, J EPIDEMIOL, V11, P144
   ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472
   Sasazuki S, 2004, CANCER CAUSE CONTROL, V15, P483, DOI 10.1023/B:CACO.0000036449.68454.42
   Song EK, 2003, ARCH PHARM RES, V26, P559, DOI 10.1007/BF02976881
   SPRIET LL, 1992, AM J PHYSIOL, V262, PE891, DOI 10.1152/ajpendo.1992.262.6.E891
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Waltner-Law ME, 2002, J BIOL CHEM, V277, P34933, DOI 10.1074/jbc.M204672200
NR 22
TC 361
Z9 409
U1 5
U2 59
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 18
PY 2006
VL 144
IS 8
BP 554
EP 562
DI 10.7326/0003-4819-144-8-200604180-00005
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 035QZ
UT WOS:000237017900002
PM 16618952
DA 2025-04-28
ER

PT J
AU Gruber, A
   Nasser, K
   Smith, R
   Sharma, JC
   Thomson, GA
AF Gruber, A
   Nasser, K
   Smith, R
   Sharma, JC
   Thomson, GA
TI Diabetes prevention: is there more to it than lifestyle changes?
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Review
DE diabetes; prevention; exercise; lifestyle
ID cardiovascular risk-factors; impaired glucose-tolerance; weight-reduction; type-2; mellitus; obesity; hypertension; pravastatin; rimonabant; exendin-4
AB Over the past years, there has been an explosive increase in the prevalence of type 2 diabetes (T2DM) and this is expected to continue, entailing associated morbidity and mortality. An increasing number of studies explore the different ways T2DM could be prevented. On-going lifestyle modifications need to be addressed. High-risk patients should be given counselling on weight loss, possibly using a low glycaemic index diet, with a target of around 7-10% over 6-12 months, as well as instruction for increasing physical activity to around 150 min of physical exercise weekly (NNT = 4-8). Moderate alcohol consumption and coffee consumption may also be of benefit (NNT = 89 and 66, respectively). Metformin (NNT = 14), acarbose (NNT = 11) and troglitazone (NNT = 6) have been shown to prevent/delay T2DM and angiotensin-converting enzyme (ACE) inhibitors and statins appear to have an adjunctive role (NNT = 42 and 112, respectively). Trials with orlistat and bariatric surgery have also prevented T2DM (NNT = 36 and 6, respectively), and forthcoming treatment with GLP1 mimetics appears promising. Diabetes prevention studies should help create well-defined strategies for screening and treating high-risk populations in the real world, as prevention is our only chance to alleviate the ever growing burden of diabetes mellitus in the world.
C1 Kings Mill Hosp, Sherwood Forest Hosp NHS Trust, Sutton In Ashfield NG18 4JL, Notts, England.
RP Kings Mill Hosp, Diabet Unit, Sutton In Ashfield NG18 4JL, Notts, England.
EM agruber@doctors.org.uk
CR Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796
   Buse JB, 2004, DIABETES CARE, V27, P2628, DOI 10.2337/diacare.27.11.2628
   Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486
   Conigrave Katherine M, 2003, TREAT ENDOCRINOL, V2, P145, DOI 10.2165/00024677-200302030-00001
   Conigrave KM, 2001, DIABETES, V50, P2390, DOI 10.2337/diabetes.50.10.2390
   Dahlöf B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1
   Deedwania PC, 2005, CARDIOL CLIN, V23, P165, DOI 10.1016/j.ccl.2004.11.003
   Freeman DJ, 2001, CIRCULATION, V103, P357
   GESLER WM, 2005, HLTH PLACE 0704, V0, P0
   Gill JMR, 2003, J NUTR BIOCHEM, V14, P122, DOI 10.1016/S0955-2863(02)00275-9
   Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492
   James PT, 2004, EUR J CARDIOV PREV R, V11, P3, DOI 10.1097/01.hjr.0000114707.27531.48
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/nejmoa012512
   Lee WJ, 2004, ARCH SURG-CHICAGO, V139, P1088, DOI 10.1001/archsurg.139.10.1088
   Masuzaki Hiroaki, 2003, CURRENT DRUG TARGETS - IMMUNE ENDOCRINE AND METABOLIC DISORDERS, V3, P255
   NAUCK MA, 2005, PRACT DIABETES INT, V22, P171
   Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537
   Pi-Sunyer FX, 2005, CIRCULATION, V111, P1727
   Pontiroli AE, 2005, DIABETES CARE, V28, P2703, DOI 10.2337/diacare.28.11.2703
   Prisant LM, 2004, J CLIN PHARMACOL, V44, P406, DOI 10.1177/0091270004263018
   Scheen AJ, 2004, DRUGS, V64, P2537, DOI 10.2165/00003495-200464220-00004
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   Sjöström L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622
   Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155
   Trento M, 2001, DIABETES CARE, V24, P995, DOI 10.2337/diacare.24.6.995
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X
   Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270
NR 30
TC 12
Z9 14
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD MAY 15
PY 2006
VL 60
IS 5
BP 590
EP 594
DI 10.1111/j.1368-5031.2006.00929.x
PG 5
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 038VV
UT WOS:000237258500020
PM 16700860
DA 2025-04-28
ER

PT J
AU Kurihara, H
   Shibata, H
   Fukui, Y
   Kiso, Y
   Xu, JK
   Yao, XS
   Fukami, H
AF Kurihara, Hiroshi
   Shibata, Hiroshi
   Fukui, Yuko
   Kiso, Yoshinobu
   Xu, Jie-Kun
   Yao, Xin-Sheng
   Fukami, Harukazu
TI Evaluation of the hypolipemic property of Camellia sinensis var. ptilophylla on postprandial hypertriglyceridemia
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE Camellia sinensis var. ptilophylla; cocoa tea; triglyceride (TG); pancreatic lipase
ID lipid absorption; tea catechins; health; caffeine; obesity; serum; polyphenols; inhibition; rats; rich
AB A naturally decaffeinated tea, Camellia sinensis var. ptilophylla (cocoa tea), has long been popular in southern China as a healthy beverage. Our experiments indicate that a single oral administration of 500 mg/kg of cocoa tea extract suppresses increases in plasma triacylgycerol (TG) levels when fed with 5 mL/kg of olive or lard oil in mice and that the inhibition rates are 22.9% and 31.5%, respectively, compared with controls. Under the same condition, cocoa tea extract did not affect the level of plasma free fatty acid. Likewise, the extract reduced the lymphatic absorption of lipids at 250 and 500 mg/kg. Also, cocoa tea extract and polyphenols isolated from cocoa tea inhibit pancreatic lipase. These findings suggest that cocoa tea has hypolipemic activity, which may be due to the suppression of digestive lipase activity by the polyphenols contained within the tea.
C1 Kyotogakuen Univ, Fac Bioenvironm Sci, Dept Biosci & Biotechnol, Kameoka City, Kyoto 6218555, Japan.
   Jinan Univ, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China.
   Suntory Ltd, Inst Hlth Care Sci, Technol Dev Ctr, Shimamoto, Osaka 6180001, Japan.
C3 Jinan University; Suntory Holdings Ltd
RP Fukami, H (corresponding author), Kyotogakuen Univ, Fac Bioenvironm Sci, Dept Biosci & Biotechnol, 1-1 Nanjo, Kameoka City, Kyoto 6218555, Japan.
EM fukami@kyotogakuen.ac.jp
CR Abelson P, 2004, SCIENCE, V304, P1413, DOI 10.1126/science.304.5676.1413
   Ashihara H, 2001, TRENDS PLANT SCI, V6, P407, DOI 10.1016/S1360-1385(01)02055-6
   Ashihara H, 1998, J PLANT RES, V111, P599, DOI 10.1007/BF02507798
   Benzie IFF, 1999, J AGR FOOD CHEM, V47, P633, DOI 10.1021/jf9807768
   Bitou N, 1999, LIPIDS, V34, P441, DOI 10.1007/s11745-999-0383-7
   CHANG H, 1988, ACTA SCI NATUR U SUN, V27, P131
   Fredholm BB, 1999, PHARMACOL REV, V51, P83
   Fujiki H, 1998, MUTAT RES-FUND MOL M, V402, P307, DOI 10.1016/S0027-5107(97)00310-2
   GROSSMAN SH, 1976, CLIN CHEM, V22, P1310
   GRUNDY SM, 1990, J LIPID RES, V31, P1149
   Hashimoto F, 1996, BIOORG MED CHEM LETT, V6, P695, DOI 10.1016/0960-894X(96)00095-9
   Ikeda I, 2003, J AGR FOOD CHEM, V51, P7303, DOI 10.1021/jf034728l
   IKEDA I, 1994, J NUTR SCI VITAMINOL, V40, P275, DOI 10.3177/jnsv.40.275
   JAMES JE, 1994, ADDICTION, V89, P1595, DOI 10.1111/j.1360-0443.1994.tb03760.x
   Lakenbrink C, 2000, J AGR FOOD CHEM, V48, P2848, DOI 10.1021/jf9908042
   Lowe ME, 1997, J NUTR, V127, P549, DOI 10.1093/jn/127.4.549
   Matsuzawa Y, 2001, NIHON RINSHO, V59, P188
   McKay DL, 2002, J AM COLL NUTR, V21, P1
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   OKABE H, 1980, CLIN CHEM, V26, P1540
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   SENIOR JR, 1964, J LIPID RES, V5, P495
   Silvarolla MB, 2004, NATURE, V429, P826, DOI 10.1038/429826a
   Smith A, 2002, FOOD CHEM TOXICOL, V40, P1243, DOI 10.1016/S0278-6915(02)00096-0
   Suzuki K, 2001, BIOL PHARM BULL, V24, P1088, DOI 10.1248/bpb.24.1088
   Thomson ABR, 1997, METHOD ENZYMOL, V286, P3
   Weisburger JH, 1997, CANCER LETT, V114, P315, DOI 10.1016/S0304-3835(97)04691-0
   Wu CD, 2002, NUTRITION, V18, P443, DOI 10.1016/S0899-9007(02)00763-3
   XIE B, 1993, LIFE SCI, V17, P77
   Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409
   YEN GC, 1995, J AGR FOOD CHEM, V43, P27, DOI 10.1021/jf00049a007
NR 32
TC 34
Z9 40
U1 0
U2 43
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JUL 12
PY 2006
VL 54
IS 14
BP 4977
EP 4981
DI 10.1021/jf0603681
PG 5
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 059IW
UT WOS:000238727500010
PM 16819905
DA 2025-04-28
ER

PT J
AU Rush, E
   Schulz, S
   Obolonkin, V
   Simmons, D
   Plank, L
AF Rush, E
   Schulz, S
   Obolonkin, V
   Simmons, D
   Plank, L
TI Are energy drinks contributing to the obesity epidemic?
SO ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE lipogenesis; caffeine; sucrose; carbonated beverage; fat oxidation; carbohydrate oxidation
ID caffeine; fructose
AB The consumption of energy drinks containing sucrose and caffeine is increasing worldwide. Ten healthy women aged 18 to 22 years and fasted overnight were randomly allocated to a standardised dose of sucrose either as an "energy" drink (containing sucrose and caffeine) or lemonade on the first day and then crossed over to the alternative drink on a second day. For thirty minutes before and thirty minutes after drinking oxygen consumption and carbon dioxide production were measured in the resting subject breath-by-breath by indirect calorimetry and the rates of carbohydrate and fat oxidation calculated. Energy drink consumption apparently caused increased carbohydrate oxidation (P = 0.004) and reduced lipid oxidation (P = 0.004) compared to lemonade. The longer term effects of combined caffeine and sucrose intake, particularly in sedentary individuals, on metabolism and body fatness needs further examination.
C1 Auckland Univ Technol, Fac Hlth & Environm Sci, Div Sport & Recreat, Auckland 1020, New Zealand.
   Waikato Clin Sch, Auckland, New Zealand.
   Univ Auckland, Dept Surg, Auckland 1, New Zealand.
C3 Auckland University of Technology; University of Auckland
RP Rush, E (corresponding author), Auckland Univ Technol, Fac Hlth & Environm Sci, Div Sport & Recreat, Private Bag 92006, Auckland 1020, New Zealand.
EM elaine.rush@aut.ac.nz
CR Bray GA, 2004, AM J CLIN NUTR, V79, P537
   Elliott SS, 2002, AM J CLIN NUTR, V76, P911, DOI 10.1093/ajcn/76.5.911
   FRAYN KN, 1983, J APPL PHYSIOL, V55, P628, DOI 10.1152/jappl.1983.55.2.628
   Graham TE, 2001, SPORTS MED, V31, P785, DOI 10.2165/00007256-200131110-00002
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x
   Hudgins LC, 2000, J LIPID RES, V41, P595
NR 7
TC 20
Z9 23
U1 0
U2 7
PU H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI SOUTHBANK
PA EMERALD HILL CLINIC 157 CLARENDON ST, SOUTHBANK, VIC 3006, AUSTRALIA
SN 0964-7058
EI 
J9 ASIA PAC J CLIN NUTR
JI Asia Pac. J. Clin. Nutr.
PD JUN 15
PY 2006
VL 15
IS 2
BP 242
EP 244
DI 
PG 3
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 041FP
UT WOS:000237439700016
PM 16672210
DA 2025-04-28
ER

PT J
AU Duffey, KJ
   Popkin, BM
AF Duffey, Kiyah J.
   Popkin, Barry M.
TI Adults with healthier dietary patterns have healthier beverage patterns
SO JOURNAL OF NUTRITION
LA English
DT Article
ID us adults; food-consumption; body-weight; trends; carbohydrate; children; obesity; young; risk; men
AB There is an absence of research examining associations between food and beverage intake patterns and most research has centered on soft drinks, whereas research on overall beverage patterns is absent. Using data from the National Health and Nutrition Examination Survey 99-02 for adults aged 19 y and older, we independently examined beverage and food intake patterns, as well as their interrelations. Cluster analysis generated mutually exclusive intake patterns for beverages and foods. Multinomial logistic regression models provided the odds of a given beverage pattern for each food pattern; we then compared the probability of a given beverage pattern for each food pattern. Six beverage and 6 food patterns emerged. Beverage patterns revealed that calorically sweetened, noncaloric, and diet beverages tended to be consumed independently of one another. Being in the Snacks and High-Fat Foods cluster increased the odds of being in the Coffee and Soda (odds ratio (OR): 1.62 [95% CI: 1.27-2.06]) or Nutrients and Soda (OR: 1.51 [95% CI: 1.14-2.00]) beverage clusters and decreased the odds of being in the Water and Tea (OR: 0.51 [95% CI: 0.52-0.97]) cluster relative to the odds of being in the Water, Coffee, and Tea cluster. The opposite was true for the Vegetable pattern. Furthermore, persons who had a healthier food pattern had a higher probability of having a noncaloric beverage pattern than persons who did not. Increasing awareness of both the contribution of calorie-containing beverages to overall energy intake and dietary patterns associated with these beverages helps inform policies targeted at reducing energy intake in the population.
C1 Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27516 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill
RP Popkin, BM (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27516 USA.
EM popkin@unc.edu
FU NCI NIH HHS [R01-CA121152, R01-CA109831] Funding Source: Medline
CR DellaValle DM, 2005, APPETITE, V44, P187, DOI 10.1016/j.appet.2004.11.003
   DiMeglio DP, 2000, INT J OBESITY, V24, P794, DOI 10.1038/sj.ijo.0801229
   Ebbeling CB, 2006, PEDIATRICS, V117, P673, DOI 10.1542/peds.2005-0983
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Forshee RA, 2003, INT J FOOD SCI NUTR, V54, P297, DOI 10.1080/09637480120092143
   Fung TT, 2004, ARCH INTERN MED, V164, P2235, DOI 10.1001/archinte.164.20.2235
   Guthrie JF, 2002, J NUTR EDUC BEHAV, V34, P140, DOI 10.1016/S1499-4046(06)60083-3
   HULSHOF T, 1993, APPETITE, V21, P273, DOI 10.1006/appe.1993.1045
   Knol LL, 2005, J AM DIET ASSOC, V105, P1765, DOI 10.1016/j.jada.2005.08.012
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   MAINS P, 1992, J AM DIET ASSOC, V92, P704
   Mattes Richard D, 1996, PHYSIOLOGY AND BEHAVIOR, V59, P179, DOI 10.1016/0031-9384(95)02007-1
   Millen BE, 2005, J AM DIET ASSOC, V105, P1723, DOI 10.1016/j.jada.2005.08.007
   Montonen J, 2005, AM J EPIDEMIOL, V161, P219, DOI 10.1093/aje/kwi039
   Nelson MC, 2005, AM J PREV MED, V28, P259, DOI 10.1016/j.amepre.2004.12.006
   Newby P, 2003, AM J CLIN NUTR, V77, P1417, DOI 10.1093/ajcn/77.6.1417
   Nielsen SJ, 2004, AM J PREV MED, V27, P205, DOI 10.1016/j.amepre.2004.05.005
   Nielsen SJ, 2002, OBES RES, V10, P370, DOI 10.1038/oby.2002.51
   Paeratakul S, 2003, J AM DIET ASSOC, V103, P1332, DOI 10.1016/S0002-8223(03)01086-1
   *PAN DIET REF INT, 2002, DIET REF INT EN CARB, V0, P0
   *PAN IET REF INT E, 2004, DIET REF INT WAT POT, V0, P0
   Popkin BM, 2006, AM J CLIN NUTR, V83, P529, DOI 10.1093/ajcn.83.3.529
   Popkin BM, 2005, OBES RES, V13, P2146, DOI 10.1038/oby.2005.266
   Popkin BM, 1999, APPETITE, V32, P8, DOI 10.1006/appe.1998.0190
   Quatromoni PA, 2002, J AM DIET ASSOC, V102, P1240
   RABEN A, 1994, AM J CLIN NUTR, V60, P544, DOI 10.1093/ajcn/60.4.544
   Raben A, 2002, AM J CLIN NUTR, V76, P721, DOI 10.1093/ajcn/76.4.721
   Rajeshwari R, 2005, J AM DIET ASSOC, V105, P208, DOI 10.1016/j.jada.2004.11.026
   Raper N, 2004, J FOOD COMPOS ANAL, V17, P545, DOI 10.1016/j.jfca.2004.02.013
   Schulze MB, 2004, JAMA-J AM MED ASSOC, V292, P927, DOI 10.1001/jama.292.8.927
   USDepartment of Health and Human Services and USDepartment of Agriculture, 2005, DIET GUID AM 2005, V0, P0
   *US DEP HHS USDA, 2005, DIET GUID ADV COMM R, V0, P0
   USDA, 2004, USDA FOOD NUTR DAT D, V0, P0
   Villegas R, 2004, PUBLIC HEALTH NUTR, V7, P1017, DOI 10.1079/PHN2004638
NR 35
TC 99
Z9 108
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD NOV 15
PY 2006
VL 136
IS 11
BP 2901
EP 2907
DI 10.1093/jn/136.11.2901
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 100DY
UT WOS:000241649000031
PM 17056820
DA 2025-04-28
ER

PT J
AU Sale, C
   Harris, RC
   Delves, S
   Corbett, J
AF Sale, C
   Harris, RC
   Delves, S
   Corbett, J
TI Metabolic and physiological effects of ingesting extracts of bitter orange, green tea and guarana at rest and during treadmill walking in overweight males
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE bitter orange; green tea; caffeine; metabolic rate and substrate utilization; dietary supplements
ID nervous-system activity; energy-expenditure; epinephrine infusion; catechin-polyphenols; caffeine consumption; exercise intensity; healthy-adults; fat oxidation; human-muscle; young-women
AB Objective: This study examined the acute effects of ingesting a widely used commercial formula containing extracts of bitter orange, green tea and guarana (Gx) on the metabolic rate and substrate utilisation in overweight, adult males at rest (study 1) and during treadmill walking (study 2). Subjects: Two different groups of 10 sedentary males with more than 20% body fat participated in studies 1 and 2. Design: In each study, subjects participated in two experimental trials during which they were given two 500mg capsules containing either Gx or a placebo (P) in a counterbalanced double-blind manner. Doses of the main active ingredients were 6mg of synephrine, 150mg caffeine and 150mg catechin polyphenols. Measurements: In study 1, subjects completed 7 h supine rest with baseline measures taken during the first hour, with expired gases, blood pressure, heart rate and venous blood being collected every 30 min for the remaining 6 h following ingestion of Gx or P. In study 2, subjects exercised for 60 min at 60% heart rate reserve following ingestion of Gx or P 1 h previously. Venous blood samples were collected twice at rest and at 5, 10, 15, 20, 30, 40, 50 and 60 min, with expired gas measurements taken at 4, 9, 14, 19, 29, 39, 49 and 59 min. In both studies, venous blood was analysed for NEFA, glycerol, glucose and lactate concentrations, while expired gases were used to calculate ATP production from carbohydrate and NEFA, as well as the total substrate utilised. Results and conclusion: The results did not show any significant effect of Gx ingestion on total ATP utilisation during 6 h rest or during 60 min treadmill walking. Changes were observed in the relative contributions of CHO and NEFA oxidation to ATP production in both studies, such that there was an increase in ATP production from CHO and a decrease from NEFA. The increase in CHO oxidation was shown to be as high as 30% at rest.
C1 Univ Chichester, Sch Sport Exercise & Hlth Sci, Chichester PO19 6PE, W Sussex, England.
C3 University of Chichester
RP Univ Chichester, Sch Sport Exercise & Hlth Sci, Coll Lane, Chichester PO19 6PE, W Sussex, England.
EM c.sale@ucc.ac.uk
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Achten J, 2002, MED SCI SPORT EXER, V34, P92, DOI 10.1097/00005768-200201000-00015
   ALBERTY RA, 1968, J BIOL CHEM, V243, P1337
   Amano M, 2001, MED SCI SPORT EXER, V33, P1287, DOI 10.1097/00005768-200108000-00007
   Bell C, 2003, INT J OBESITY, V27, P1315, DOI 10.1038/sj.ijo.0802413
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   CHASIOTIS D, 1983, J APPL PHYSIOL, V54, P45, DOI 10.1080/07303084.1983.10630537
   Colker CM, 1999, CURR THER RES CLIN E, V60, P145, DOI 10.1016/S0011-393X(00)88523-9
   DANFORTH WH, 1962, P NATL ACAD SCI USA, V48, P1191, DOI 10.1073/pnas.48.7.1191
   Draper SB, 2003, EUR J APPL PHYSIOL, V90, P92, DOI 10.1007/s00421-003-0877-4
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DUPPORT C, 2003, BIOCHIM BIOPHYS ACTA, V1629, P34
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461
   Engels HJ, 1999, INT J SPORT NUTR, V9, P361, DOI 10.1123/ijsn.9.4.361
   KASVINSKY PJ, 1978, J BIOL CHEM, V253, P9102
   KOOT P, 1995, ANN NUTR METAB, V39, P135, DOI 10.1159/000177854
   Lamont LS, 1997, MED SCI SPORT EXER, V29, P769, DOI 10.1097/00005768-199706000-00006
   Lane JD, 2002, PSYCHOSOM MED, V64, P595, DOI 10.1097/01.PSY.0000021946.90613.DB
   Matsumoto T, 2001, OBES RES, V9, P78, DOI 10.1038/oby.2001.10
   Matsumoto T, 2000, J NUTR SCI VITAMINOL, V46, P309, DOI 10.3177/jnsv.46.309
   Pedersen SB, 1999, METABOLISM, V48, P461, DOI 10.1016/S0026-0495(99)90104-X
   Penzak SR, 2001, J CLIN PHARMACOL, V41, P1059, DOI 10.1177/00912700122012652
   Preuss Harry G, 2002, JOURNAL OF MEDICINE (WESTBURY), V33, P247
   Ravussin E, 1999, INT J OBESITY, V23, P37, DOI 10.1038/sj.ijo.0800793
   SAHLIN K, 2004, PRINCIPLES EXERCISE, V46, P87
   Samra JS, 1996, AM J PHYSIOL-ENDOC M, V271, PE834, DOI 10.1152/ajpendo.1996.271.5.E834
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   Smith DA, 1997, J APPL PHYSIOL, V82, P156, DOI 10.1152/jappl.1997.82.1.156
   SPRAUL M, 1993, J CLIN INVEST, V92, P1730, DOI 10.1172/JCI116760
   STEINER RF, 1980, BIOCHIM BIOPHYS ACTA, V611, P269, DOI 10.1016/0005-2744(80)90062-5
   WELLE S, 1991, METABOLISM, V40, P619, DOI 10.1016/0026-0495(91)90053-Y
NR 34
TC 30
Z9 32
U1 0
U2 23
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD MAY 15
PY 2006
VL 30
IS 5
BP 764
EP 773
DI 10.1038/sj.ijo.0803209
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 036UE
UT WOS:000237100400005
PM 16418760
DA 2025-04-28
ER

PT J
AU Hughes, TA
   Stentz, F
   Gettys, T
   Smith, SR
AF Hughes, TA
   Stentz, F
   Gettys, T
   Smith, SR
TI Combining β-adrenergic and peroxisome proliferator-activated receptor 7 stimulation improves lipoprotein composition in healthy moderately obese subjects
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID low-density-lipoprotein; gene-expression; ppar-gamma; lipase activity; hepatic lipase; sr-bi; receptor; plasma; metabolism; rat
AB Current pharmacological regimens for hypertriglyceridemia and low high-density lipoprotein (HDL) are limited to the peroxisome proliferator-activated receptor (PPAR) alpha activating fibrates, niacin, and statins. This pilot study examined the impact of simultaneous stimulation of cyclic adenosine monophosphate with a beta-adrenergic agonist and PPAR gamma with pioglitazone (PIO) on lipoprotein composition in moderately obese, healthy subjects. Subjects were treated with PIO (45 mg) to stimulate PPAR or a combination of ephedrine (25 mg TID), a beta-agonist, with caffeine (200 mg TID), a phosphodiesterase inhibitor (ephedrine plus caffeine), or both for 16 weeks. Lipoproteins were separated by gradient ultracentrifugation into very low-density lipoprotein (VLDL), intermediate-density lipoprotein, low-density lipoprotein (LDL), and 3 HDL (L, M, and D) subfractions. Apolipoproteins were measured by high-performance liquid chromatography. PIO alone reduced the core triglyceride (TG) content relative to cholesterol ester (CE) in VLDL (-40%), IDL (-25%), and HDL-M (-38%). Ephedrine plus caffeine alone reduced LDL CE (-13%), phospholipids (-9%), and apolipoprotein (apo) B (-13%); increased HDL-M LpA-I (HDL containing apoA-I without apoA-II, 28%), CE/TG (23%), and CE/apoA-I (8%) while reducing apoA-II (-10%); and increased HDL-L LpA-I (29%). Combination therapy reduced total plasma TG (-28%), LDL cholesterol (LDL-C, -10%), apoB (-16%), apoB/apoA-I ratio (-21%) while increasing HDL cholesterol (HDL-C, 21%), total plasma apoA-I (12%), LpA-1 (43%), and apoC-I (26%). It also reduced VLDL total mass (-34%) and apoC-III (-39%), LDL CE (-13%), apoB (-13%), and total mass (-11%). Combination therapy increased HDL-L CE/TG (32%), apoC-I (30%), apoA-I (56%), and LpA-I (70%), as well as HDL-M CE (35%), phospholipids (24%), total mass (19%), apoC-I (25%), apoA-I (18%), and LpA-I (56%). In conclusion, simultaneous beta-adrenergic and PPAR gamma activation produced beneficial effects on VLDL, LDL, HDL-L, and HDL-M. Perhaps the most important impact of combination therapy was dramatic increases in LpA-I and apoC-I in HDL-L and HDL-M, which were much greater than the sum of the monotherapies. Because LpA-1 appears to be the most efficient mediator of reverse-cholesterol transport and a major negative risk factor for cardiovascular disease, this combination therapy may provide very effective treatment of atherosclerosis. (c) 2005 Elsevier Inc. All fights reserved.
C1 Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA.
   Pennington Biomed Res Ctr, Mol Endocrinol Lab, Baton Rouge, LA 70808 USA.
   Pennington Biomed Res Ctr, Adipose Tissue Signaling Lab, Baton Rouge, LA 70808 USA.
C3 University of Tennessee System; University of Tennessee Health Science Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center
RP Hughes, TA (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA.
EM thughes303@aol.com
FU NCRR NIH HHS [P20 RR021945] Funding Source: Medline; NIDDK NIH HHS [R01 DK074772, P30 DK072476, R01 DK074772-01A1] Funding Source: Medline; NIGMS NIH HHS [P30 GM118430] Funding Source: Medline
CR AIRAYYES O, 1998, DIABETES, V47, P1193
   ARNER P, 1993, ARTERIOSCLER THROMB, V13, P967, DOI 10.1161/01.ATV.13.7.967
   Ballart X, 2003, BIOCHIMIE, V85, P971, DOI 10.1016/j.biochi.2003.09.001
   BJORNSSON OG, 1994, EUR J CLIN INVEST, V24, P137, DOI 10.1111/j.1365-2362.1994.tb00979.x
   Blaak EE, 2003, P NUTR SOC, V62, P753, DOI 10.1079/PNS2003290
   Boquist S, 1998, ATHEROSCLEROSIS, V137, P391, DOI 10.1016/S0021-9150(97)00278-5
   Conde-Knape K, 2002, J LIPID RES, V43, P2136, DOI 10.1194/jlr.M200210-JLR200
   de Beer MC, 2004, J LIPID RES, V45, P706, DOI 10.1194/jlr.M300417-JLR200
   DESHAIES Y, 1993, HORM METAB RES, V25, P13, DOI 10.1055/s-2007-1002036
   Duriez P, 1999, CLIN CHIM ACTA, V286, P97, DOI 10.1016/S0009-8981(99)00096-0
   Duvillard L, 2003, DIABETES CARE, V26, P1540, DOI 10.2337/diacare.26.5.1540
   EGUSA G, 1983, J LIPID RES, V24, P1261
   Fredenrich A, 1998, DIABETES METAB, V24, P490
   Gautier T, 2002, J BIOL CHEM, V277, P31354, DOI 10.1074/jbc.M203151200
   Gautier T, 2000, J BIOL CHEM, V275, P37504, DOI 10.1074/jbc.M007210200
   GOLDBERG RB, 2005, IN PRESS DIABETES CA, V0, P0
   Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200
   Hodgkinson CP, 2003, BIOCHEM BIOPH RES CO, V308, P505, DOI 10.1016/S0006-291X(03)01416-5
   HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X
   Hsueh WA, 2001, ARTERIOSCL THROM VAS, V21, P1891, DOI 10.1161/hq1201.100261
   HUGHES TA, 1988, J LIPID RES, V29, P363
   HUGHES TA, 1991, THER DRUG MONIT, V13, P289, DOI 10.1097/00007691-199107000-00002
   Kageyama H, 2003, BIOCHEM BIOPH RES CO, V305, P22, DOI 10.1016/S0006-291X(03)00663-6
   Kuusela P, 1997, BIOCHEM J, V321, P759, DOI 10.1042/bj3210759
   Laplante M, 2003, DIABETES, V52, P291, DOI 10.2337/diabetes.52.2.291
   Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756
   Liu JQ, 2000, EUR J ENDOCRINOL, V142, P677, DOI 10.1530/eje.0.1420677
   Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214
   Maki KC, 1996, METABOLISM, V45, P712, DOI 10.1016/S0026-0495(96)90136-5
   Neve BP, 1998, BIOCHEM J, V330, P701
   Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200
   RABKIN SW, 1994, HYPERTENSION, V24, P241, DOI 10.1161/01.HYP.24.2.241
   Rinninger F, 2003, ATHEROSCLEROSIS, V166, P31, DOI 10.1016/S0021-9150(02)00311-8
   SHEN MMS, 1981, J LIPID RES, V22, P236
   Tan MH, 2000, EXP CLIN ENDOCR DIAB, V108, P0
NR 35
TC 10
Z9 12
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA
SN 0026-0495
EI 
J9 METABOLISM
JI Metab.-Clin. Exp.
PD JAN 15
PY 2006
VL 55
IS 1
BP 26
EP 34
DI 10.1016/j.metabol.2005.06.022
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 995KE
UT WOS:000234098400005
PM 16324916
DA 2025-04-28
ER

PT J
AU Inoue, H
   Kobayashi-Hattori, K
   Horiuchi, Y
   Oishi, Y
   Arai, S
   Takita, T
AF Inoue, Hiroko
   Kobayashi-Hattori, Kazuo
   Horiuchi, Yumi
   Oishi, Yuichi
   Arai, Souichi
   Takita, Toshichika
TI Regulation of the body fat percentage in developmental-stage rats by methylxanthine derivatives in a high-fat diet
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE high-fat diet; rat; methylxanthine derivative; body fat percentage; abdominal adipose tissue
ID coronary-heart-disease; insulin-resistance; serum-cholesterol; obese children; visceral fat; caffeine; risk; agents; cells; tea
AB We investigated the regulatory effects of structural differences among methylxanthine derivatives on the elevation of body fat percentage in developmental-stage rats. Caffeine, theophylline and theobromine were used as the methylxanthines. High-fat diets (20% lard) containing each methylxanthine (0.025%) were administered to male Sprague-Dawley rats for 12 weeks, with the result that the body fat percentage was generally reduced in each methylxanthine-fed group. The abdo minal adipose tissue weight in the caffeine group was also significantly lower than that in the control group, the serum cholesterol and triglyceride levels in the caffeine group also being significantly lower than the levels in the control group. The study results suggest that caffeine could contribute most to preventing arteriosclerotic diseases.
C1 Tokyo Univ Agr, Setagaya Ku, Fac Appl Biosci, Dept Nutr Sci, Tokyo 1568502, Japan.
   Chubu Univ, Coll Biosci & Biotechnol, Dept Nutr & Food Sci, Kasugai, Aichi 4878501, Japan.
C3 Tokyo University of Agriculture; Chubu University
RP Takita, T (corresponding author), Tokyo Univ Agr, Setagaya Ku, Fac Appl Biosci, Dept Nutr Sci, 1-1-1 Sakuragaoka, Tokyo 1568502, Japan.
EM takita@nodai.ac.jp
CR DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173
   DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270
   DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478
   GEORGE AB, 1970, J LIPID RES, V11, P517
   GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849
   *HLTH WELF STAT AS, 2004, KOUSEI SHIHYO, V51, P45
   Hokanson J E, 1996, J CARDIOVASC RISK, V3, P213, DOI 10.1097/00043798-199604000-00014
   Hongu N, 2000, J NUTR, V130, P152, DOI 10.1093/jn/130.2.152
   Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665
   INOUE H, 2005, ITE LETT BATT NEW TE, V6, P61
   Iso H, 2001, AM J EPIDEMIOL, V153, P490, DOI 10.1093/aje/153.5.490
   KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1
   KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514
   Klish William J, 1995, ACTA PAEDIATRICA JAPONICA, V37, P1
   Kobayashi-Hattori K, 2005, BIOSCI BIOTECH BIOCH, V69, P2219, DOI 10.1271/bbb.69.2219
   KOMABAYASHI T, 1978, FOLIA PHARMACOL JPN, V74, P459, DOI 10.1254/fpj.74.459
   Kotani K, 1997, INT J OBESITY, V21, P912, DOI 10.1038/sj.ijo.0800492
   KUO JF, 1969, J BIOL CHEM, V244, P2252
   Matsuzawa Yuji, 2005, SEMIN VASC MED, V5, P34, DOI 10.1055/s-2005-871744
   Morimoto C, 2001, J LIPID RES, V42, P120
   NAKAMURA T, 1994, ATHEROSCLEROSIS, V107, P239, DOI 10.1016/0021-9150(94)90025-6
   Pyorala K, 1979, DIABETES CARE, V2, P131, DOI 10.2337/diacare.2.2.131
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5
   Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800
   Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448
   STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823
   STAVRIC B, 1988, FOOD CHEM TOXICOL, V26, P111, DOI 10.1016/0278-6915(88)90107-X
   SUZUKI M, 1983, J NUTR SCI VITAMINOL, V29, P399, DOI 10.3177/jnsv.29.399
   Togashi K, 2002, INT J OBESITY, V26, P770, DOI 10.1038/sj.ijo.0801992
   Welborn T A, 1979, DIABETES CARE, V2, P154, DOI 10.2337/diacare.2.2.154
   WILCOX AR, 1982, MED SCI SPORT EXER, V14, P317, DOI 10.1249/00005768-198204000-00011
   Zheng GD, 2004, IN VIVO, V18, P55
   Bieri JG, 1977, JOURNAL OF NUTRITION, V107, P1394
NR 34
TC 17
Z9 19
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD MAY 15
PY 2006
VL 70
IS 5
BP 1134
EP 1139
DI 10.1271/bbb.70.1134
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry; Food Science & Technology
GA 049ZJ
UT WOS:000238056500010
PM 16717413
DA 2025-04-28
ER

PT J
AU McMenamin, JP
   Tiglio, AD
AF McMenamin, Joseph P.
   Tiglio, Andrea D.
TI Not the next tobacco: Defenses to obesity claims
SO FOOD AND DRUG LAW JOURNAL
LA English
DT Review
ID body-mass index; nutrition examination survey; increased dopamine release; medial forebrain-bundle; plasma ghrelin levels; human coffee-drinking; sedentary life-style; fat dietary pattern; induced weight-gain; physical-activity
C1 McGuireWoods LLP, Richmond, VA USA.
   McGuireWoods LLP, Mclean, VA USA.
RP McMenamin, JP (corresponding author), McGuireWoods LLP, Richmond, VA USA.
CR Ahima RS, 2000, FRONT NEUROENDOCRIN, V21, P263, DOI 10.1006/frne.2000.0197
   Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0
   Ahmed SH, 1997, PSYCHOPHARMACOLOGY, V132, P289, DOI 10.1007/s002130050347
   AHREN B, 1991, CELL TISSUE RES, V264, P263, DOI 10.1007/BF00313963
   Air EL, 2002, NAT MED, V8, P179, DOI 10.1038/nm0202-179
   Alderman J, 2006, AM J PREV MED, V30, P82, DOI 10.1016/j.amepre.2005.08.036
   Allison DB, 1996, INT J OBESITY, V20, P501
   Allison DB, 2001, J CLIN PSYCHIAT, V62, P22
   *AM AC PED COUNC S, 1835, PEDIATRICS, V17, P1834
   Unknown -, 2000, DIAGNOSTIC ANS STATISTICAL MANUAL OF MENTAL DISORDERS, V4th, P191
   Unknown -, 2002, FAST FOOD NATION DAR, V0, P0
   Unknown -, 1997, WHO TECHN REP SER, V0, P0
   Unknown -, 1997, HIST PSYCHIAT, V0, P0
   Unknown -, 2004, MMWR-MORBID MORTAL W, V53, P82
   Arcavi L, 2004, ARCH INTERN MED, V164, P2206, DOI 10.1001/archinte.164.20.2206
   Arif AA, 2005, BMC PUBLIC HEALTH, V5, P0, DOI 10.1186/1471-2458-5-126
   ASCHERIO A, 1999, T FATTY ACIDS CORONA, V340, P1933
   ASIMOV N, 2006, SAN FRANCISCO C 0608, V0, PB1
   Avena NM, 2003, NEUROSCIENCE, V122, P17, DOI 10.1016/S0306-4522(03)00502-5
   Babey SH, 2005, ACCESS TO SAFE PARKS HELPS INCREASE PHYSICAL ACTIVITY AMONG TEENAGERS, V0, P1
   BADMAN MK, 2005, SCI, V307, P1904
   Baird J, 2005, BMJ-BRIT MED J, V331, P929, DOI 10.1136/bmj.38586.411273.E0
   BAKER DP, 1997, WASH POST 0531, V0, PA3
   BALE J, 2005, LONDON TIMES 1219, V0, P0
   Balk EM, 2006, ATHEROSCLEROSIS, V184, P237, DOI 10.1016/j.atherosclerosis.2005.06.042
   BANZHAF J, 2003, COMMUNICATION 0619, V0, P0
   Baptista T, 2004, CURR DRUG TARGETS, V5, P279, DOI 10.2174/1389450043490514
   Bar-on ME, 2001, PEDIATRICS, V107, P423, DOI 10.1542/peds.107.2.423
   Barnes PM, 2003, ADVANCED DATA FROM VITAL AND HEALTH STATISTICS, V333, P1
   BARNES PM, 2003, ADV DATA VITAL HLTH, V333, P19
   Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519
   Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204
   Bays HE, 2004, OBES RES, V12, P1197, DOI 10.1038/oby.2004.151
   BELANGER A, 1988, FRAMINGHAM PUBLICATI, V0, P0
   BELL CG, 2004, RECENT PROG HORM RES, V59, P409
   BELL CG, 2003, OBES REV, V4, P139
   BELL CG, 2005, NATURE REV GENETICS, V0, P221
   BENNETT WI, 1995, NEW ENGL J MED, V332, P673, DOI 10.1056/NEJM199503093321009
   Benoit SC, 2002, J NEUROSCI, V22, P9048
   Berg K, 2005, AM J HUM GENET, V77, P519
   Bernstein IM, 2005, OBSTET GYNECOL, V106, P986, DOI 10.1097/01.AOG.0000182580.78402.d2
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   BERTINO M, 1991, AM J PHYSIOL, V261, PR59, DOI 10.1152/ajpregu.1991.261.1.R59
   Birch LL, 1999, ANNU REV NUTR, V19, P41, DOI 10.1146/annurev.nutr.19.1.41
   BIRCH LL, 1980, CHILD DEV, V51, P489, DOI 10.2307/1129283
   Bjorntorp P, 1996, INT J OBESITY, V20, P291
   Björntorp P, 2001, LANCET, V358, P1006, DOI 10.1016/S0140-6736(01)06110-4
   BJORNTORP P, 1970, METABOLIS, V19, P631, DOI 10.1016/0026-0495(70)90020-X
   Blair SN, 2002, MAYO CLIN PROC, V77, P109
   Bloche MG, 2005, GEORGETOWN LAW J, V93, P1335
   BLOCHE MG, 2005, GEORGETOWN, V93, P1341
   Blum K, 1996, PHARMACOGENETICS, V6, P297, DOI 10.1097/00008571-199608000-00003
   Blum K, 1996, AM SCI, V84, P132
   BLUM K, 2000, PSYCHOACTIVE DRUGS S, V32, P1
   BLUNDELL J, 1991, TRENDS PHARMACOL SCI, V12, P147, DOI 10.1016/0165-6147(91)90532-W
   Blundell JE, 2000, BRIT J NUTR, V83, P0
   Bolton RN, 1983, CURRENT ISSUES RES A, V0, P173
   BOLTON RN, 1983, CURRENT ISSUES RES A, V6, P187
   BORAHGIDDENS J, 1993, J NUTR EDUC, V25, P102
   BOUCHARD C, 1990, INT J OBESITY, V14, P57
   BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101
   Bouchard Claude, 1994, THE GENETICS OF OBESITY, V0, P0
   Branson R, 2003, NEW ENGL J MED, V348, P1096, DOI 10.1056/NEJMoa021971
   Breen FM, 2006, PHYSIOL BEHAV, V88, P443, DOI 10.1016/j.physbeh.2006.04.016
   Brooks GA, 2004, AM J CLIN NUTR, V79, P921
   BROWN D, 2002, WASH POST 0408, V0, PA2
   BROWN ER, 2005, HALF CALIFORNIA ADUL, V0, P1
   BURGESON CR, 2003, J PHYS ED REC DANCE, V174, P20
   BURGESON CR, 2001, J SCH HLTH, V71, P292
   BURNS DM, 1991, CLIN CHEST MED, V12, P631
   BURTZOS FM, 2004, COLO LAWYER, V33, P53
   Butler LM, 2004, AM J RESP CRIT CARE, V170, P279, DOI 10.1164/rccm.200306-789OC
   BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306
   BUTTERFIELD PS, 1988, ADDICT BEHAV, V13, P131, DOI 10.1016/0306-4603(88)90002-0
   CABANAC M, 1970, SCIENCE, V168, P496, DOI 10.1126/science.168.3930.496
   CABANAC M, 1971, SCIENCE, V173, P1103, DOI 10.1126/science.173.4002.1103
   Cannon CM, 2003, J NEUROSCI, V23, P10827
   Cannon CM, 2004, PHYSIOL BEHAV, V81, P741, DOI 10.1016/j.physbeh.2004.04.020
   CAPLAN PH, 1995, THEY SAY YOURE CRAZY, V0, P85
   Carelli RM, 2000, J NEUROSCI, V20, P4255
   CARMONA RH, 2003, AM ENT I OB C WASH D, V0, P0
   Castañeda TR, 2005, J NUTR, V135, P1314, DOI 10.1093/jn/135.5.1314
   *CDC, 2002, MMWR-MORBID MORTAL W, V300, P51
   Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKLY REP, V52, P785
   Challis BG, 2000, DIABETES, V49, P872, DOI 10.2337/diabetes.49.5.872
   Chandler KE, 2003, J MED GENET, V40, P233, DOI 10.1136/jmg.40.4.233
   Chaput JP, 2006, INT J OBESITY, V30, P1080, DOI 10.1038/sj.ijo.0803291
   Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489
   Chin-Chance C, 2000, J CLIN ENDOCR METAB, V85, P2685, DOI 10.1210/jc.85.8.2685
   Chou SY, 2004, J HEALTH ECON, V23, P565, DOI 10.1016/j.jhealeco.2003.10.003
   Christakis DA, 2004, J PEDIATR-US, V145, P652, DOI 10.1016/j.jpeds.2004.06.078
   Clément K, 1998, NATURE, V392, P398, DOI 10.1038/32911
   Clement Karine, 2002, AM J PHARMACOGENOMICS, V2, P177, DOI 10.2165/00129785-200202030-00003
   Cochran RF, 2000, PEPP L REV, V27, P701
   Cogan JC, 1999, J SOC ISSUES, V55, P187, DOI 10.1111/0022-4537.00112
   Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66
   COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211
   Collin GB, 2002, NAT GENET, V31, P74, DOI 10.1038/ng867
   COMMUZZIE A, 1997, NAT GENET, V15, P1
   Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273
   CONNELLY M, 2003, NY TIMES 0513, V0, PF5
   Cooke LJ, 2004, PUBLIC HEALTH NUTR, V7, P295, DOI 10.1079/PHN2003527
   Coombes Rebecca, 2004, BRITISH MEDICAL JOURNAL, V328, P1572
   COOMBS R, 2001, TEX BAR J, V64, P166
   COOMBS R, 2001, TEX BAR J, V64, P171
   Crawford FranklinE, 2002, OHIO ST LJ, V63, P1165
   Crespo CJ, 2001, ARCH PEDIAT ADOL MED, V155, P360, DOI 10.1001/archpedi.155.3.360
   CULTER DM, 2003, EC PERSP, V17, P97
   Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714
   Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908
   CUPP RL, 1998, U KAN L REV, V46, P465
   Curtis KM, 1997, AM J EPIDEMIOL, V146, P32, DOI 10.1093/oxfordjournals.aje.a009189
   CUSTOMS JE, 2003, BMJ-BRIT MED J, V326, P326
   Cutler DM, 2003, J ECON PERSPECT, V17, P93, DOI 10.1257/089533003769204371
   CUTLER DM, 2003, 9446 NAT BUR EC RES, V0, P0
   Dabelea D, 2000, DIABETES, V49, P2208, DOI 10.2337/diabetes.49.12.2208
   Dansicker AndrewM, 2004, MD BJ, V37, P12
   Datar A, 2004, AM J PUBLIC HEALTH, V94, P1501, DOI 10.2105/AJPH.94.9.1501
   Davidson M, 2006, J ADV NURS, V54, P342, DOI 10.1111/j.1365-2648.2006.03812.x
   Davis C, 2004, APPETITE, V42, P131, DOI 10.1016/j.appet.2003.07.004
   DECASTRO JM, 1991, PHYSIOL BEHAV, V50, P729, DOI 10.1016/0031-9384(91)90010-L
   DECASTRO JM, 1993, PHYSIOL BEHAV, V53, P777, DOI 10.1016/0031-9384(93)90188-L
   DECASTRO JM, 1993, PHYSIOL BEHAV, V54, P633, DOI 10.1016/0031-9384(93)90070-V
   DeCastro JM, 1996, NEUROSCI BIOBEHAV R, V20, P119, DOI 10.1016/0149-7634(95)00047-I
   DECASTRO JM, 1995, PHYSIOL BEHAV, V57, P439, DOI 10.1016/0031-9384(94)00232-T
   DECASTRO JM, 1991, PHYSIOL BEHAV, V50, P243, DOI 10.1016/0031-9384(91)90527-U
   DECASTRO JM, 1989, AM J CLIN NUTR, V50, P237, DOI 10.1093/ajcn/50.2.237
   DECASTRO JM, 1994, PHYSIOL BEHAV, V56, P445, DOI 10.1016/0031-9384(94)90286-0
   Dennison BA, 2002, PEDIATRICS, V109, P1028, DOI 10.1542/peds.109.6.1028
   DERTHICK MA, 2002, SMOKE LEGISLATION LI, V0, P39
   Deshmukh R, 2003, CLEV CLIN J MED, V70, P614, DOI 10.3949/ccjm.70.7.614
   Deurenberg P, 1998, INT J OBESITY, V22, P1164, DOI 10.1038/sj/ijo/0800741
   DEVEREUX M, 2004, NZ HERALD 0717, V0, P0
   Dhurandhar NV, 2002, J NUTR, V132, P3155, DOI 10.1093/jn/131.10.3155
   Dietz WH, 1997, J NUTR, V127, PS1884, DOI 10.1093/jn/127.9.1884S
   DIETZ WH, 1985, PEDIATRICS, V75, P807
   DOLE VP, 1986, ALCOHOL CLIN EXP RES, V10, P361, DOI 10.1111/j.1530-0277.1986.tb05107.x
   Dorey G, 2001, BR J NURS, V10, P455
   DUENWALD M, 2005, NY TIMES 0816, V0, PF5
   Duggirala R, 1996, AM J HUM GENET, V59, P694
   DYR W, 1993, ALCOHOL, V10, P207, DOI 10.1016/0741-8329(93)90037-O
   DYRENFORTH SR, 1980, WOMANS CONFLICT SPEC, V0, P0
   EDELSTEIN EL, 1973, BRIT J ADDICT, V68, P365
   Eisenmann JC, 2002, OBES RES, V10, P379, DOI 10.1038/oby.2002.52
   Engell D, 1991, THIRST PHYSL PSYCHOL, V0, P382
   Epstein LH, 2000, ARCH PEDIAT ADOL MED, V154, P220, DOI 10.1001/archpedi.154.3.220
   Epstein LH, 2005, AM J CLIN NUTR, V81, P361
   Epstein RA, 2005, GEORGETOWN LAW J, V93, P1361
   Eyny YS, 2003, J NEUROSCI, V23, P1584
   Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200
   Faivre L, 2002, J MED GENET, V39, P594, DOI 10.1136/jmg.39.8.594
   Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0
   Farooqi IS, 2005, BEST PRACT RES CL EN, V19, P359, DOI 10.1016/j.beem.2005.04.004
   Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204
   Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050
   Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693
   Farrell SW, 2002, OBES RES, V10, P417, DOI 10.1038/oby.2002.58
   Fava M, 2000, J CLIN PSYCHIAT, V61, P863, DOI 10.4088/JCP.v61n1109
   Fava M, 2000, J CLIN PSYCHIAT, V61, P37
   FELDER RA, 1989, AM J PHYSIOL, V257, PF315, DOI 10.1152/ajprenal.1989.257.3.F315
   Feldman DE, 2003, ARCH PEDIAT ADOL MED, V157, P797, DOI 10.1001/archpedi.157.8.797
   Fernández JR, 2003, OBES RES, V11, P904, DOI 10.1038/oby.2003.124
   Field AE, 2004, INT J OBESITY, V28, P1210, DOI 10.1038/sj.ijo.0802762
   FIELD J, 1980, METABOLISM, V29, P296, DOI 10.1016/0026-0495(80)90072-4
   Firestone A, 2005, MED J AUSTRALIA, V182, P652, DOI 10.5694/j.1326-5377.2005.tb06860.x
   Flier JS, 1998, J CLIN ENDOCR METAB, V83, P1407, DOI 10.1210/jc.83.5.1407
   FLINT A, 2001, BOSTON GLOBE 1008, V0, PB2
   Flynn MC, 1999, PHYSIOL BEHAV, V65, P901
   Frank LD, 2004, AM J PREV MED, V27, P87, DOI 10.1016/j.amepre.2004.04.011
   FRENCH SA, 2001, ANNU REV PUBL HEALTH, V22, P319
   FRIEDMAN J, 2004, NAT MED, V10, P567
   Friedman JM, 2004, NAT MED, V10, P563, DOI 10.1038/nm0604-563
   Friedman JM, 2003, SCIENCE, V299, P856, DOI 10.1126/science.1079856
   Friedman SL, 2003, ARCH PEDIAT ADOL MED, V157, P185
   FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949
   GAESSER G, 2002, BIG FAT LIES TRUTH Y, V0, P75
   Gale SM, 2004, J NUTR, V134, P295, DOI 10.1093/jn/134.2.295
   Gardner E, 1997, SUBSTANCE ABUSE COMP, V0, P0
   GARDNER EL, 1999, ADDICTION ENTRIES EX, V0, P80
   GARDNER EL, 1999, ADDICTION ENTRIES EX, V0, P59
   GARN SM, 1986, AM J CLIN NUTR, V43, P879, DOI 10.1093/ajcn/43.6.879
   GARN SM, 1985, AM J DIS CHILD, V139, P181, DOI 10.1001/archpedi.1985.02140040083033
   GARNER DW, 1977, EMORY LAW J, V26, P269
   GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673
   GERACI C, 2004, EDITOR PUBLISHE 0524, V0, P0
   Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461
   GILLMAN MW, 2003, PEDIATRICS, V111, P3
   Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0
   GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1
   Glazer G, 2001, ARCH INTERN MED, V161, P1814, DOI 10.1001/archinte.161.15.1814
   GOLD M, 2003, PSYCHIAT ANN, V33, P118
   Gold MS, 2003, PSYCHIAT ANN, V33, P117, DOI 10.3928/0048-5713-20030201-08
   GONUL AS, 2004, YENI S, V42, P139
   GOODRICH K, 1999, DRUGS SOC, V15, P124
   Gordon CJ, 1993, TEMPERATURE REGULATI, V0, P0
   Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356, DOI 10.1001/archpedi.1996.02170290022003
   GRAHAM A, 1992, J CONTEMP PSYCHOTHER, V22, P28
   Graham A, 1992, JOURNAL OF CONTEMPORARY PSYCHOTHERAPY, V22, P21, DOI 10.1007/BF00952339
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   GRATTON A, 1994, J NEUROSCI, V14, P4130
   Gratton A, 1996, J PSYCHIATR NEUROSCI, V21, P264
   GRAY S, 2004, WALL ST J 1214, V0, PD1
   Greenway F, 2006, AM J PHYSIOL-REG I, V290, PR188, DOI 10.1152/ajpregu.00607.2005
   Guo SS, 2000, INT J OBESITY, V24, P1628, DOI 10.1038/sj.ijo.0801461
   Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980
   Halatchev IG, 2005, CELL METAB, V1, P159, DOI 10.1016/j.cmet.2005.02.003
   Haney M, 1997, PSYCHOPHARMACOLOGY, V132, P311, DOI 10.1007/s002130050350
   HARDY SC, 1994, J PEDIATR-US, V125, PS69, DOI 10.1016/S0022-3476(06)80739-0
   HARPER LV, 1975, J EXP CHILD PSYCHOL, V20, P206, DOI 10.1016/0022-0965(75)90098-3
   Havel PJ, 2002, CURR OPIN LIPIDOL, V13, P51, DOI 10.1097/00041433-200202000-00008
   Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194
   HEDIGER ML, 2004, JAMA-J AM MED ASSOC, V285, P2453
   Hellström PM, 2004, BRIT J NUTR, V92, PS47, DOI 10.1079/BJN20041142
   Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779
   Hernán MA, 2002, ANN NEUROL, V52, P276, DOI 10.1002/ana.10277
   HERNANDEZ L, 1990, BRAIN RES BULL, V25, P975, DOI 10.1016/0361-9230(90)90197-8
   HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1
   HILL JO, 2003, SCI, V301, P598
   HOEBEL BG, 1962, SCIENCE, V135, P375, DOI 10.1126/science.135.3501.375
   Holder JL, 2000, HUM MOL GENET, V9, P101
   Howard BV, 1997, CIRCULATION, V95, P2591, DOI 10.1161/01.CIR.95.11.2591
   Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655
   Hu FB, 2003, JAMA-J AM MED ASSOC, V289, P1785, DOI 10.1001/jama.289.14.1785
   *I MED, 2001, DIET REF INT, V0, P142
   *I MED, 2005, FOOD MARK CHILD YOUT, V0, P0
   IARC, 2002, IARC MON EV CARC RIS, V83, P0
   JAFF D, 2004, CAT POL FOR JUN 7, V0, P0
   Jensen CL, 2002, CLIN PERINATOL, V29, P261, DOI 10.1016/S0095-5108(02)00010-6
   Jéquier E, 1999, AM J CLIN NUTR, V69, P173
   JOHNS E, 2004, STAR TRIB 0209, V0, PA6
   JOHNSON SL, 1994, PEDIATRICS, V94, P653
   *KAIS FDN, 2000, ISS BRIEF ROL MED CH, V0, P0
   KALIVAS PW, 1993, J NEUROSCI, V13, P266
   KALRA SP, 1991, PHYSIOL BEHAV, V50, P5, DOI 10.1016/0031-9384(91)90490-F
   KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931
   Katsanis N, 2004, HUM MOL GENET, V13, PR65, DOI 10.1093/hmg/ddh092
   Katsanis N, 2001, HUM MOL GENET, V10, P2293, DOI 10.1093/hmg/10.20.2293
   Katsoulis S, 1996, SCAND J GASTROENTERO, V31, P446, DOI 10.3109/00365529609006763
   KATZENSTEIN AW, 1992, ENVIRON INT, V18, P341, DOI 10.1016/0160-4120(92)90064-B
   Kawachi I, 1999, J CLIN PSYCHIAT, V60, P5
   KEEFE KA, 1992, NEUROSCIENCE, V47, P325, DOI 10.1016/0306-4522(92)90248-Z
   KEESEY RE, 1984, EATING ITS DISORDERS, V0, P87
   Kelley AE, 2004, NEUROSCI BIOBEHAV R, V27, P765, DOI 10.1016/j.neubiorev.2003.11.015
   Kimm SYS, 2005, LANCET, V366, P301, DOI 10.1016/S0140-6736(05)66837-7
   Kimmel HL, 2002, NEUROPEPTIDES, V36, P9, DOI 10.1054/npep.2002.0884
   King C, 2001, NEW ENGL J MED, V345, P504, DOI 10.1056/NEJMsa003149
   Kleiner KD, 2004, J ADDICT DIS, V23, P105, DOI 10.1300/J069v23n03_08
   Koeppen-Schomerus G, 2001, INT J OBESITY, V25, P838, DOI 10.1038/sj.ijo.0801589
   Kojima M, 2005, PHYSIOL REV, V85, P495, DOI 10.1152/physrev.00012.2004
   KOOB GF, 1988, SCI, V4, P716
   Korner J, 2004, J CLIN ENDOCR METAB, V89, P2616, DOI 10.1210/jc.2004-0341
   KRAMER MS, 1985, J PEDIATR-US, V107, P104, DOI 10.1016/S0022-3476(85)80627-2
   Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94
   KRONDL M, 1982, J AM DIET ASSOC, V80, P523
   Kruk ZL, 1998, J NEUROSCI METH, V79, P9, DOI 10.1016/S0165-0270(97)00156-8
   KUNKEL D, 1992, J COMMUN, V42, P134, DOI 10.1111/j.1460-2466.1992.tb00803.x
   KWON HY, 1994, P NATL ACAD SCI USA, V91, P9760, DOI 10.1073/pnas.91.21.9760
   LAFETRA DJ, 2003, IND L REV, V36, P645
   LAKDAWALLA D, 2002, NBER WORKING PAPER, V8946, P2
   LAMARCHE B, 1992, METABOLISM, V41, P1249, DOI 10.1016/0026-0495(92)90017-5
   Lanza E, 2001, AM J CLIN NUTR, V74, P387
   Larsen TM, 2003, INT J OBESITY, V27, P147, DOI 10.1038/sj.ijo.802223
   Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973
   Lee CD, 1999, AM J CLIN NUTR, V69, P373
   LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001
   LEIBEL RL, 1990, WORLD REV NUTR DIET, V63, P90
   LEVINE HG, 1979, STUDIES ALCOHOL, V15, P493
   Levine JA, 2005, SCIENCE, V307, P584, DOI 10.1126/science.1106561
   Levine JA, 2003, P NUTR SOC, V62, P667, DOI 10.1079/PNS2003281
   Levine JA, 2002, BEST PRACT RES CL EN, V16, P679, DOI 10.1053/beem.2002.0227
   Levine James A, 1999, SCIENCE (WASHINGTON D C), V283, P212, DOI 10.1126/science.283.5399.212
   Lichtenstein AH, 1998, NUTR REV, V56, P0
   Lichtenstein AH, 2006, CIRCULATION, V114, P82, DOI 10.1161/CIRCULATIONAHA.106.176158
   Lipanovich A, 2005, GOLDEN GATE L REV, V35, P429
   Livingstone MBE, 2003, P NUTR SOC, V62, P681, DOI 10.1079/PNS2003291
   LONGMORE M, 2002, OXFORD HDB CLIN MED, V0, P232
   Lowinson JH, 1997, SUBSTANCE ABUSE COMP, V0, P0
   Lowry R, 2002, J SCHOOL HEALTH, V72, P413, DOI 10.1111/j.1746-1561.2002.tb03551.x
   LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0
   Ludwig DS, 2004, LANCET, V364, P226, DOI 10.1016/S0140-6736(04)16688-9
   MAGID B, 1995, J PSYCHOTHERAP PRAC, V4, P8
   Marchal-Victorion S, 2002, PHARMACOGENETICS, V12, P23, DOI 10.1097/00008571-200201000-00004
   MARGULES DL, 1962, SCIENCE, V135, P374, DOI 10.1126/science.135.3501.374
   Marlett GA, 1985, RELAPSE PREVENTION M, V0, P0
   Marshall SJ, 2004, INT J OBESITY, V28, P1238, DOI 10.1038/sj.ijo.0802706
   MARTIN M, 2003, CHICAGO TRIBUNE 1101, V0, P9
   Martínez-González MA, 1999, INT J OBESITY, V23, P1192, DOI 10.1038/sj.ijo.0801049
   Masuzaki Hiroaki, 2003, CURRENT DRUG TARGETS - IMMUNE ENDOCRINE AND METABOLIC DISORDERS, V3, P255
   Matson CA, 2000, AM J PHYSIOL-REG I, V278, PR882, DOI 10.1152/ajpregu.2000.278.4.R882
   MCCARTY MF, 1995, MED HYPOTHESES, V45, P193, DOI 10.1016/0306-9877(95)90068-3
   MELCHIOR JC, 1991, PHYSIOL BEHAV, V49, P1217, DOI 10.1016/0031-9384(91)90354-Q
   Mello MM, 2003, HEALTH AFFAIR, V22, P207, DOI 10.1377/hlthaff.22.6.207
   Mickleborough TD, 2006, CHEST, V129, P39, DOI 10.1378/chest.129.1.39
   MILLER NS, 1993, PSYCHIAT CLIN N AM, V16, P105
   Miltenberger RJ, 1997, J NUTR, V127, PS1902, DOI 10.1093/jn/127.9.1902S
   MITTENBERGER RJ, 1997, J NUTR, V127, P0
   Mogenson GJ, 1982, THE NEURAL BASIS OF FEEDING AND REWARD, V0, P275
   Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185
   Moore H, 1999, BIOL PSYCHIAT, V46, P40, DOI 10.1016/S0006-3223(99)00078-5
   MORRISEY S, 2004, ABA J EREPORT, V0, P11
   MORSE RM, 1992, JAMA-J AM MED ASSOC, V268, P1012, DOI 10.1001/jama.268.8.1012
   Moyad M A, 2001, SEMIN UROL ONCOL, V19, P247
   Munger LeeJ, 2004, CONN PUB INTL LJ, V3, P456
   MUNGER LJ, 2004, CONN PUB INT LJ, V3, P478
   Murphy KG, 2004, EXP PHYSIOL, V89, P507, DOI 10.1113/expphysiol.2004.027789
   Nagai K, 2003, EXP BIOL MED, V228, P1138, DOI 10.1177/153537020322801007
   Nagareda RA, 1998, MICH LAW REV, V96, P1121, DOI 10.2307/1290177
   *NCHS, 2001, PUB HLTH REP, V116, P274
   *NCHS, 2001, PUB HLTH REP, V116, P273
   NEEL JV, 1962, AM J HUM GENET, V14, P353
   Nemets H, 2006, AM J PSYCHIAT, V163, P1098, DOI 10.1176/appi.ajp.163.6.1098
   NETTER P, 1996, PLEASURE QUALITY LIF, V0, P84
   Nielsen Samara Joy, 2003, JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), V289, P450, DOI 10.1001/jama.289.4.450
   *NIH, 1998, NIH PUBL, V0, PR11
   NOBLE EP, 1994, INT J EAT DISORDER, V15, P205, DOI 10.1002/1098-108X(199404)15:3<205::AID-EAT2260150303>3.0.CO;2-P
   ORahilly S, 2003, ENDOCRINOLOGY, V144, P3757, DOI 10.1210/en.2003-0373
   Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861
   OLDS J, 1962, PHYSIOL REV, V42, P554, DOI 10.1152/physrev.1962.42.4.554
   OLDS ME, 1969, AM J PHYSIOL, V217, P1253, DOI 10.1152/ajplegacy.1969.217.5.1253
   OLIVER JE, 2006, FAT POLITICS REAL ST, V0, P133
   Ollmann MM, 1998, GENE DEV, V12, P316, DOI 10.1101/gad.12.3.316
   Olson RE, 2000, J AM DIET ASSOC, V100, P28, DOI 10.1016/S0002-8223(00)00012-2
   Oncken C, 2001, PSYCHOPHARMACOLOGY, V154, P397, DOI 10.1007/s002130000666
   Otsuka R, 2001, JAMA-J AM MED ASSOC, V286, P436, DOI 10.1001/jama.286.4.436
   OWEN DG, 2000, MADDEN OWEN PRODUCTS, V1, P0
   Paracchini V, 2005, AM J EPIDEMIOL, V162, P101, DOI 10.1093/aje/kwi174
   Peters J C, 2002, OBES REV, V3, P69, DOI 10.1046/j.1467-789X.2002.00059.x
   Phillips SM, 2004, OBES RES, V12, P461, DOI 10.1038/oby.2004.52
   Pietiläinen KH, 1999, INT J OBESITY, V23, P107, DOI 10.1038/sj.ijo.0800767
   Pinto-Sietsma SJ, 2000, ANN INTERN MED, V133, P585, DOI 10.7326/0003-4819-133-8-200010170-00008
   POLLOCK F, 1920, LAW TORTS, V0, P455
   Pool R, 2001, FAT: FIGHTING THE OBESITY EPIDEMIC, V0, P0
   PRENTICE AM, 1995, INT J OBESITY, V19, P0
   PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437
   Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629
   Price GM, 2006, AM J CLIN NUTR, V84, P449
   PRINGLE H, 2004, MEDIA WEEK 0116, V0, P0
   Proctor MH, 2003, INT J OBESITY, V27, P827, DOI 10.1038/sj.ijo.0802294
   PROSSER W, 1971, HDB LAW TORTS, V0, P240
   Putnam J, 1999, FOODREVIEW, V22, P2
   Raben A, 2003, AM J CLIN NUTR, V77, P91, DOI 10.1093/ajcn/77.1.91
   RABIN RL, 1992, STANFORD LAW REV, V44, P853, DOI 10.2307/1229002
   RADHAKISHUN FS, 1988, NEUROSCI LETT, V85, P351, DOI 10.1016/0304-3940(88)90591-5
   RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701
   RAVUSSIN E, 1992, LANCET, V340, P404, DOI 10.1016/0140-6736(92)91480-V
   Ravussin E, 1999, SCIENCE, V283, P184, DOI 10.1126/science.283.5399.184
   RAVUSSIN E, 1992, AMERICAN JOURNAL OF CLINICAL NUTRITION, V55, P242S, DOI 10.1093/ajcn/55.1.242s
   Ravussin E, 2002, ANN ENDOCRINOL-PARIS, V63, P96
   REAVAN G, 2000, SYNDROME 10 SILENT K, V0, P0
   REDD M, 1992, PHYSIOL BEHAV, V52, P749, DOI 10.1016/0031-9384(92)90409-U
   REPACE JL, 1990, RISK ANAL, V10, P27, DOI 10.1111/j.1539-6924.1990.tb01017.x
   RICE D, 1990, EC COST ALCOHOL DRUG, V0, P2
   ROBBINS TW, 1989, NEUROSCI BIOBEHAV R, V13, P155, DOI 10.1016/S0149-7634(89)80025-9
   Robbins TW, 1992, SEMIN NEUROSCI, V4, P119
   Robinson JP, 1997, TIME LIFE, V0, P0
   ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P411, DOI 10.1007/BF02247414
   Robinson TN, 2001, PEDIATR CLIN N AM, V48, P1017, DOI 10.1016/S0031-3955(05)70354-0
   Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561
   Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381
   ROGERS PJ, 1980, APPETITE, V1, P85
   Rogers PJ, 2000, PHARMACOL BIOCHEM BE, V66, P3, DOI 10.1016/S0091-3057(00)00197-0
   Rogers PJ, 1999, P NUTR SOC, V58, P59, DOI 10.1079/PNS19990009
   Rosenbaum M, 1988, ADV PEDIATR, V35, P73
   Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424
   Rosenbaum M, 1998, PEDIATRICS, V101, P525
   ROSENBLOOM M, 2005, TOXICITY VITAMIN, V0, P0
   ROSS GL, 2003, CIGARETTES WHAT WARN, V0, P0
   Rotimi C, 1997, GENET EPIDEMIOL, V14, P255, DOI 10.1002/(SICI)1098-2272(1997)14:3<255::AID-GEPI4>3.0.CO;2-4
   Rozin P, 1996, WHY WE EAT WHAT WE EAT: THE PSYCHOLOGY OF EATING, V0, PP233, DOI 10.1037/10291-009
   Sacks Oliver, 1998, THE MAN WHO MISTOOK HIS WIFE FOR A HAT, V0, P43
   Saelens BE, 2002, J DEV BEHAV PEDIATR, V23, P0, DOI 10.1097/00004703-200206000-00001
   Sainsbury A, 2002, BEST PRACT RES CL EN, V16, P623, DOI 10.1053/beem.2002.0230
   Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6
   Sakurai Y, 1997, EUR J EPIDEMIOL, V13, P893, DOI 10.1023/A:1007416322031
   Saleens BE, 2003, OBESITY, V0, P217
   SALLIS JF, 1993, CRIT REV FOOD SCI, V33, P403, DOI 10.1080/10408399309527639
   SALSBERRY PJ, 1900, P1329, V0, P0
   SANJUR D, 1982, SOCIAL CULTURAL PERS, V0, P336
   Saris WHM, 2003, CURR OPIN CLIN NUTR, V6, P609, DOI 10.1097/00075197-200311000-00001
   SCHAEF AW, 1987, SOC BECOMES ADDICT, V0, P18
   SCHARF I, 1995, HOUS L REV, V32, P615
   Schousboe K, 2003, TWIN RES, V6, P409, DOI 10.1375/twin.6.5.409
   SCHULTZ SG, 1998, ESSENTIAL MED PHYSL, V0, P0
   SCHWARTZ A, 1989, VA LAW REV, V75, P509, DOI 10.2307/1073251
   Schwartz MW, 2003, DIABETES, V52, P232, DOI 10.2337/diabetes.52.2.232
   Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534
   SEBOK AJ, 2002, BIF FAT CLASS ACTION, V0, P0
   Segal-Lieberman G, 2003, P NATL ACAD SCI USA, V100, P10085, DOI 10.1073/pnas.1633636100
   SEID R, 1989, NEVER TOO LATE, V0, P0
   SEIDMAN DS, 1991, AM J DIS CHILD, V145, P782
   Shell ER, 2002, THE HUNGRY GENE: THE SCIENCE OF FAT AND THE FUTURE OF THIN, V0, P0
   SHLAES A, 2002, CHICAGO TRIBUNE 1127, V0, P25
   SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2
   Smith GP, 1992, MULTIPLE CHOLECYSTOK, V0, P166
   Smith H E, 1985, TOP EMERG MED, V7, P69
   SMITH L, 2005, LONDON TIMES 1217, V0, P0
   SMITH L, 2005, TIMES LONDON 1217, V0, P0
   Snitker S, 2001, INT J OBESITY, V25, P1481, DOI 10.1038/sj.ijo.0801746
   Snyder EE, 2004, OBES RES, V12, P369, DOI 10.1038/oby.2004.47
   Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699
   SORENSEN TIA, 1995, METABOLISM, V44, P4, DOI 10.1016/0026-0495(95)90310-0
   Spiegel K, 2004, ANN INTERN MED, V141, P846, DOI 10.7326/0003-4819-141-11-200412070-00008
   SPITZER R, 1980, COMPREHENSIVE TXB PS, V3, P1053
   STEIGER WR, 2004, COMMUNICATION 0105, V0, P0
   Stein WE, 1999, APPL STOCH MODEL BUS, V15, P103, DOI 10.1002/(SICI)1526-4025(199904/06)15:2<103::AID-ASMB369>3.0.CO;2-C
   STERN JS, 1972, LANCET, V2, P948
   Stettler N, 2004, OBES RES, V12, P896, DOI 10.1038/oby.2004.109
   Stettler N, 2002, PEDIATRICS, V109, P194, DOI 10.1542/peds.109.2.194
   Strauss RS, 1997, J PEDIATR-US, V130, P95, DOI 10.1016/S0022-3476(97)70316-0
   Strauss RS, 2001, ARCH PEDIAT ADOL MED, V155, P897, DOI 10.1001/archpedi.155.8.897
   Stricker EM, 2000, NUTRITION, V16, P821, DOI 10.1016/S0899-9007(00)00412-3
   STROBEL A, 1999, NAT GENET, V18, P213
   Strong WB, 2005, J PEDIATR-US, V146, P732, DOI 10.1016/j.jpeds.2005.01.055
   STUNKARD AJ, 1986, JAMA-J AM MED ASSOC, V256, P51, DOI 10.1001/jama.256.1.51
   STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401
   STUNKARD AJ, 1959, PSYCHIAT QUART, V33, P284, DOI 10.1007/BF01575455
   STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102
   SUNSTEIN CR, 1986, U CHICAGO LAW REV, V53, P1129, DOI 10.2307/1599746
   SUNSTEIN CR, 1986, U CHICAGO LAW REV, V53, P1159
   SUTHERLAND L, 2003, FED AM SOC EXP BIOL, V0, P0
   SWANSON DW, 1970, ARCH GEN PSYCHIAT, V22, P120
   Swinburn BA, 2004, PUBLIC HEALTH NUTR, V7, P123, DOI 10.1079/PHN2003585
   Taber MT, 1997, NEUROSCIENCE, V76, P1105, DOI 10.1016/S0306-4522(96)00450-2
   Taheri S, 2004, PLOS MED, V1, P210, DOI 10.1371/journal.pmed.0010062
   Talamini R, 2005, INT J CANCER, V115, P606, DOI 10.1002/ijc.20891
   TANGCHRISTENSEN M, 2003, P 85 ANN M END SOC P, V497, P93
   Tapson Victor F, 2005, PROC AM THORAC SOC, V2, P71, DOI 10.1513/pats.200407-038MS
   Taubes G, 2001, SCIENCE, V291, P2536, DOI 10.1126/science.291.5513.2536
   Taylor DM, 2000, ACTA PSYCHIAT SCAND, V101, P416, DOI 10.1034/j.1600-0447.2000.101006416.x
   THOMPSON PDR, 2005, PHYS DESK REFERENCE, V0, P1746
   Tidey JW, 1997, PSYCHOPHARMACOLOGY, V130, P203, DOI 10.1007/s002130050230
   TOCOPHEROL A, 1994, NEW ENGL J MED, V330, P1029
   Troiano RP, 2000, AM J CLIN NUTR, V72, P1343S, DOI 10.1093/ajcn/72.5.1343s
   Tschöp M, 2000, NATURE, V407, P908, DOI 10.1038/35038090
   TSCHOP M, 2000, J ENDOCRINOL INVEST, V24, P19
   Turley J, 2000, HARVARD J LEGIS, V37, P433
   *U MAR SCH LAW REG, 2003, TOBACCO REG REV, V2, P616
   Uauy R, 2000, AM J CLIN NUTR, V72, P1354S, DOI 10.1093/ajcn/72.5.1354s
   Utter J, 2003, J AM DIET ASSOC, V103, P1298, DOI 10.1016/S0002-8223(03)01079-4
   van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029
   VANDALL FJ, 1999, VILL J REV, V44, P558
   Vandall FrankJ, 1999, VILLANOVA LAW REV, V44, P547
   VANHAASTEREN GAC, 1995, J ENDOCRINOL, V145, P143, DOI 10.1677/joe.0.1450143
   VARIYAM JN, 2001, FOOD REV MAY, V0, P18
   VARIYAM JN, 2001, FOOD REV MAY, V0, P20
   Velasco M, 1998, AM J THER, V5, P37, DOI 10.1097/00045391-199801000-00007
   Vereecken CA, 2004, APPETITE, V43, P93, DOI 10.1016/j.appet.2004.04.002
   von Kries R, 1999, BRIT MED J, V319, P147, DOI 10.1136/bmj.319.7203.147
   WALLACE L, 1987, ARCH ENVIRON HEALTH, V42, P272, DOI 10.1080/00039896.1987.9935820
   Wang GJ, 2004, NEUROIMAGE, V21, P1790, DOI 10.1016/j.neuroimage.2003.11.026
   Wannamethee SG, 2003, AM J CLIN NUTR, V77, P1312, DOI 10.1093/ajcn/77.5.1312
   Wardle J, 2003, EUR J CLIN NUTR, V57, P341, DOI 10.1038/sj.ejcn.1601541
   WEIGLE D, 2002, SCI, V88, P2462
   WELSH MJ, 1978, J CLIN INVEST, V61, P708, DOI 10.1172/JCI108983
   Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301
   Whitaker RC, 1998, J PEDIATR-US, V132, P768, DOI 10.1016/S0022-3476(98)70302-6
   Whitaker RC, 1998, PEDIATRICS, V101, P0, DOI 10.1542/peds.101.2.e9
   WHITEAKER RC, 1996, OESS RES, V4, P215
   *WHO, 2002, OB PREV MAN GLOB EP, V0, P116
   *WHO, 2006, WHO TECHN REP SER, V916, P0
   *WHO IARC, 1986, IARC MON, V38, P421
   Widdowson PS, 1997, BRAIN RES, V774, P1, DOI 10.1016/S0006-8993(97)81680-0
   Wightman RM, 1996, SOCIETY FOR NEUROSCIENCE ABSTRACTS, V22, P832
   WILDING JPH, 1992, J ENDOCRINOL, V132, P299, DOI 10.1677/joe.0.1320299
   Williams G, 2000, P NUTR SOC, V59, P385, DOI 10.1017/S0029665100000434
   Wilmore J H, 1994, PHYSIOLOGY OF SPORTS AND EXERCISE, V0, P0
   WILMORE JH, 2004, PRESIDENTS COUNCIL P, V0, P0
   WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223
   WILSON GT, 1991, ADV BEHAV RES THER, V13, P27, DOI 10.1016/0146-6402(91)90013-Z
   WOO R, 1982, AM J CLIN NUTR, V36, P470, DOI 10.1093/ajcn/36.3.470
   WOODS SC, 1991, PSYCHOL REV, V98, P488, DOI 10.1037/0033-295X.98.4.488
   Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378
   Woods SC, 1996, NEUROSCI BIOBEHAV R, V20, P139, DOI 10.1016/0149-7634(95)00044-F
   Wortley KE, 2004, REGUL PEPTIDES, V117, P89, DOI 10.1016/j.regpep.2003.08.005
   YEARY J, 1987, J PSYCHOACTIVE DRUGS, V19, P303, DOI 10.1080/02791072.1987.10472417
   Yeomans MR, 1996, PHYSIOL BEHAV, V60, P439, DOI 10.1016/S0031-9384(96)80017-5
   Yeomans MR, 2002, NEUROSCI BIOBEHAV R, V26, P713, DOI 10.1016/S0149-7634(02)00041-6
   Yeomans MR, 2003, CURR OPIN CLIN NUTR, V6, P639, DOI 10.1097/00075197-200311000-00006
   YEOMANS MR, 2003, CURR OPIN NUTR METAB, V6, P640
   YEOMANS MR, 2003, CURR OPIN NUTR METAB, V6, P641
   York D, 2000, ENDOCRINE, V13, P143, DOI 10.1385/ENDO:13:2:143
   YOSHIDA M, 1992, NEUROSCI LETT, V139, P73, DOI 10.1016/0304-3940(92)90861-Z
   YOUNG AMJ, 1992, NEUROSCIENCE, V48, P871, DOI 10.1016/0306-4522(92)90275-7
   Young B, 1996, ROLE TELEVISION ADVE, V0, P0
   Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5
   Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255
   Zhang M, 1998, J PHARMACOL EXP THER, V285, P908
   ZHANG M, 1998, J PHARM EXPT THERAPE, V285, P914
   ZURLO F, 1990, AM J PHYSIOL, V259, P0
   ZYWICKI TJ, 2004, GEO MASON L REV, V12, P1000
   1998, 1900, V29, V0, P699
   2004, 1900, V328, V0, P1572
   1998, 1900, V29, V0, P700
   2006, 1900, PR8, V0, P0
   ABELIN T, 1989, LANCET, V1, P7
   ABRAHAM SF, 1982, PSYCHOL MED, V12, P625, DOI 10.1017/S0033291700055732
   alAbsi M, 2002, PHARMACOL BIOCHEM BE, V72, P707, DOI 10.1016/S0091-3057(02)00739-6
   Ärnlöv J, 2004, JAMA-J AM MED ASSOC, V291, P1199, DOI 10.1001/jama.291.10.1199-b
   ATKINSON RL, 1985, CLIN PHARMACOL THER, V38, P419, DOI 10.1038/clpt.1985.197
   Baird J Kevin, 2002, METHODS MOL MED, V72, P13, DOI 10.1385/1-59259-271-6:13
   Baldessarini R, 1996, GOODMAN AND GILMANS THE PHARMACOLOGICAL OF THE THERAPEUTICS, V9th, P431
   BANZHAF J, 2002, SAN FRANCISCO D 0104, V0, P0
   Baptista T, 1999, ACTA PSYCHIAT SCAND, V100, P3, DOI 10.1111/j.1600-0447.1999.tb10908.x
   BAPTISTA T, 1998, NEUROSCI ANN M, V24, P706
   BARNARD N, 2003, BREAKING FOOD SEDUCT, V0, P51
   Benowitz NL, 1999, PRIMARY CARE, V26, P611, DOI 10.1016/S0095-4543(05)70120-2
   BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303
   BERKEN GH, 1984, J AFFECT DISORDERS, V7, P133, DOI 10.1016/0165-0327(84)90031-4
   BLASS EM, 1989, ANN NY ACAD SCI, V575, P292, DOI 10.1111/j.1749-6632.1989.tb53251.x
   BORYS DJ, 1988, VET HUM TOXICOL, V30, P20
   BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81
   BRESLAU N, 1993, ARCH GEN PSYCHIAT, V50, P31
   Carchman SH, 1996, FOOD DRUG LAW J, V51, P85
   CARTER WR, 1984, SOC BEHAV MED, V0, P40
   *CDC, 1995, MMWR-MORBID MORTAL W, V44, P830
   COHAN JA, 2003, WIDENER LJ, V12, P116
   Cohan JohnAlan, 2003, WIDENER LJ, V12, P103
   Cooper SJ, 1988, ENDORPHINS OPIATES B, V0, P143
   Corcos M, 2000, ANN MED INTERNE, V151, P0
   Croft H, 1999, CLIN THER, V21, P643, DOI 10.1016/S0149-2918(00)88317-4
   Dani JA, 2005, NAT NEUROSCI, V8, P1465, DOI 10.1038/nn1580
   Davis C, 1998, ADDICT BEHAV, V23, P463, DOI 10.1016/S0306-4603(98)00009-4
   DAVIS WM, 2006, DRUG TOPICS 0418, V0, P128
   DAWBER TR, 1974, NEW ENGL J MED, V291, P871, DOI 10.1056/NEJM197410242911703
   *DHHS, 1988, DHH PUBL, V0, P0
   diTomaso E, 1996, NATURE, V382, P677, DOI 10.1038/382677a0
   DJORDJEVIC MV, 1995, CARCINOGENESIS, V16, P2627, DOI 10.1093/carcin/16.11.2627
   DREWNOWSKI A, 1992, PHYSIOL BEHAV, V51, P371, DOI 10.1016/0031-9384(92)90155-U
   Drewnowski A, 1997, ANNU REV NUTR, V17, P237, DOI 10.1146/annurev.nutr.17.1.237
   DREWNOWSKI A, 1987, AM J CLIN NUTR, V46, P703, DOI 10.1093/ajcn/46.4.703
   DREWNOWSKI A, 1995, AM J CLIN NUTR, V61, P1206, DOI 10.1093/ajcn/61.6.1206
   DREWNOWSKI A, 1990, ANN NY ACAD SCI, V575, P99
   Fairburn Christopher G, 1993, P317, V0, P0
   FERNO O, 1977, DHEW PUB, V0, P0
   Fingarette H, 1998, HEAVY DRINKING, V0, P0
   Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244
   FOLTIN W, 1990, PHARM BIOCH BEHAV, V36, P873
   FOULDS J, 1992, PSYCHOPHARMACOLOGY, V106, P421, DOI 10.1007/BF02245429
   GARLAND EJ, 1988, J CLIN PSYCHOPHARM, V8, P323
   GARVEY AJ, 1992, ADDICT BEHAV, V17, P367, DOI 10.1016/0306-4603(92)90042-T
   Gattellari M, 1997, INT J EAT DISORDER, V21, P377, DOI 10.1002/(SICI)1098-108X(1997)21:4<377::AID-EAT11>3.0.CO;2-W
   Gibson EL, 1999, APPETITE, V32, P219, DOI 10.1006/appe.1998.0207
   Glassman AH, 1996, NATURE, V379, P677, DOI 10.1038/379677a0
   Goffman E, 1961, ASYLUMS: ESSAYS ON THE SOCIAL SITUATION OF MENTAL PATIENTS AND OTHER INMATES, V0, P0, DOI DOI 10.4324/9781351327763
   GOLDFEIN JA, 1993, INT J EAT DISORDER, V14, P427, DOI 10.1002/1098-108X(199312)14:4<427::AID-EAT2260140405>3.0.CO;2-H
   GOLDSTEIN A, 1965, J PHARMACOL EXP THER, V150, P146
   Gonzalez VMM, 2004, APPETITE, V43, P155, DOI 10.1016/j.appet.2004.03.006
   GREDEN JF, 1974, AM J PSYCHIAT, V131, P1089
   GRIFFITHS RR, 1986, J EXP ANAL BEHAV, V45, P133, DOI 10.1901/jeab.1986.45-133
   GRIFFITHS RR, 1976, PSYCHOPHARMACOLOGY, V50, P251, DOI 10.1007/BF00426841
   GRIFFITHS RR, 1988, PHARMACOL BIOCHEM BE, V29, P419, DOI 10.1016/0091-3057(88)90180-3
   GRIFFITHS RR, 1986, J PHARMACOL EXP THER, V239, P416
   GRIFFITHS RR, 2003, PRINCIPLES ADDICTION, V0, P194
   GROTTA JC, 2003, STROKE, V34, P1242
   GRUNBERG N, 1999, BROWN U DIGEST ADDIC, V18, P0
   HARRIE JR, 1970, J AMER MED ASSOC, V213, P628, DOI 10.1001/jama.1970.03170300072029
   Heishman S J, 1999, NICOTINE TOB RES, V1 Suppl 2, P0
   HEISHMAN SJ, 1994, PHARMACOPSYCHOECOLOG, V7, P127
   Henningfield Jack E, 1995, P1715, V0, P0
   HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T
   HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743
   HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI 10.1056/NEJM199511023331807
   Henningfield JE, 1998, FOOD DRUG LAW J, V53, P75
   HEPPNER CC, 1986, PHARMACOL BIOCHEM BE, V24, P1555, DOI 10.1016/0091-3057(86)90484-3
   HETHERINGTON MM, 1991, PHARMACOL BIOCHEM BE, V40, P185, DOI 10.1016/0091-3057(91)90343-Z
   HETHERINGTON MM, 1993, APPETITE, V21, P233, DOI 10.1006/appe.1993.1042
   HETHERINGTON MM, 1991, APPETITE, V17, P199
   Heubner HF, 1993, ENDORPHINS, V0, P0
   *HHS, 1988, HLTH CONS SMOK NIC A, V0, P11
   Hughes J, 1994, DSM 4 SOURCEBOOK, V0, P129
   HUGHES JR, 1992, AM J PSYCHIAT, V149, P33
   Hughes JR, 1999, JAMA-J AM MED ASSOC, V281, P72, DOI 10.1001/jama.281.1.72
   HUGHES JR, 1984, JAMA-J AM MED ASSOC, V252, P2855, DOI 10.1001/jama.252.20.2855
   HUGHES JR, 1994, ADDICTION, V89, P1461, DOI 10.1111/j.1360-0443.1994.tb03744.x
   HUGHES JR, 1999, JAMA-J AM MED ASSOC, V281, P75
   HUGHES JR, 1990, RECENT ADV ALCOHOL D, V0, P10
   HURST WJ, 1981, ANALYST, V106, P394, DOI 10.1039/an9810600394
   HURST WJ, 1982, NUTR REP INT, V26, P1081
   Ibanez Angela, 2003, J GAMBL STUD, V19, P11, DOI 10.1023/A:1021271029163
   JARVIS MJ, 1991, HDB ADDICTION BEHAV, V0, P97
   KALES EF, 1990, PHYSIOL BEHAV, V48, P837, DOI 10.1016/0031-9384(90)90236-W
   KAROUM F, 1979, J NEUROCHEM, V33, P201, DOI 10.1111/j.1471-4159.1979.tb11722.x
   Kelder GrahamE, 1997, STAN L POLY REV, V8, P63
   Kessler DA, 1996, NEW ENGL J MED, V335, P988, DOI 10.1056/NEJM199609263351321
   KOZLOWSKI LT, 1976, NATURE, V264, P354, DOI 10.1038/264354a0
   LAVOIE F W, 1991, JOURNAL OF EMERGENCY MEDICINE, V9, P133, DOI 10.1016/0736-4679(91)90318-A
   LONDON WM, 2000, PRIORITIES HLTH, V12, P11
   Lopez-Garcia E, 2006, CIRCULATION, V113, P2045, DOI 10.1161/CIRCULATIONAHA.105.598664
   MACDIARMID JI, 1995, BRIT J CLIN PSYCHOL, V34, P129, DOI 10.1111/j.2044-8260.1995.tb01445.x
   MALCOLM R, 1985, INT J OBESITY, V9, P347
   Marley E, 1970, ADV PHARMACOL CHEMOTHER, V8, P185
   MARRAZZI MA, 1986, INT J EAT DISORDER, V5, P191, DOI 10.1002/1098-108X(198602)5:2<191::AID-EAT2260050202>3.0.CO;2-I
   MARX V, 1973, LANCET, V301, P827
   MAX B, 1900, V10, V0, P390
   McNaughton L R, 1986, BR J SPORTS MED, V20, P109
   Meier Benjamin Mason, 2005, YALE J HEALTH POLICY LAW ETHICS, V5, P137
   MERTINO M, 1991, AM J PHYSIOL, V261, P59
   MICHENER W, 1994, PHYSIOL BEHAV, V56, P419, DOI 10.1016/0031-9384(94)90283-6
   MITCHELL JE, 1987, BIOL PSYCHIAT, V22, P35, DOI 10.1016/0006-3223(87)90127-2
   MONALTO NK, 1994, AM BD FAM PRACT, V7, P417
   NESBITT PD, 1973, J PERS SOC PSYCHOL, V25, P137, DOI 10.1037/h0034256
   PARROTT AC, 1995, INT J ADDICT, V30, P1509, DOI 10.3109/10826089509055846
   Parrott AC, 1998, ADDICTION, V93, P27, DOI 10.1046/j.1360-0443.1998.931274.x
   PARROTT AC, 1994, PSYCHOPHARMACOLOGY, V115, P389, DOI 10.1007/BF02245082
   Patton GC, 1998, AM J PUBLIC HEALTH, V88, P1518, DOI 10.2105/AJPH.88.10.1518
   PEELE G, 1989, DIS AM, V0, P79
   PERKINS KA, 1992, CLIN PHARMACOL THER, V52, P627, DOI 10.1038/clpt.1992.201
   PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61
   RABIN RL, 2001, REGULATING TOBACCO, V0, P201
   REIMANN HA, 1967, JAMA-J AM MED ASSOC, V202, P131
   RUSSELL M, 1995, WORLD HLTH F, V16, P19
   RUSSELL M, 1995, WORLD HLTH F, V16, P20
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   SAXENA K, 1985, VET HUM TOXICOL, V27, P495
   Schroeter H, 2006, P NATL ACAD SCI USA, V103, P1024, DOI 10.1073/pnas.0510168103
   SCHUSTER, 1969, ABUSE CENTRAL STIMUL, V0, P339
   SHERWOOD N, 1993, HUM PSYCHOPHARM CLIN, V8, P155, DOI 10.1002/hup.470080303
   Singh T K, 2003, COMPR REV FOOD SCI FOOD SAF, V2, P166, DOI 10.1111/j.1541-4337.2003.tb00021.x
   SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225
   STERN KN, 1989, PSYCHOPHARMACOLOGY, V98, P81, DOI 10.1007/BF00442010
   Sussman S, 1999, SUBST USE MISUSE, V34, P1469, DOI 10.3109/10826089909039411
   THOMAS A, 1992, US PHARM S, V0, P1
   THOMPSON WG, 1994, AM J MED SCI, V308, P49, DOI 10.1097/00000441-199407000-00011
   TONNESEN P, 1993, JAMA-J AM MED ASSOC, V269, P1268, DOI 10.1001/jama.269.10.1268
   Trotzky Arthur S, 2002, INT J ADOLESC MED HEALTH, V14, P269
   TURNER MS, 1991, PSYCHOL MED, V21, P123, DOI 10.1017/S0033291700014719
   VANDEREYCKEN W, 1990, INT J EAT DISORDER, V9, P95, DOI 10.1002/1098-108X(199001)9:1<95::AID-EAT2260090111>3.0.CO;2-Z
   VELEBER DM, 1984, J ABNORM PSYCHOL, V93, P120, DOI 10.1037/0021-843X.93.1.120
   Woolf A, 1997, PEDIATRICS, V99, Part. no., DOI 10.1542/peds.99.5.e4
   Yancey AK, 2006, OBESITY, V14, P980, DOI 10.1038/oby.2006.112
   YANOVSKI SZ, 1992, AM J CLIN NUTR, V56, P975, DOI 10.1093/ajcn/56.6.975
   YEOMANS MR, 1990, PSYCHOPHARMACOLOGY, V100, P426, DOI 10.1007/BF02244618
   ZIMMERS T, 1994, AM J EMERG MED, V12, P374, DOI 10.1016/0735-6757(94)90164-3
NR 641
TC 6
Z9 6
U1 0
U2 6
PU FOOD DRUG LAW INST
PI WASHINGTON
PA 1000 VERMONT AVE NW, SUITE 1200, WASHINGTON, DC 20005-4903 USA
SN 1064-590X
EI 
J9 FOOD DRUG LAW J
JI Food Drug Law J.
PD JUN 15
PY 2006
VL 61
IS 3
BP 445
EP 518
DI 
PG 74
WC Food Science & Technology; Law; Nutrition & Dietetics; Pharmacology & Pharmacy
SC Food Science & Technology; Government & Law; Nutrition & Dietetics; Pharmacology & Pharmacy
GA 085KJ
UT WOS:000240602700002
PM 16989036
DA 2025-04-28
ER

PT J
AU Opala, T
   Rzymski, P
   Pischel, I
   Wilczak, M
   Wozniak, J
AF Opala, T.
   Rzymski, P.
   Pischel, I.
   Wilczak, M.
   Wozniak, J.
TI Efficacy of 12 weeks supplementation of a botanical extract-based weight loss formula on body weight, body composition and blood chemistry in healthy, overweight subjects - A randomised double-blind placebo-controlled clinical trial
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE dietary supplement; weight reduction; obesity; body composition
ID energy-expenditure; fat oxidation; food-intake; obesity; orlistat; (-)-hydroxycitrate; triglycerides; caffeine; satiety; humans
AB Objective: The aim of this study was to evaluate the efficacy and safety of composite extracts in reducing weight, as the main outcome measure. Secondary measures of the study were body composition change. Design: Randomised, double blind, placebo-controlled clinical trial. Setting: Tertiary university clinic. Subjects: hundred and five subjects, 5 of them withdrawn consent, 2 drop-outs not related to study preparation. Intervention: two tablet per meal concept supposed to generate a "psychological" therapy-like approach during 12 weeks supported by measured physical activity. The tablets 1 (one hour before meals, comprises extracts of Asparagus, Green tea, Black tea, Guarana, Mate and Kidney beans) and 2 (taken half an hour after meals, comprises extracts of Kidney bean pods, Garcinia cambogia, and Chromium yeast) are taken twice daily with two main meals. Results: A significant change of the Body Composition Improvement Index (BCI) was observed in the active extract group compared to placebo (p = 0.012). Weight, BMI, waist-to-hip ratio was not statistically different between groups. Body fat loss was greater in active group (p = 0.011) compared to placebo. A weight loss parameter corrected for exercise was introduced and found to be higher in active group (p = 0.046) than in placebo, meaning that the formula was more efficacious, due to a concurrently performed exercise program - a recommended strategy for life style modification. Conclusions: A significant change of the Body Composition Improvement Index and the decrease in body fat was statistically significant in active extract subjects compared to placebo. A change in some outcome measures like: weight, BMI failed to produce significant difference between groups.
C1 Poznan Univ Med Sci, Dept Mothers & Childs Hlth, Poznan, Poland.
   Finzelberg GmbH & Co KG, Andernach, Germany.
   Poznan Univ Med Sci, Dept Educ Med, Poznan, Poland.
C3 Poznan University of Medical Sciences; Poznan University of Medical Sciences
RP Rzymski, P (corresponding author), Poznan Univ Med Sci, Dept Mothers & Childs Hlth, Polna St 33, Poznan, Poland.
EM parzymsk@gpsk.am.poznan.pl
CR Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   Campbell ML, 2001, AM J HEALTH-SYST PH, V58, P1301, DOI 10.1093/ajhp/58.14.1301
   Chanoine JP, 2005, JAMA-J AM MED ASSOC, V293, P2873, DOI 10.1001/jama.293.23.2873
   Coffey CS, 2004, INT J OBESITY, V28, P1411, DOI 10.1038/sj.ijo.0802784
   Colak R, 2004, PHYSIOL RES, V53, P53, DOI 10.33549/physiolres.930279
   Doucet E, 1997, EUR J CLIN NUTR, V51, P846, DOI 10.1038/sj.ejcn.1600497
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581
   Greenway F L, 2001, OBES REV, V2, P199, DOI 10.1046/j.1467-789x.2001.00038.x
   Heymsfield SB, 1998, JAMA-J AM MED ASSOC, V280, P1596, DOI 10.1001/jama.280.18.1596
   Juhel C, 2000, J NUTR BIOCHEM, V11, P45, DOI 10.1016/S0955-2863(99)00070-4
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Kelley DE, 2004, DIABETES CARE, V27, P33, DOI 10.2337/diacare.27.1.33
   Koukiekolo R, 1999, EUR J BIOCHEM, V265, P20, DOI 10.1046/j.1432-1327.1999.00611.x
   Kovacs EMR, 2001, INT J OBESITY, V25, P1087, DOI 10.1038/sj.ijo.0801605
   LEBERREANTON V, 1900, V93, V0, P131
   Lenz Thomas L, 2004, J AM PHARM ASSOC (2003), V44, P59, DOI 10.1331/154434504322713246
   Mathus-Vliegen E M, 1998, NED TIJDSCHR GENEESKD, V142, P1982
   Moro CO, 2000, FITOTERAPIA, V71, PS73, DOI 10.1016/S0367-326X(00)00177-5
   Pittler MH, 2004, AM J CLIN NUTR, V79, P529
   Pittler MH, 2003, INT J OBESITY, V27, P522, DOI 10.1038/sj.ijo.0802262
   Rippe JM, 1998, J AM DIET ASSOC, V98, PS9, DOI 10.1016/S0002-8223(98)00704-4
   Soni MG, 2004, FOOD CHEM TOXICOL, V42, P1513, DOI 10.1016/j.fct.2004.04.014
   Westerterp-Plantenga M, 2002, INT J OBESITY, V26, P870, DOI 10.1038/sj.ijo.0801979
NR 25
TC 48
Z9 51
U1 0
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD AUG 30
PY 2006
VL 11
IS 8
BP 343
EP 350
DI 
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 087FR
UT WOS:000240728800005
PM 17052970
DA 2025-04-28
ER

PT J
AU Takebayashi, J
   Kubo, K
   Saeki, A
   Saito, M
AF Takebayashi, Jun
   Kubo, Kazuhiro
   Saeki, Akiko
   Saito, Morio
TI Effect of Citrus aurantium combined with caffeine and/or tea catechins on body fat accumulation and its safety in rats
SO JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
LA English
DT Article
DE Citrus aurantium; caffeine; tea catechins; body fat accumulation; safety
ID ephedra-free; green tea; synephrine stereoisomers; garcinia-cambogia; overweight; octopamine; diet; polyphenols; supplement; oxidation
AB We investigated the weight loss efficacy and safety of Citrus aurantium (CA, 1,000 mg/kg diet) along with usual levels of adrenergic stimulants in foods, i.e. caffeine (100 mg/kg diet) and/or tea catechins (500 mg/kg diet), in rats for 44 or 45 days. Even in combination with caffeine and tea catechins, the suppressive effect of CA against body fat accumulation was negligible, whereas no deleterious influences concerning cardiotoxicity were observed. Thus, although the efficacy of CA for weight loss seems to be questionable, no safety problems may occur even in people who habitually consume coffee and tea. However, it is noteworthy that the intake of CA markedly elevated the urinary excretion of adrenaline, and this was not affected by intake of caffeine and/or tea catechins at the usual levels. Therefore, the safety of CA intake with high levels of caffeine and tea catechins, especially in people at risk of heart disease, remains to be elucidated further.
C1 Natl Inst Hlth & Nutrit, Div Food Sci, Incorporated Adm Agcy, Shinjuku Ku, Tokyo 1628636, Japan.
C3 National Institute of Health & Nutrition - Japan
RP Kubo, K (corresponding author), Natl Inst Hlth & Nutrit, Div Food Sci, Incorporated Adm Agcy, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.
EM msaito@nih.go.jp
CR Armstrong WJ, 2001, JOURNAL OF EXERCISE PHYSIOLOGY ONLINE, V4, P28
   Behonick GS, 2001, J APPL TOXICOL, V21, PS15, DOI 10.1002/jat.793
   Bouchard NC, 2005, MAYO CLIN PROC, V80, P541, DOI 10.4065/80.4.541
   BROWN CM, 1988, BRIT J PHARMACOL, V93, P417, DOI 10.1111/j.1476-5381.1988.tb11449.x
   Calapai G, 1999, FITOTERAPIA, V70, P586, DOI 10.1016/S0367-326X(99)00093-3
   Carpéné C, 1999, N-S ARCH PHARMACOL, V359, P310, DOI 10.1007/PL00005357
   Colker CM, 1999, CURR THER RES CLIN E, V60, P145, DOI 10.1016/S0011-393X(00)88523-9
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Fugh-Berman A, 2004, EXP BIOL MED, V229, P698, DOI 10.1177/153537020422900802
   GARCIACARMONA F, 1987, BIOCHEM INT, V14, P1003
   Goto T, 1996, J CHROMATOGR A, V749, P295, DOI 10.1016/0021-9673(96)00456-6
   Gougeon R, 2005, OBES RES, V13, P1187, DOI 10.1038/oby.2005.141
   Haaz S, 2006, OBES REV, V7, P79, DOI 10.1111/j.1467-789X.2006.00195.x
   Haller CA, 2005, AM J MED, V118, P998, DOI 10.1016/j.amjmed.2005.02.034
   JORDAN R, 1987, J PHARM PHARMACOL, V39, P752, DOI 10.1111/j.2042-7158.1987.tb06986.x
   Jordan Scott, 2004, CMAJ, V171, P993
   Kalman DS, 2000, CURR THER RES CLIN E, V61, P199, DOI 10.1016/S0011-393X(00)89034-7
   Kiyose C, 2006, J CLIN BIOCHEM NUTR, V38, P180, DOI 10.3164/jcbn.38.180
   Kobayashi-Hattori K, 2005, BIOSCI BIOTECH BIOCH, V69, P2219, DOI 10.1271/bbb.69.2219
   Kubo K, 2005, J CLIN BIOCHEM NUTR, V36, P11, DOI 10.3164/jcbn.36.11
   Marcus DM, 2003, SCIENCE, V301, P1669
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nasir JM, 2004, MAYO CLIN PROC, V79, P1059, DOI 10.4065/79.8.1059
   Nykamp DL, 2004, ANN PHARMACOTHER, V38, P812, DOI 10.1345/aph.1D473
   Pellati F, 2002, J PHARMACEUT BIOMED, V29, P1113, DOI 10.1016/S0731-7085(02)00153-X
   Preuss Harry G, 2002, JOURNAL OF MEDICINE (WESTBURY), V33, P247
   REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939
   Saito M, 2005, FOOD CHEM TOXICOL, V43, P411, DOI 10.1016/j.fct.2004.11.008
NR 30
TC 0
Z9 0
U1 0
U2 5
PU JOURNAL CLINICAL BIOCHEMISTRY & NUTRITION
PI KYOTO
PA KYOTO PREFECTURAL UNIV MED, GRAD SCH MEDICAL SCIENCE, DEPT MOLECULAR GASTROENTEROLOGY & HEPATOLOGY, KYOTO, 602-8566, JAPAN
SN 0912-0009
EI 1880-5086
J9 J CLIN BIOCHEM NUTR
JI J. Clin. Biochem. Nutr.
PD NOV 15
PY 2006
VL 39
IS 3
BP 172
EP 179
DI 
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 107XX
UT WOS:000242205400009
DA 2025-04-28
ER

PT J
AU Storey, ML
   Forshee, RA
   Anderson, PA
AF Storey, Maureen L.
   Forshee, Richard A.
   Anderson, Patricia A.
TI Beverage consumption in the US population
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID body-mass index; childhood obesity; secular trends; children; calcium; weight; associations; demographics; adolescents; choices
AB Objective The purpose of this study was to examine beverage consumption across age, sex, and race/ethnicity categories using the most current data available, the National Health and Nutrition Examination Survey 1999-2002. Design Beverage consumption that included fluid milk, fruit juices, regular and diet carbonated soft drinks, regular and diet fruit drinks/ades, coffee, and tea was examined among white, African-American, and Mexican-American persons in age groups 6 to 11 years, 12 to 19 years, 20 to 39 years, 40 to 59 years, and >60 years. Data from the National Health and Nutrition Examination Survey 1999-2002 were used in this study. Statistical analysis Group means were estimated for the age group, sex, and race/ethnicity subgroups. The probability that any of these group means were equal to one another was tested using statistical software. Results The data,showed marked differences in beverage consumption depending on age, sex, and race/ethnicity. In general, males consumed more beverages than did females. Specifically, white and Mexican-American persons of all ages consumed more milk than did African-American persons. On average, African-American males and females of all ages consumed significantly more fruit drinks/ades than did other race/ethnicity groups. In contrast, white persons consumed more carbonated soft drinks than did other race/ethnicity groups. Conclusion Average beverage consumption varied depending on age, sex, and race/ethnicity. Knowledge of differences in beverage consumption patterns is important for food and nutrition professionals and nutrition policymakers. Better understanding of the many factors that influence beverage consumption levels is needed.
C1 Univ Maryland, Ctr Food Nutr & Agr Policy, Special Res Initiat, College Pk, MD 20742 USA.
C3 University System of Maryland; University of Maryland College Park
RP Storey, ML (corresponding author), Univ Maryland, Ctr Food Nutr & Agr Policy, Special Res Initiat, 1122 Patapsco, College Pk, MD 20742 USA.
EM storey@umd.edu
CR Unknown -, 2006, NAT HLTH NUTR EX SUR, V0, P0
   Barr SI, 2005, J NUTR, V135, P1336, DOI 10.1093/jn/135.5.1336
   Berkey CS, 2004, OBES RES, V12, P778, DOI 10.1038/oby.2004.94
   Briefel RR, 2004, ANNU REV NUTR, V24, P401, DOI 10.1146/annurev.nutr.23.011702.073349
   CARRIQUIRY AL, 1992, J14654 IOW AGR HOM E, V0, P0
   Field AE, 2004, INT J OBESITY, V28, P1210, DOI 10.1038/sj.ijo.0802762
   Fisher JO, 2004, AM J CLIN NUTR, V79, P698
   Forshee RA, 2006, J AM COLL NUTR, V25, P108, DOI 10.1080/07315724.2006.10719520
   Forshee RA, 2005, RISK ANAL, V25, P1121, DOI 10.1111/j.1539-6924.2005.00667.x
   Forshee RA, 2005, J NUTR, V135, P1337, DOI 10.1093/jn/135.5.1337
   Forshee RA, 2004, INT J FOOD SCI NUTR, V55, P463, DOI 10.1080/09637480400015729
   Forshee RA, 2004, J NUTR, V134, P2733, DOI 10.1093/jn/134.10.2733
   Forshee RA, 2003, INT J FOOD SCI NUTR, V54, P297, DOI 10.1080/09637480120092143
   French SA, 2003, J AM DIET ASSOC, V103, P1326, DOI 10.1016/S0002-8223(03)01076-9
   French Simone A, 2004, BMJ, V329, PE315, DOI 10.1136/bmj.329.7462.E315
   Hanson NI, 2005, PUBLIC HEALTH NUTR, V8, P77, DOI 10.1079/PHN2005661
   James J, 2004, BMJ-BRIT MED J, V328, P1237, DOI 10.1136/bmj.38077.458438.EE
   James J, 2004, BRIT MED J, V328, P1236
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   Murphy SP, 2003, J NUTR, V133, P585S, DOI 10.1093/jn/133.2.585S
   Newby PK, 2004, J AM DIET ASSOC, V104, P1086, DOI 10.1016/j.jada.2004.04.020
   Nielsen SJ, 2004, AM J PREV MED, V27, P205, DOI 10.1016/j.amepre.2004.05.005
   Nielsen SJ, 2002, PREV MED, V35, P107, DOI 10.1006/pmed.2002.1037
   Nielsen SJ, 2002, OBES RES, V10, P370, DOI 10.1038/oby.2002.51
   Nusser SM, 1996, J AM STAT ASSOC, V91, P1440, DOI 10.2307/2291570
   Popkin BM, 2005, OBES RES, V13, P2146, DOI 10.1038/oby.2005.266
   Rajeshwari R, 2005, J AM DIET ASSOC, V105, P208, DOI 10.1016/j.jada.2004.11.026
   Storey ML, 2004, J AM COLL NUTR, V23, P18, DOI 10.1080/07315724.2004.10719339
   Storey ML, 2003, INT J FOOD SCI NUTR, V54, P491, DOI 10.1080/09637480310001622350
   Tran NL, 2004, RISK ANAL, V24, P19, DOI 10.1111/j.0272-4332.2004.00408.x
   *USDA, 1998, 1994 96 CONT SURV FO, V0, P0
   Wooten WJ, 2004, J NATL MED ASSOC, V96, P0
   Woteki CE, 2003, J NUTR, V133, P582S, DOI 10.1093/jn/133.2.582S
NR 38
TC 134
Z9 172
U1 0
U2 13
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA
SN 0002-8223
EI 
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD DEC 15
PY 2006
VL 106
IS 12
BP 1992
EP 2000
DI 10.1016/j.jada.2006.09.009
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 112YH
UT WOS:000242563600016
PM 17126630
DA 2025-04-28
ER

PT J
AU Friedman, M
   Levin, CE
   Choi, SH
   Kozukue, E
   Kozukue, N
AF Friedman, Mendel
   Levin, Carol E.
   Choi, Suk-Hyun
   Kozukue, Etsuko
   Kozukue, Nobuyuki
TI HPLC analysis of catechins, theaflavins, and alkaloids in commercial teas and green tea dietary supplements: Comparison of water and 80% ethanol/water extracts
SO JOURNAL OF FOOD SCIENCE
LA English
DT Article
DE alkaloids; dietary supplements; flavonoids; HPLC; tea leaves
ID bran extracts; medicinal benefits; caffeine; polyphenols; black; consumption; obesity; herbs
AB To help meet the needs of consumers, producers of dietary tea supplements, and researchers for information on health-promoting tea compounds, we compared the following conditions for the extraction of tea leaves and green tea-containing dietary supplements: 80% ethanol/water at 60 degrees C for 15 min and boiled water for 5 min. The following 7 catechins, 4 theaflavins, and 3 alkaloids were seperated in a 70-min single HPLC analysis(-)-epigallocatechin, (-)catechin, (+)-epicatechin, (-)-epigallocatechin-3-gallate, (-)gallocatechin-3-gallate, (-)-epicatechin-3-gallate, (-)-catechin-3-gallate, theaflavin-3'-gallate, theaflavin-3,3'-digallate, caffeine, theobromine, and theophylline. The following ranges of concentrations of flavonoids (catechins plus theaflavins) in the tea leaves extracted with 80% ethanol were observed (in mg/g): in 32 black teas, 19.8 to 115.1; in 24 green teas, 12.3 to 136.3; in 14 speciality teas, 4.9 to 118.5; in 7 herbal teas, 0 to 46.0. Total alkaloids in all teas ranged from 0 to 32.6 mg/g. Significantly greater amounts of flavonoids were extracted from the tea leaves with aqueous ethanol than with boiled water. Levels of tea catechins in 10 capsules sold as dietary supplements were about 50 to 75% lower than the amounts listed on the labels. Catechin content of 4 commercial green tea extracts ranged from 96 to 696 mg/g. The results make it possible to maximize the extraction of tea compounds to better relate the flavonoid and alkaloid content of teas and dietary tea supplements to their health-promoting effects.
C1 USDA, ARS, Western Reg Res Ctr, Albany, CA 94710 USA.
   Dept Food Serv Ind, Gyeongju 780713, Gyongbuk, South Korea.
C3 United States Department of Agriculture (USDA)
RP Friedman, M (corresponding author), USDA, ARS, Western Reg Res Ctr, Albany, CA 94710 USA.
EM mfried@pw.usda.gov
CR Astill C, 2001, J AGR FOOD CHEM, V49, P5340, DOI 10.1021/jf010759+
   Aucamp JP, 2000, J CHROMATOGR A, V876, P235, DOI 10.1016/S0021-9673(00)00145-X
   Barnes PJ, 2006, BRIT J PHARMACOL, V147, PS297, DOI 10.1038/sj.bjp.0706437
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Bettuzzi S, 2006, CANCER RES, V66, P1234, DOI 10.1158/0008-5472.CAN-05-1145
   Bonoli M, 2003, J AGR FOOD CHEM, V51, P1141, DOI 10.1021/jf020907b
   Brown MS, 1999, J AGR FOOD CHEM, V47, P2331, DOI 10.1021/jf981124m
   Cabrera C, 2003, J AGR FOOD CHEM, V51, P4427, DOI 10.1021/jf0300801
   Camouse MM, 2005, EXPERT REV ANTICANC, V5, P1061, DOI 10.1586/14737140.5.6.1061
   Choe E, 2005, J FOOD SCI, V70, PR142, DOI 10.1111/j.1365-2621.2005.tb08329.x
   Cooper R, 2005, J ALTERN COMPLEM MED, V11, P639, DOI 10.1089/acm.2005.11.639
   Cooper R, 2005, J ALTERN COMPLEM MED, V11, P521, DOI 10.1089/acm.2005.11.521
   Cushnie TPT, 2005, INT J ANTIMICROB AG, V26, P343, DOI 10.1016/j.ijantimicag.2005.09.002
   Del Rio D, 2004, J AGR FOOD CHEM, V52, P2807, DOI 10.1021/jf0354848
   Fernández PL, 2002, J AGR FOOD CHEM, V50, P1833, DOI 10.1021/jf0114435
   Ferrara L, 2001, FARMACO, V56, P397, DOI 10.1016/S0014-827X(01)01104-1
   Friedman M, 1997, J AGR FOOD CHEM, V45, P1523, DOI 10.1021/jf960900s
   Friedman M, 2006, J FOOD PROTECT, V69, P354, DOI 10.4315/0362-028X-69.2.354
   Friedman M, 2005, J FOOD SCI, V70, PC550, DOI 10.1111/j.1365-2621.2005.tb08304.x
   Fukino Y, 2005, J NUTR SCI VITAMINOL, V51, P335, DOI 10.3177/jnsv.51.335
   Goldstein J, 2005, HEADACHE, V45, P973, DOI 10.1111/j.1526-4610.2005.05177.x
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Khokhar S, 2002, J AGR FOOD CHEM, V50, P565, DOI 10.1021/jf010153l
   Lai PK, 2004, CURR MED CHEM, V11, P1451, DOI 10.2174/0929867043365107
   Lee BL, 2000, J CHROMATOGR A, V881, P439, DOI 10.1016/S0021-9673(00)00215-6
   Lin YS, 2003, J AGR FOOD CHEM, V51, P1864, DOI 10.1021/jf021066b
   Manning Jared, 2003, JOURNAL OF HERBAL PHARMACOTHERAPY, V3, P19, DOI 10.1080/J157v03n03_03
   Maron DJ, 2003, ARCH INTERN MED, V163, P1448, DOI 10.1001/archinte.163.12.1448
   McLellan TM, 2005, AVIAT SPACE ENVIR MD, V76, P647
   Menet MC, 2004, J AGR FOOD CHEM, V52, P2455, DOI 10.1021/jf035427e
   Murase T, 2006, INT J OBESITY, V30, P561, DOI 10.1038/sj.ijo.0803135
   Nam SH, 2006, FOOD CHEM, V94, P613, DOI 10.1016/j.foodchem.2004.12.010
   Nam SH, 2005, FOOD CHEM TOXICOL, V43, P741, DOI 10.1016/j.fct.2005.01.014
   Nam SH, 2005, J AGR FOOD CHEM, V53, P816, DOI 10.1021/jf0490293
   Piñeiro Z, 2004, J CHROMATOGR A, V1026, P19, DOI 10.1016/j.chroma.2003.10.096
   Rao A, 2005, NUTR NEUROSCI, V8, P141, DOI 10.1080/10284150500096994
   Ruhl CE, 2005, GASTROENTEROLOGY, V129, P1928, DOI 10.1053/j.gastro.2005.08.056
   Sakakibara H, 2003, J AGR FOOD CHEM, V51, P571, DOI 10.1021/jf020926l
   *SAS I, 2000, REL 9 1 3, V0, P0
   Schmidt B, 2005, BIOL NEONATE, V88, P208, DOI 10.1159/000087584
   Schulz-Stübner S, 2005, ANESTH ANALG, V101, P1809, DOI 10.1213/01.ANE.0000184203.52747.7D
   Seely Dugald, 2005, INTEGR CANCER THER, V4, P144, DOI 10.1177/1534735405276420
   Thornfeldt C, 2005, DERMATOL SURG, V31, P873
   Wang LF, 2000, J AGR FOOD CHEM, V48, P4227, DOI 10.1021/jf0003597
   Xu JZ, 2004, BRIT J NUTR, V91, P873, DOI 10.1079/BJN20041132
   Yang CS, 2005, EXP LUNG RES, V31, P135, DOI 10.1080/01902140490495525
NR 46
TC 108
Z9 113
U1 2
U2 93
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-1147
EI 1750-3841
J9 J FOOD SCI
JI J. Food Sci.
PD AUG 15
PY 2006
VL 71
IS 6
BP C328
EP C337
DI 10.1111/j.1750-3841.2006.00090.x
PG 10
WC Food Science & Technology
SC Food Science & Technology
GA 080ZK
UT WOS:000240286800004
DA 2025-04-28
ER

PT J
AU Hsu, CL
   Huang, SL
   Yen, GC
AF Hsu, Chin-Lin
   Huang, Shih-Li
   Yen, Gow-Chin
TI Inhibitory effect of phenolic acids on the proliferation of 3T3-L1 preadipocytes in relation to their antioxidant activity
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE phenolic acid; preadipocytes; proliferation; antiobesity; antioxidant activity
ID conjugated linoleic-acid; induced apoptosis; heart-disease; tea catechins; gallic acid; cell-lines; obesity; adipogenesis; flavonoids; cancer
AB Obesity is an important topic in the world of public health and preventive medicine. Inhibition of preadipocyte proliferation plays an important role in the mechanisms of proposed antiobesity. In this in vitro study, the inhibitory effect of phenolic acids on 3T3-L1 preadipocytes was evaluated, and a relationship analysis was then conducted. The results showed that the addition of phenolic acids to the growth medium decreased the cell population growth of 3T3-L1 preadipocytes. The IC50 values of chlorogenic acid, gallic acid, o- coumaric acid and m-coumaric acid on 3T3-L1 preadipocytes were 72.3, 43.3, 48.2, and 49.2 mu M, respectively. A relationship analysis indicated that there is a significant linear correlation between the influence of phenolic acids on cell population growth and their antioxidant activity (r=0.77, p < 0.01). The cell cycle assay indicated that the treatment of 3T3-L1 preadipocytes with chlorogenic acid, o- coumaric acid, and m-coumaric acid caused cell cycle arrest in the G(1) phase. Gallic acid did not affect the cell cycle profile; however, it increased the number of apoptotic cells (sub-G(1) phase) in a time- and dose- dependent manner. Annexin V- fluorescein isothiocyanate (FITC) propidium iodide (PI) apoptosis flow cytometric assay showed that gallic acid increased the number of early apoptotic (annexin-FITC+/ PI-) and late apoptotic cells (annexin V-FITC+/ PI+) but not necrotic cells (annexin V- FITC-/PI+). The treatment of cells with gallic acid caused the loss of mitochondrial membrane potential (Delta Psi(m)). These results indicate that the inhibition of preadipocyte population growth by some phenolic acids might have further implication in in vivo antiobesity effects.
C1 Natl Chung Hsing Univ, Dept Food Sci & Biotechnol, Taichung 40227, Taiwan.
   Kaohsiung Hospital Coll, Dept Baking Technol & Management, Kaohsiung 81271, Taiwan.
C3 National Chung Hsing University; Kaohsiung Medical University
RP Yen, GC (corresponding author), Natl Chung Hsing Univ, Dept Food Sci & Biotechnol, 250 Kuokuang Rd, Taichung 40227, Taiwan.
EM gcyen@nchu.edu.tw
CR Aejmelaeus RT, 1997, FREE RADICAL BIO MED, V23, P69, DOI 10.1016/S0891-5849(96)00591-6
   ARAI Y, 2001, J NUTR, V130, P2378
   Artico M, 1998, J MED CHEM, V41, P3948, DOI 10.1021/jm9707232
   Benavente-García O, 1997, J AGR FOOD CHEM, V45, P4505, DOI 10.1021/jf970373s
   CAO G, 1995, CLIN CHEM, V41, P1738
   Cao GH, 1996, J AGR FOOD CHEM, V44, P3426, DOI 10.1021/jf9602535
   Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6
   Carrière A, 2003, FEBS LETT, V550, P163, DOI 10.1016/S0014-5793(03)00862-7
   Evans M, 2000, LIPIDS, V35, P899, DOI 10.1007/S11745-000-0599-6
   FERGUSON LR, 1994, MUTAT RES, V307, P395, DOI 10.1016/0027-5107(94)90313-1
   Furuyashiki T, 2004, BIOSCI BIOTECH BIOCH, V68, P2353, DOI 10.1271/bbb.68.2353
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3
   Halliwell B, 2005, AM J CLIN NUTR, V81, P268S, DOI 10.1093/ajcn/81.1.268S
   Heim KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955-2863(02)00208-5
   HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381
   Hua KJ, 2004, CYTOKINE, V25, P61, DOI 10.1016/j.cyto.2003.09.008
   Hung PF, 2005, AM J PHYSIOL-CELL PH, V288, PC1094, DOI 10.1152/ajpcell.00569.2004
   Jensen B, 2004, EXP CELL RES, V301, P280, DOI 10.1016/j.yexcr.2004.08.030
   Kao Y, 2000, AM J CLIN NUTR, V72, P1232
   Kohen R, 1999, METHOD ENZYMOL, V300, P285
   Konishi Y, 2005, J AGR FOOD CHEM, V53, P9928, DOI 10.1021/jf051962y
   KOPELMAN PG, 1994, MED INT, V22, P385
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Lin YT, 2005, BIOCHEM PHARMACOL, V70, P1469, DOI 10.1016/j.bcp.2005.07.035
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Montpied P, 2003, MOL BRAIN RES, V115, P111, DOI 10.1016/S0169-328X(03)00178-5
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Niesler CU, 2000, J ENDOCRINOL, V167, P165, DOI 10.1677/joe.0.1670165
   Nyska A, 2003, TOXICOL PATHOL, V31, P39, DOI 10.1080/01926230390173833
   Ohno Y, 1999, ANTI-CANCER DRUG, V10, P845, DOI 10.1097/00001813-199910000-00008
   ROSS SE, 2000, SCIENCE, V289, P950, DOI 10.1126/SCIENCE.289.5481.950
   SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473
   Salucci M, 2002, BRIT J CANCER, V86, P1645, DOI 10.1038/sj.bjc.6600295
   Serrano A, 1998, ARCH BIOCHEM BIOPHYS, V350, P49, DOI 10.1006/abbi.1997.0474
   Son S, 2002, J AGR FOOD CHEM, V50, P468, DOI 10.1021/jf010830b
   SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823
   STAVRIC B, 1994, CLIN BIOCHEM, V27, P319, DOI 10.1016/0009-9120(94)00039-5
   Takada E, 2001, J IMMUNOL, V166, P1641, DOI 10.4049/jimmunol.166.3.1641
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Wang YW, 2004, INT J OBESITY, V28, P941, DOI 10.1038/sj.ijo.0802641
NR 44
TC 139
Z9 149
U1 1
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JUN 14
PY 2006
VL 54
IS 12
BP 4191
EP 4197
DI 10.1021/jf0609882
PG 7
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 050PR
UT WOS:000238100900019
PM 16756346
DA 2025-04-28
ER

PT J
AU Tarantino, G
   Conca, P
   Capone, D
   Gentile, A
   Polichetti, G
   Basile, V
AF Tarantino, Giovanni
   Conca, Paolo
   Capone, Domenico
   Gentile, Antonio
   Polichetti, Giuliano
   Basile, Vincenzo
TI Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients
SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE caffeine intake; cirrhosis; liver function; total overnight salivary caffeine assessment
ID c-virus core; hepatitis-c; nonalcoholic steatohepatitis; cyp1a2 activity; clearance; plasma; cytochrome-p450; elimination; capacity; fibrosis
AB Systemic caffeine clearance is considered the gold standard for phenotyping cytochrome P450 1A2 in epidemiological studies, and has been recommended for the non-invasive assessment of liver function in chronic liver disease. Our aim was to find a valid, simple and reliable alternative to this method, and therefore focused our attention on the measurement of an unique salivary caffeine concentration, without drug exposure. Our evaluation included 36 healthy controls, 47 patients with compensated liver cirrhosis of viral origin, and 48 obese and diabetic patients with cryptogenetic (likely metabolic) cirrhosis. All shared the same caffeine consumption habits (regular daily use of caffeinated beverages, mainly coffee). The total overnight salivary caffeine assessment (TOSCA) was determined by using a single-point concentration of salivary caffeine, after an overnight period of abstinence. Daily routine caffeine intake of our population was adequate for studying the TOSCA. This single-point concentration correlated well with caffeine clearance, measured by salivary concentrations of caffeine. Mean TOSCA in cirrhotic patients was significantly higher than in controls (p < 0.001; sensitivity (%) 84.2 and specificity (%) 97.2; negative likelihood ratio=0.16 and positive likelihood ratio=30.32). A cut-off set at 4.2 mu g/ml (sensitivity (%) 95.8 and specificity (%) 68.1; negative likelihood ratio=0.06 and positive likelihood ratio=3.0) successfully differentiated the type of cirrhosis. Rapid (with higher metabolism of caffeine) metabolizers were more frequent in the group of patients with cirrhosis of metabolic origin (70.8%; p < 0.0001), and the opposite was true for the group of patients with cirrhosis of viral origin, which comprised many poor metabolizers (85.1%; p < 0.001). Serum transforming growth factor-beta 1 concentration, mirroring ongoing fibrosis, ranked high in poor metabolizers. The association between overnight assessment and homeostasis model assessment in rapid metabolizers could result from similar roles for cytochrome P450 1A2 and insulin resistance in determining metabolic liver cirrhosis. The TOSCA, although differential between the viral and metabolic etiologies, could be considered a good diagnostic use to verify the presence and eventually the type of compensated liver cirrhosis
C1 Univ Naples Federico II, Sch Med, Sect Hepatol Internal Med, Dept Clin & Expt Med, Naples, Italy.
   Univ Naples Federico II, Sch Med, Pharmacol Sect, Dept Neurosci, Naples, Italy.
C3 University of Naples Federico II; University of Naples Federico II
RP Tarantino, G (corresponding author), Univ Naples Federico II, Sch Med, Sect Hepatol Internal Med, Dept Clin & Expt Med, Naples, Italy.
EM tarantin@unina.it
CR ABDELRAZZAK Z, 1994, MOL PHARMACOL, V46, P1100
   ABERNETHY DR, 1985, EUR J CLIN PHARMACOL, V28, P425, DOI 10.1007/BF00544361
   Unknown -, 2001, GUID DOC US IN VITR, V0, P0
   Bataller R, 2004, GASTROENTEROLOGY, V126, P529, DOI 10.1053/j.gastro.2003.11.018
   BROUGHTON LJ, 1981, BRIT J CLIN PHARMACO, V12, P155
   BUNKER ML, 1979, J AM DIET ASSOC, V74, P28
   CARBO ML, 1989, CLIN PHARMACOL THER, V45, P234, DOI 10.1038/clpt.1989.23
   Carrillo JA, 2000, THER DRUG MONIT, V22, P409, DOI 10.1097/00007691-200008000-00008
   de Leon J, 2003, PROG NEURO-PSYCHOPH, V27, P165, DOI 10.1016/S0278-5846(02)00348-2
   Faber MS, 2005, BASIC CLIN PHARMACOL, V97, P125, DOI 10.1111/j.1742-7843.2005.pto_973160.x
   Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977
   Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247
   Garello E, 1999, DIGEST DIS SCI, V44, P782, DOI 10.1023/A:1026678228967
   Hasegawa T, 2001, ALIMENT PHARM THERAP, V15, P1667, DOI 10.1046/j.1365-2036.2001.01083.x
   Hayden Melvin R, 2004, NUTR METAB (LOND), V1, P10, DOI 10.1186/1743-7075-1-10
   HOLSTEGE A, 1989, KLIN WOCHENSCHR, V67, P6, DOI 10.1007/BF01736528
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   JOST G, 1987, HEPATOLOGY, V7, P338, DOI 10.1002/hep.1840070221
   Jover R, 1997, AM J GASTROENTEROL, V92, P1905
   Jürgens G, 2002, CLIN PHARMACOL THER, V71, P162, DOI 10.1067/mcp.2002.121373
   LEWIS FW, 1992, J HEPATOL, V14, P157, DOI 10.1016/0168-8278(92)90152-F
   McCusker RR, 2003, J ANAL TOXICOL, V27, P520, DOI 10.1093/jat/27.7.520
   MICELI JN, 1984, THER DRUG MONIT, V6, P344, DOI 10.1097/00007691-198409000-00015
   Mohamed-Ali V, 1999, CLIN ENDOCRINOL, V50, P221
   Niemelä O, 2000, J HEPATOL, V33, P893, DOI 10.1016/S0168-8278(00)80120-8
   Nordmark A, 1999, BRIT J CLIN PHARMACO, V47, P397, DOI 10.1046/j.1365-2125.1999.00918.x
   Ou-Yang DS, 2000, BRIT J CLIN PHARMACO, V49, P145, DOI 10.1046/j.1365-2125.2000.00128.x
   Park GJH, 2003, HEPATOLOGY, V38, P1227, DOI 10.1053/jhep.2003.50475
   Peterson TC, 2000, HEPATOL RES, V17, P112, DOI 10.1016/S1386-6346(99)00068-6
   Powell EE, 2000, HEPATOLOGY, V31, P828, DOI 10.1053/he.2000.6253
   Qureshi Mabood, 2003, JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, V8, P261, DOI 10.1177/107424840300800403
   RODOPOULOS N, 1995, SCAND J CLIN LAB INV, V55, P229, DOI 10.3109/00365519509089618
   Sepulveda-Flores Ricardo N, 2002, ANN HEPATOL, V1, P36
   Smith Andrew G, 2003, ENVIRONMENTAL HEALTH PERSPECTIVES, V111, P45
   Sreekumar R, 2003, HEPATOLOGY, V38, P244, DOI 10.1053/jhep.2003.50290
   Taniguchi H, 2004, J MED VIROL, V72, P52, DOI 10.1002/jmv.10545
   Wittayalertpanya S, 1996, TOKAI JOURNAL OF EXPERIMENTAL AND CLINICAL MEDICINE, V21, P195
NR 37
TC 20
Z9 20
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0031-6970
EI 
J9 EUR J CLIN PHARMACOL
JI Eur. J. Clin. Pharmacol.
PD AUG 15
PY 2006
VL 62
IS 8
BP 605
EP 612
DI 10.1007/s00228-006-0146-7
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 067RQ
UT WOS:000239320700003
PM 16841221
DA 2025-04-28
ER

PT J
AU Lin, JK
   Lin-Shiau, SY
AF Lin, JK
   Lin-Shiau, SY
TI Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Review
DE catechins; fatty acid synthase; tea; tea polyphenols; theaflavins
ID fatty-acid synthase; green tea; epigallocatechin gallate; (-)-epigallocatechin gallate; catechin-polyphenols; galloyl moiety; caffeine; suppression; induction; oolong
AB Among the health-promoting effects of tea and tea polyphenols, the cancer-chemopreventive effects in various animal model systems have been intensively investigated; meanwhile, the hypolipidemic and antiobesity effects in animals and humans have also become a hot issue for molecular nutrition and food research. It has been demonstrated that the body weights of rats and their plasma triglyceride, cholesterol, and LDL-cholesterol have been significantly reduced by feedings of oolong, black, pu-erh, and green tea leaves to the animals. It has been suggested that the inhibition of growth and suppression of lipogenesis in MCF-7 breast cancer cells may be through down-regulation of fatty acid synthase gene expression in the nucleus and stimulation of cell energy expenditure in the mitochondria. The experimental data indicated that the molecular mechanisms of fatty acid synthase gene suppression by tea polyphenols (EGCG, theaflavins) may invite down-regulation of EGFR/PI3K/Akt/Sp1 signal transduction pathways.
C1 Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei, Taiwan.
   Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University
RP Natl Taiwan Univ, Coll Med, Inst Biochem, 1,Sect 1 Jen Ai Rd, Taipei, Taiwan.
EM jklin@ha.mc.ntu.edu.tw
CR Ashida H, 2004, BIOFACTORS, V22, P135, DOI 10.1002/biof.5520220126
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Chung JY, 2001, FASEB J, V15, P2022, DOI 10.1096/fj.01-0031fje
   Crespy V, 2004, J NUTR, V134, P3431S, DOI 10.1093/jn/134.12.3431S
   Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Dulloo AG, 1998, BRIT J NUTR, V80, P493, DOI 10.1017/S0007114598001573
   Furuyashiki T, 2004, BIOSCI BIOTECH BIOCH, V68, P2353, DOI 10.1271/bbb.68.2353
   Han LK, 1999, INT J OBESITY, V23, P98, DOI 10.1038/sj.ijo.0800766
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   HO CT, 1992, PREV MED, V21, P520, DOI 10.1016/0091-7435(92)90059-Q
   Hung PF, 2005, AM J PHYSIOL-CELL PH, V288, PC1094, DOI 10.1152/ajpcell.00569.2004
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Komatsu Tatsushi, 2003, JOURNAL OF MEDICAL INVESTIGATION, V50, P170
   Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897
   Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X
   Kuo KL, 2005, J AGR FOOD CHEM, V53, P480, DOI 10.1021/jf049375k
   LANDSBERG L, 1993, INT J OBESITY, V65, P829
   Lee HH, 2004, CARCINOGENESIS, V25, P1109, DOI 10.1093/carcin/bgh106
   Liang YC, 1999, J CELL BIOCHEM, V75, P1
   Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V
   Liao S, 2001, HONG KONG MEDICAL JOURNAL, V7, P369
   Lin J, 2005, OBES RES, V13, P982, DOI 10.1038/oby.2005.115
   Lin JK, 1999, BIOCHEM PHARMACOL, V58, P911, DOI 10.1016/S0006-2952(99)00112-4
   Lin JK, 2002, ARCH PHARM RES, V25, P561, DOI 10.1007/BF02976924
   Lin YL, 1998, J AGR FOOD CHEM, V46, P1893, DOI 10.1021/jf970963q
   Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465
   Lin YS, 2003, J AGR FOOD CHEM, V51, P1864, DOI 10.1021/jf021066b
   Mayes P, 2003, HARPERS ILLUSTRATED BIOCHEMISTRY, V26th, P173
   Moon YS, 2002, J LIPID RES, V43, P691
   Muralt P, 2002, MICROSYST SER, V9, P3
   Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   NORMURA M, 2001, J BIOL CHEM, V276, P46624
   Rietveld A, 2003, J NUTR, V133, P3285S, DOI 10.1093/jn/133.10.3285S
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737
   St-Onge MP, 2005, AM J CLIN NUTR, V81, P7
   VISON JA, 2004, J AGR FOOD CHEM, V52, P3661
   Wang X, 2003, BIOCHEM PHARMACOL, V66, P2039, DOI 10.1016/S0006-2952(03)00585-9
   Wang X, 2001, BIOCHEM BIOPH RES CO, V288, P1200, DOI 10.1006/bbrc.2001.5923
   Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409
   Yeh CW, 2003, PHARMACOGENOMICS J, V3, P267, DOI 10.1038/sj.tpj.6500192
   Zheng GD, 2004, IN VIVO, V18, P55
NR 48
TC 249
Z9 280
U1 11
U2 159
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD FEB 15
PY 2006
VL 50
IS 2
BP 211
EP 217
DI 10.1002/mnfr.200500138
PG 7
WC Food Science & Technology
SC Food Science & Technology
GA 016EH
UT WOS:000235603000012
PM 16404708
DA 2025-04-28
ER

PT J
AU Hackman, RM
   Havel, PJ
   Schwartz, HJ
   Rutledge, JC
   Watnik, MR
   Noceti, EM
   Stohs, SJ
   Stern, JS
   Keen, CL
AF Hackman, R. M.
   Havel, P. J.
   Schwartz, H. J.
   Rutledge, J. C.
   Watnik, M. R.
   Noceti, E. M.
   Stohs, S. J.
   Stern, J. S.
   Keen, C. L.
TI Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE (MeSH) ephedra; weight loss; dietary supplement; lipids; insulin; leptin
ID dietary-supplement; herbal supplement; body-weight; short-term; leptin; safety; overweight; efficacy; prevalence; vitamins
AB Objective: To determine the safety and efficacy of a dietary supplement with a low dose of ephedra and caffeine in overweight/obese premenopausal female subjects. Design: A 9-month, double-blind, randomized control study compared the efficacy and safety of a dietary supplement with ephedra and caffeine to a control supplement. Subjects: Sixty-one healthy, premenopausal women with body mass index (BMI) from 27 to 39 kg/m(2) were randomly assigned and received a dietary supplement (40 mg/day ephedra alkaloids, 100 mg/day caffeine, high potency mixture of vitamins, minerals, omega-3 fatty acids) or a control supplement for 9 months. Measurements: Efficacy: changes in body weight, body composition, lipids, insulin, leptin, adiponectin, ghrelin, and self-reports of physical activity, diet and quality of life indices. Safety: blood pressure, heart rate, electrocardiograms, urinalysis, blood histology, serum chemistry measures and self-reported symptoms. Results: Forty-one women completed the study. The treatment group lost significantly more body weight (-7.18 kg) and body fat (-5.33 kg) than the control group (-2.25 and -0.99 kg, respectively), and showed significant declines in heart rate, serum cholesterol, triglycerides, cholesterol to high-density lipoprotein ratio, glucose, fasting insulin, and leptin. Blood pressure, electrocardiograms, other clinical chemistry measures, blood histology, urinalysis, and self- reported physical activity were similar in the groups. Minor symptoms included dry mouth, insomnia, nervousness and palpitations. The treatment group reported more energy and decreased appetite compared to controls and scored higher on a quality of life domain assessing vitality. Conclusion: A dietary supplement containing a low potency ephedra/caffeine mixture appeared safe and effective in causing loss of weight and body fat, and improving several metabolic parameters, including insulin sensitivity and lipid profiles when tested under physician supervision. Such supplements could be a useful tool to assist with weight loss.
C1 Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.
   Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA.
   Calif State Univ, Dept Stat, E bay, CA USA.
   Creighton Univ, Dept Pharm Sci, Omaha, NE 68178 USA.
C3 University of California System; University of California Davis; University of California System; University of California Davis; Creighton University
RP Hackman, RM (corresponding author), Univ Calif Davis, Dept Nutr, 1 Shields Ave, Davis, CA 95616 USA.
EM rmhackman@ucdavis.edu
CR Unknown -, 1997, ARCH INTERN MED, V157, P2413, DOI 10.1001/ARCHINTE.157.21.2413
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163
   Bland JM, 1996, BRIT MED J, V312, P1079
   BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B
   Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   Chen MD, 2000, LIFE SCI, V66, P2143, DOI 10.1016/S0024-3205(00)00541-5
   Coffey CS, 2004, INT J OBESITY, V28, P1411, DOI 10.1038/sj.ijo.0802784
   Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908
   DALLAL G, 2003, RANDOMIZATION, V0, P0
   DALY PA, 1993, INT J OBESITY, V17, P0
   Dubuc GR, 1998, METABOLISM, V47, P429, DOI 10.1016/S0026-0495(98)90055-5
   DULLOO AG, 1993, INT J OBESITY, V17, P0
   Fairfield KM, 2002, JAMA-J AM MED ASSOC, V287, P3116, DOI 10.1001/jama.287.23.3116
   Faraj M, 2003, J CLIN ENDOCR METAB, V88, P1594, DOI 10.1210/jc.2002-021309
   Fine JT, 1999, JAMA-J AM MED ASSOC, V282, P2136, DOI 10.1001/jama.282.22.2136
   Finkelstein EA, 2004, OBES RES, V12, P18, DOI 10.1038/oby.2004.4
   Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Gadbury G L, 2003, OBES REV, V4, P175, DOI 10.1046/j.1467-789X.2003.00109.x
   Greenway FL, 2004, OBES RES, V12, P1152, DOI 10.1038/oby.2004.144
   Haller CA, 2005, CLIN PHARMACOL THER, V77, P560, DOI 10.1016/j.clpt.2005.01.023
   Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502
   Haller CA, 2002, CLIN PHARMACOL THER, V71, P421, DOI 10.1067/mcp.2002.124523
   Havel PJ, 2004, DIABETES, V53, PS143, DOI 10.2337/diabetes.53.2007.S143
   Hutton B, 2004, AM J CLIN NUTR, V80, P1461, DOI 10.1093/ajcn/80.6.1461
   Keim NL, 1998, AM J CLIN NUTR, V68, P794, DOI 10.1093/ajcn/68.4.794
   Lee H C, 1993, OBES RES, V1, P371
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   McBride BF, 2004, JAMA-J AM MED ASSOC, V291, P216, DOI 10.1001/jama.291.2.216
   Neter J, 1995, APPL LINEAR STAT MOD, V4th, P0
   PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460
   Ray S, 2005, ARCH TOXICOL, V79, P330, DOI 10.1007/s00204-005-0672-6
   Rosenbaum M, 2002, J CLIN ENDOCR METAB, V87, P2391, DOI 10.1210/jc.87.5.2391
   *SAS I I, 2003, SAS SYST WIND VERS 9, V0, P0
   Shara M, 2003, MOL CELL BIOCHEM, V254, P339, DOI 10.1023/A:1027358106407
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   Singh RB, 1998, MAGNESIUM RES, V11, P3
   Stafford RS, 2000, ARCH FAM MED, V9, P631, DOI 10.1001/archfami.9.7.631
   Unnebrink K, 2001, STAT MED, V20, P3931, DOI 10.1002/sim.1149
   *US DEP HHS, 1990, COD SYMB THES ADV EV, V0, P0
   VANLOAN MD, 1993, BASIC LIFE SCI, V0, P67
   Wadden TA, 2000, ARCH FAM MED, V9, P854, DOI 10.1001/archfami.9.9.854
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Westerterp-Plantenga M, 2002, INT J OBESITY, V26, P870, DOI 10.1038/sj.ijo.0801979
NR 46
TC 67
Z9 72
U1 2
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD OCT 15
PY 2006
VL 30
IS 10
BP 1545
EP 1556
DI 10.1038/sj.ijo.0803283
PG 12
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 096MI
UT WOS:000241380800012
PM 16552410
DA 2025-04-28
ER

PT J
AU Belpoggi, F
   Soffritti, M
   Tibaldi, E
   Falcioni, L
   Bua, L
   Trabucco, F
AF Belpoggi, Fiorella
   Soffritti, Morando
   Tibaldi, Eva
   Falcioni, Laura
   Bua, Luciano
   Trabucco, Francesca
TI Results of long-term carcinogenicity bioassays on Coca-Cola administered to Sprague-Dawley rats
SO LIVING IN A CHEMICAL WORLD: FRAMING THE FUTURE IN LIGHT OF THE PAST
LA English
DT Article; Proceedings Paper
DE Coca-Cola; carcinogenicity; long-term bioassay; rat
ID cancer; obesity; cohort; adults
AB Coca-Cola was invented in May 1886 in Atlanta, Georgia by a pharmacist who, by accident or design, mixed carbonated water with the syrup of sugar, phosphoric acid, caffeine, and other natural flavors to create what is known as "the world's favorite soft drink." Coca-Cola is currently sold in more than 200 countries and in early 2000, the company sold its 10 billionth unit case of Coca-Cola branded products. Given the worldwide consumption of Coca-Cola, a project of experimental bioassays to study its long-term effects when administered as substitute for drinking water on male and female Sprague-Dawley rats was planned and executed. The objective of the project was to study whether and how long-term consumption of Coca-Cola affects the basic tumorigram of test animals. The bioassays were performed on rats beginning at different ages, namely: (a) on males and females exposed since embryonic life or from 7 weeks of age; and (b) on males and females exposed from 30, 39, or 55 weeks of age. Overall, the project included 1999 rats. During the biophase, data were collected on fluid and feed consumption, body weight, and survival. Animals were kept under observation until spontaneous death and underwent complete necropsy. The results indicate: (a) an increase in body weight in all treated animals; (b) a statistically significant increase of the incidence in females, both breeders and offspring, bearing malignant mammary tumors; (c) a statistically significant increase in the incidence of exocrine ademonas of the pancreas in both male and female breeders and offspring; and (d) an increased incidence, albeit not statistically significant, of pancreatic islet cell carcinomas in females, a malignant tumor which occurs very rarely in our historical controls. On the basis of the results of this study, excessive consumption of regular soft-drinks should be generally discouraged, in particular for children and adolescents.
C1 European Ramazzini Fdn, Cesare Maltoni Canc Res Ctr, I-40010 Bentivoglio, BO, Italy.
RP Soffritti, M (corresponding author), European Ramazzini Fdn, Cesare Maltoni Canc Res Ctr, I-40010 Bentivoglio, BO, Italy.
EM crcfr@ramazzini.it
CR Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Rapp K, 2005, BRIT J CANCER, V93, P1062, DOI 10.1038/sj.bjc.6602819
   Soffritti M, 1996, INT CONGR SER, V1120, P241
   SOFFRITTI M, 1999, ANN NY ACAD SCI, V895, P43
   Tannebaum A, 1940, AMERICAN JOURNAL OF CANCER, V38, P335
   TANNENBAUM A, 1953, ADV CANCER RES, V1, P451, DOI 10.1016/S0065-230X(08)60009-3
NR 6
TC 17
Z9 18
U1 0
U2 19
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2006
VL 1076
IS 
BP 736
EP 752
DI 10.1196/annals.1371.078
PG 17
WC Environmental Sciences; Public, Environmental & Occupational Health; Multidisciplinary Sciences; Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Science & Technology - Other Topics; Toxicology
GA BFH91
UT WOS:000241943500062
PM 17119251
DA 2025-04-28
ER

PT J
AU de Sotillo, DVR
   Hadley, M
   Sotillo, JE
AF de Sotillo, DVR
   Hadley, M
   Sotillo, JE
TI Insulin receptor exon 11<SUP>+/-</SUP> is expressed in Zucker (fa/fa) rats, and chlorogenic acid modifies their plasma insulin and liver protein and DNA
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE increased protein concentration; liver DNA; chlorogenic acid; insulin sensitizer
ID potato peel extract; age-related-changes; biological parameters; glucose-tolerance; diabetes-mellitus; fatty rats; obese; resistance; glucose-6-phosphatase; atherosclerosis
AB In vivo studies confirmed that chlorogenic acid (CGA) improved glucose tolerance and mineral pool distribution in obese Zucker (fa/fa) rats. We found a significant decrease (P < .05) in postprandial blood glucose concentrations, which may have been due to an improved sensitivity to insulin. Impaired glucose tolerance and insulin resistance have been associated with differences in the hepatic mRNA expression of the spliced variants of the insulin receptor at exon 11. Spliced variants of the insulin receptor have not been studied in obese Zucker (fa/fa) rats, and no information exists about the effects of CGA in vivo as a possible insulin sensitizer. Thus, we studied the in vivo effect of CGA on plasma insulin concentrations during a glucose tolerance test, liver protein and DNA concentrations, the hepatic activity of glucose-6-phosphatase (G-6-PASE) and the mRNA expression of the two variants of the insulin receptor at exon 11. Zucker (fa/fa) rats were implanted with jugular vein catheters. Chlorogenic acid was administered (5 mg/kg body weight per day) for 3 weeks via intravenous infusion. In the CGA-treated group, areas under the curve (AUC) for blood glucose and plasma insulin improved (P < .005), and the protein and DNA concentrations in the liver increased (P < .05). No significant differences (P > .05) were found between groups for the hepatic G-6-PASE activity. The insulin receptor exon 11(+) and the exon 11(-) variants were expressed in the liver of Zucker (fa/fa) rats without significant changes (P > .05). Chlorogenic acid improved some cellular mechanisms that are stimulated by insulin. (c) 2006 Elsevier Inc. All rights reserved.
C1 Minnesota State Univ, Dept Chem, Mankato, MN 56001 USA.
   Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA.
   N Dakota State Univ, Dept Food & Nutr, Fargo, ND 58105 USA.
C3 Minnesota State Colleges & Universities; Minnesota State University Mankato; University of Minnesota System; University of Minnesota Twin Cities; North Dakota State University Fargo
RP Minnesota State Univ, Dept Chem, Mankato, MN 56001 USA.
EM mary.hadley@mnsu.edu
CR Ames BN, 1966, METHODS IN ENZYMOLOGY, V8, P115, DOI 10.1016/0076-6879(66)08014-5
   BACH A, 1981, LIPIDS, V16, P841, DOI 10.1007/BF02535040
   BACH A, 1977, LIFE SCI, V20, P541, DOI 10.1016/0024-3205(77)90399-X
   BALON TW, 1995, AM J PHYSIOL, V269, P745
   BOLLAG D, 1996, PROTEIN METHODS, V0, PCH1
   BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F
   BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2
   CLARK JB, 1982, ENDOCRINOLOGY, V111, P964, DOI 10.1210/endo-111-3-964
   De Sotillo DR, 1998, J FOOD SCI, V63, P907, DOI 10.1111/j.1365-2621.1998.tb17924.x
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   DESOTILLO DR, 1994, J FOOD SCI, V59, P649, DOI 10.1111/j.1365-2621.1994.tb05584.x
   DESOTILLO DR, 1994, J FOOD SCI, V59, P131
   EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4
   FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549
   GOLDSTEIN BJ, 1990, MOL ENDOCRINOL, V4, P235, DOI 10.1210/mend-4-2-235
   GOSNELL BA, 1995, PSYCHOPHARMACOLOGY, V117, P248, DOI 10.1007/BF02245194
   Granberry MC, 1998, PHARMACOTHERAPY, V18, P973
   Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360
   Henriksen EJ, 1998, AM J PHYSIOL-REG I, V275, PR40, DOI 10.1152/ajpregu.1998.275.1.R40
   Huang Z, 1996, J CLIN ENDOCR METAB, V81, P1552, DOI 10.1210/jc.81.4.1552
   JOOST HG, 1995, CELL SIGNAL, V7, P85, DOI 10.1016/0898-6568(94)00071-I
   Kao WHL, 1999, ARCH INTERN MED, V159, P2151, DOI 10.1001/archinte.159.18.2151
   KARINCH M, 1994, JOSLINS DIABETES MEL, V0, P116
   Kennedy KJ, 1998, J NUTR, V128, P43, DOI 10.1093/jn/128.1.43
   KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350
   Kono Y, 1998, BIOSCI BIOTECH BIOCH, V62, P22, DOI 10.1271/bbb.62.22
   Levin NW, 2001, CURR OPIN NEPHROL HY, V10, P563, DOI 10.1097/00041552-200109000-00003
   Mazur A, 1989, MAGNES RES, V2, P189
   MITHIEUX G, 1993, EUR J BIOCHEM, V213, P461, DOI 10.1111/j.1432-1033.1993.tb17782.x
   Mithieux G, 1996, REPROD NUTR DEV, V36, P357, DOI 10.1051/rnd:19960402
   Nakatani T, 1998, BIOCHEM BIOPH RES CO, V243, P797, DOI 10.1006/bbrc.1998.8168
   NORGREN S, 1993, DIABETES, V42, P675, DOI 10.2337/diabetes.42.5.675
   Poirier B, 2000, NEPHROL DIAL TRANSPL, V15, P467, DOI 10.1093/ndt/15.4.467
   ROHNERJEANRENAUD F, 1986, DIABETES, V35, P1350, DOI 10.2337/diabetes.35.12.1350
   SALADINO CF, 1992, ARTERY, V19, P297
   *SAS I INC, 1985, SAS US GUID BAS STAT, V0, P0
   SCHERNTHANER G, 1985, HORM METAB RES S, V0, P15116
   SCHIRARDIN H, 1979, ARCH INT PHYSIOL BIO, V87, P275, DOI 10.3109/13813457909070500
   *SPSS INC, 1998, SPSS SIGM GEL 1 0, V0, P0
   ZAIBI MS, 1995, BIOCHEM PHARMACOL, V50, P775, DOI 10.1016/0006-2952(95)00199-A
NR 40
TC 34
Z9 37
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD JAN 15
PY 2006
VL 17
IS 1
BP 63
EP 71
DI 10.1016/j.jnutbio.2005.06.004
PG 9
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 002JG
UT WOS:000234607100009
PM 16169204
DA 2025-04-28
ER

PT J
AU Lopez-Garcia, E
   van Dam, RM
   Qi, L
   Hu, FB
AF Lopez-Garcia, Esther
   van Dam, Rob M.
   Qi, Lu
   Hu, Frank B.
TI Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE coffee; inflammation; C-reactive protein; CRP; endothelial dysfunction; cross-sectional study; Nurses' Health Study; type 2 diabetes; women
ID coronary-heart-disease; plasma biomarkers; fatty-acids; risk; atherosclerosis; obesity; men
AB Background: In several short-term studies, coffee consumption has been associated with impairment of endothelial function. Objective: The objective was to assess the relation between long-term caffeinated and decaffeinated filtered coffee consumption and markers of inflammation and endothelial dysfunction. Design: We conducted a cross-sectional study of 730 healthy women and 663 women with type 2 diabetes from the Nurses' Health Study I cohort, who were aged 43-70 y and free of cardiovascular disease and cancer at the time blood was drawn (1989-1990). Dietary intake was assessed with a validated food-frequency questionnaire in 1986 and 1990. Results: About 77% of the healthy women consumed >= 1 cup (237 mL) caffeinated coffee/mo and 75% consumed >= 1 cup decaffeinated coffee/mo; the corresponding intakes for women with type 2 diabetes were 74% and 63%, respectively. In healthy women, no appreciable differences in plasma concentrations of the markers were found across categories of caffeinated coffee intake. In women with type 2 diabetes, higher caffeinated coffee consumption was associated with lower plasma concentrations of E-selectin (adjusted percentage change per I cup/d increment = -3.2%; P = 0.05) and C-reactive protein (adjusted percentage change = -10.2%; P < 0.001). Higher decaffeinated coffee consumption was associated with lower plasma concentrations of E-selectin (adjusted percentage change = -2.5%; P = 0.08) and C-reactive protein (adjusted percentage change = -7.9%; P = 0.02) only in healthy women. The results were similar when we also adjusted the models for other dietary factors and blood lipids and when we excluded participants with hypertension or hypercholesterolemia. Conclusions: These results indicate that neither caffeinated nor decaffeinated filtered coffee has a detrimental effect on endothelial function. In contrast, the results suggest that coffee consumption is inversely associated with markers of inflammation and endothelial dysfunction.
C1 Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School
RP Lopez-Garcia, E (corresponding author), Univ Autonoma Madrid, Dept Prevent Med, Arzobispo Morcillo,2, Madrid, Spain.
EM esther.lopez@uam.es
FU NHLBI NIH HHS [HL65582] Funding Source: Medline; NIDDK NIH HHS [DK58845] Funding Source: Medline
CR Aderka Dan, 1996, CYTOKINE AND GROWTH FACTOR REVIEWS, V7, P231, DOI 10.1016/S1359-6101(96)00026-3
   Blake GJ, 2003, J AM COLL CARDIOL, V41, P37S, DOI 10.1016/S0735-1097(02)02953-4
   Dandona P, 2005, CIRCULATION, V111, P1448, DOI 10.1161/01.CIR.0000158483.13093.9D
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810
   Hu FB, 2004, DIABETES, V53, P693, DOI 10.2337/diabetes.53.3.693
   Huang JJ, 2004, J NUTR BIOCHEM, V15, P722, DOI 10.1016/j.jnutbio.2004.07.002
   Hwang SJ, 1997, CIRCULATION, V96, P4219
   KAWACHI I, 1994, BRIT HEART J, V72, P269
   Kleemola P, 2000, ARCH INTERN MED, V160, P3393, DOI 10.1001/archinte.160.22.3393
   Lopez-Garcia E, 2005, J NUTR, V135, P562, DOI 10.1093/jn/135.3.562
   Lopez-Garcia E, 2004, J NUTR, V134, P1806, DOI 10.1093/jn/134.7.1806
   Lopez-Garcia E, 2004, AM J CLIN NUTR, V80, P1029, DOI 10.1093/ajcn/80.4.1029
   Meisinger C, 2005, CIRCULATION, V112, P651, DOI 10.1161/CIRCULATIONAHA.104.529297
   Pai JK, 2002, CLIN CHEM, V48, P1781
   Pai JK, 2004, NEW ENGL J MED, V351, P2599, DOI 10.1056/NEJMoa040967
   PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294
   Papamichael CM, 2005, CLIN SCI, V109, P55, DOI 10.1042/CS20040358
   Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6
   Rimm E B, 1990, EPIDEMIOLOGY, V1, P466, DOI 10.1097/00001648-199011000-00009
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858
   SAS/STAT, 2001, GUID PERS COMP VERS, V0, P0
   Shai I, 2005, DIABETES CARE, V28, P1376, DOI 10.2337/diacare.28.6.1376
   *USDA AGR RES SERV, 1993, USDA NUTR DAT STAND, V0, P0
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   Vlachopoulos C, 2005, AM J CLIN NUTR, V81, P1307
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   Willett WC, 1996, JAMA-J AM MED ASSOC, V275, P458, DOI 10.1001/jama.275.6.458
   WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991
   Woodward M, 1999, J EPIDEMIOL COMMUN H, V53, P481, DOI 10.1136/jech.53.8.481
   Yukawa GS, 2004, BIOCHEMISTRY-MOSCOW+, V69, P70, DOI 10.1023/B:BIRY.0000016354.05438.0f
   Zampelas A, 2004, AM J CLIN NUTR, V80, P862, DOI 10.1093/ajcn/80.4.862
   ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q
NR 34
TC 198
Z9 214
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT 15
PY 2006
VL 84
IS 4
BP 888
EP 893
DI 10.1093/ajcn/84.4.888
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 093AX
UT WOS:000241140700028
PM 17023717
DA 2025-04-28
ER

PT J
AU Rurik, I
AF Rurik, I
TI Nutritional differences between elderly men and women - Primary care evaluation in Hungary
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Article
DE elderly, nutritional differences; gender, nutritional habits; nutritional habits; Hungary, nutritional habits
ID gender-differences; dietary; food; patterns; habits; population; breakfast; people; adults; older
AB Background: Many differences exist between the two genders, i.e., biological, sociological, and also behavioral, which often depend on age. Objectives: The aim of this study was to find characteristic differences between nutritional habits of elderly men and women. Methods: 266 elderly people (109 men >65 years, and 157 women >60 years) were consecutively selected from primary care patients, in Budapest, Hungary. A self-managed questionnaire was filled in on lifestyle and eating habits, including a food frequency questionnaire. Medical checkup, registration of anthropometrical parameters, and laboratory tests were also performed. 53 subjects were also involved in a 3-day dietary recall. Results: The meal frequency was increased during aging in both genders, especially in men. Lunch was preferred by most of the women as a principal meal, but one quarter of the men had a filling dinner instead of lunch. Alcoholic beverages were consumed more and frequently by men. The fluid intake was low, especially in women. Milk and diary products, fresh fruit, bread, biscuits, chocolate, coffee and vitamin supplements were consumed more frequently by women. Almost all types of meat, eggs, and vegetables were more preferred by men and their energy intake was also higher (9.75 vs. 8.78 MJ). In both genders, fat represented a higher ratio (39%) of energy intake than recommended. The increase of body weight from youth to elderly was greater in women (14.04 vs. 10.65 kg). Prices had a higher impact on food purchases by women. Conclusion: High energy intake over decades led to overweight in both genders (BMI > 27 kg/m(2)). It seemed that the eating habits and food choices of women were closer to healthy ones and recent recommendations, although due to metabolic reasons and to the lower energy expenditure, they gained more weight. The elderly are the target population on every level of medical care. Further evaluations are needed to determine the differences in nutrition and to promote better administration of drugs and to establish public health suggestions. Copyright (C) 2006 S. Karger AG, Basel.
C1 Primary Care Off, Budapest, Hungary.
   Hungarian Inst Food Safety & Nutr, Budapest, Hungary.
RP Vorosmarty 5-7, HU-1201 Budapest, Hungary.
EM rurik.dr@axelero.hu
CR Antal M, 1997, INT J VITAM NUTR RES, V67, P115
   BARONCOHEN S, 2004, ESSENTIAL DIFFERENCE, V0, P271
   BARTOSHUK LM, 1986, J GERONTOL, V41, P51, DOI 10.1093/geronj/41.1.51
   Bates CJ, 1999, EUR J CLIN NUTR, V53, P694, DOI 10.1038/sj.ejcn.1600834
   Beaufrère B, 2000, EUR J CLIN NUTR, V54, PS162, DOI 10.1038/sj.ejcn.1601040
   Biro G, 1996, EUR J CLIN NUTR, V50, P201
   Burger J, 2000, ENVIRON RES, V83, P140, DOI 10.1006/enrs.2000.4060
   Cho S, 2003, J AM COLL NUTR, V22, P296, DOI 10.1080/07315724.2003.10719307
   Davis MA, 2000, J NUTR, V130, P2256, DOI 10.1093/jn/130.9.2256
   del Pozo S, 2003, NUTR HOSP, V18, P348
   DESOR JA, 1975, SCIENCE, V190, P686, DOI 10.1126/science.1188365
   Dynesen AW, 2003, EUR J CLIN NUTR, V57, P1586, DOI 10.1038/sj.ejcn.1601728
   Fagerli RA, 1999, APPETITE, V32, P171, DOI 10.1006/appe.1998.0188
   FODOR GJ, 2004, J MENT HLTH GENDER, V1, P32
   GOODWIN JS, 1989, AM J CLIN NUTR, V50, P1201, DOI 10.1093/ajcn/50.5.1201
   Gregory J, 1990, DIETARY NUTR SURVEY, V0, P0
   Grumbach M, 2004, JOURNAL OF MENS HEALTH AND GENDER, V1, P12
   Gy Biro, 1994, NEPEGESZSEGUGY, V75, P129
   HAUTVAST JGAJ, 1991, EUR J CLIN NUTR, V45, P3
   *HUNG CENTR STAT O, 2001, YB HLTH STAT 2000, V0, P0
   Leite MLC, 2003, EUR J CLIN NUTR, V57, P1522, DOI 10.1038/sj.ejcn.1601720
   Moore AA, 1999, J AM GERIATR SOC, V47, P412, DOI 10.1111/j.1532-5415.1999.tb07232.x
   MORO NH, 1989, NUTR AGING ELDERLY, V0, P75
   MURPHY C, 1989, NUTR AGING ELDERLY, V0, P79
   NES M, 1991, EUR J CLIN NUTR, V45, P97
   Rurik I, 2003, ACTA ALIMENT HUNG, V32, P363, DOI 10.1556/AAlim.32.2003.4.4
   Rurik I, 2003, ACTA ALIMENT HUNG, V32, P77, DOI 10.1556/AAlim.32.2003.1.9
   Schafer RB, 1999, SOC SCI MED, V48, P787, DOI 10.1016/S0277-9536(98)00377-3
   Shatenstein B, 2004, J NUTR HEALTH AGING, V8, P83
   Siega-Riz AM, 2000, PREV MED, V30, P415, DOI 10.1006/pmed.2000.0651
   THIERNEY LM, 1999, CURRENT MED DIAGNOSI, V0, P0
   THOMPSON FE, 1994, J NUTR, V124, PS2245, DOI 10.1093/jn/124.suppl_11.2245s
   1992, 1900, P1, V0, P0
NR 33
TC 17
Z9 20
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
EI 1421-9697
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PD JUN 15
PY 2006
VL 50
IS 1
BP 45
EP 50
DI 10.1159/000089564
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 003ZB
UT WOS:000234720700008
PM 16276075
DA 2025-04-28
ER

PT J
AU Nasreddine, L
   Hwalla, N
   Sibai, A
   Hamzé, M
   Parent-Massin, D
AF Nasreddine, L
   Hwalla, N
   Sibai, A
   Hamzé, M
   Parent-Massin, D
TI Food consumption patterns in an adult urban population in Beirut, Lebanon
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE individual dietary survey; quantitative food-frequency questionnaire; dietary pattern; Lebanon
ID nutritional-status; children
AB Objectives To investigate, measure and assess the food consumption pattern of the adult population living in Beirut, Lebanon, and to identify inadequate or excessive intake of food groups particularly linked to non-communicable diseases. Design A cross-sectional food consumption survey was conducted in 2001. Dietary habits were assessed by means of a quantitative food-frequency questionnaire. Setting Dietary survey of the urban population (Beirut). Subjects Random sample of 444 adult subjects (aged 25-54 years) in Beirut. Results The mean consumption of food by the study population was estimated to be 3030 g day(-1), providing an energy intake of 2523.57 kcal day(-1). Fat contributed 38.9% to the average daily energy intake, protein 13.4% and carbohydrates 47.2%. Mean consumption of fruits and vegetables was approximately 367 g day(-1) and 45.3% of subjects consumed less than the recommended 400 g daily. Cereals contributed 324.5 g day(-1), providing 35.0% of daily energy intake, with bread being the most highly consumed (146.2 g day(-1)) in this food group. The mean intake of meat and poultry products was 91.7 g day(-1) and provided 8.8% of daily energy intake, with consumption of butchery products especially beef being the highest (47.6 g day(-1)) followed by poultry (36.1 g day(-1)). A low consumption of fish was noted (19.7 g day(-1)), with 73.6% of subjects consuming less than the recommended 2 servings of fish per week. Dairy products contributed 243.1 g day(-1) or 10.9% of daily energy intake, and milk was the least consumed dairy product (56.8% of consumers). The intake of added fats and oils, excluding those in cooked recipes, was 20.4 g day(-1); olive oil was not used in cooking but was added solely at the table and its mean intake was 5 g day(-1). The consumption of butter was low (0.86 g day(-1)) and vegetable oil was the type of fat mostly used in cooking. The average intake of alcoholic beverages was low (33.6 g day(-1)), accounting for 0.7% of total energy intake. Women had significantly higher intakes of milk, dairy products, vegetables and coffee than men (P < 0.05). The percentage of women who reported the use of low-fat items was significantly higher than that of men. Younger people (25-34 years) ate significantly more meat, sugar, alcoholic beverages and soft drinks, and consumed significantly less cooked vegetables and legumes, than older ones (P < 0.05). Conclusions The rather high contribution of fat to daily energy intake, the low intake of fish and the relatively high percentage of people consuming less than the recommended amount of fruits and vegetables observed in this study suggest that the adult Lebanese population is at increased risk of cardiovascular diseases, obesity and other non-communicable diseases, which provides the basis for recommending increased intakes of fish, particularly fatty fish, and fruits and vegetables.
C1 Amer Univ Beirut, Fac Agr & Food Sci, Dept Nutr & Food Sci, Beirut 1107 2020, Lebanon.
   Lebanese Council Sci Res, Beirut, Lebanon.
   UBO, ESMISAB, Lab Toxicol Alimentaire, F-29280 Plouzane, France.
   Amer Univ Beirut, Fac Hlth Sci, Dept Epidemiol & Populat Hlth, Beirut, Lebanon.
C3 American University of Beirut; Universite de Bretagne Occidentale; American University of Beirut
RP Amer Univ Beirut, Fac Agr & Food Sci, Dept Nutr & Food Sci, POB 11-0236,Riad El Salh, Beirut 1107 2020, Lebanon.
EM nahla@aub.edu.lb
CR *ADM CENTR STAT, 1998, ET STAT ADM CENTR ST, V9, P0
   Unknown -, 1998, WHOFSFFOS983, V0, P0
   Aranceta J, 1998, PUBLIC HEALTH NUTR, V1, P185, DOI 10.1079/PHN19980029
   ARANCETA J, 1994, 18 DIR GEN PREV PROM, V0, P0
   BABA N, 1994, ECOL FOOD NUTR, V32, P247, DOI 10.1080/03670244.1994.9991405
   Baba N, 1996, J HUM NUTR DIET, V9, P89, DOI 10.1046/j.1365-277X.1996.00435.x
   BABA NH, 1900, V76, V0, P193
   Brandstetter BR, 1999, ANN NUTR METAB, V43, P246, DOI 10.1159/000012791
   BRIEFEL RR, 1992, J AM DIET ASSOC, V92, P959
   Committee on Diet and Health, 1989, DIET HLTH IMPL RED C, V0, P0
   COWAN JW, 1964, J AM DIET ASSOC, V30, P753
   ELABIDINE SZ, 1996, THESIS AM U BEIRUT B, V0, P0
   Fagerli RA, 1999, APPETITE, V32, P171, DOI 10.1006/appe.1998.0188
   *FAO, 1995, NUTR COUNTR PROF SEL, V0, P0
   FLEGAL KM, 1988, AM J EPIDEMIOL, V128, P749, DOI 10.1093/oxfordjournals.aje.a115028
   FLEGAL KM, 1990, AM J EPIDEMIOL, V131, P1046, DOI 10.1093/oxfordjournals.aje.a115596
   GREGORY J, 1990, DIET NUTR SURVEY BRI, V0, P0
   Horwath CC, 1990, AUSTRALIAN JOURNAL OF NUTRITION AND DIETETICS, V47, P71
   Hu FB, 2003, AM J CLIN NUTR, V78, P544S, DOI 10.1093/ajcn/78.3.544S
   *IFN, 1996, AB METH ENQ CONS AL, V0, P0
   *INT COMM NUTR NAT, 1962, REP LEB NUTR SURV 19, V0, P0
   KAMAL S, 1995, AB ALTABKH, V0, P0
   Krauss RM, 2000, CIRCULATION, V102, P2284
   Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94
   Kroes R, 2002, FOOD CHEM TOXICOL, V40, P327, DOI 10.1016/S0278-6915(01)00113-2
   KUSHI LH, 1994, AM J CLIN NUTR, V59, P180S, DOI 10.1093/ajcn/59.1.180S
   LEEHAN H, 1989, J CLIN EPIDEMIOL, V42, P269, DOI 10.1016/0895-4356(89)90062-0
   PETERSEN BJ, 1994, AM J CLIN NUTR, V59, P240S, DOI 10.1093/ajcn/59.1.240S
   SABRY J, 1963, CANADIAN NUTR, V19, P121
   Saleh ZA, 1998, FOOD CHEM, V63, P535, DOI 10.1016/S0308-8146(98)00005-3
   WANDEL M, 1995, INT J FOOD SCI NUTR, V46, P291, DOI 10.3109/09637489509012561
   WHO, 2003, WHO TECHN REP SER, V0, P0
   Worsley A, 1988, INTERNATIONAL JOURNAL OF BIOSOCIAL RESEARCH, V10, P107
NR 36
TC 104
Z9 110
U1 0
U2 10
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD APR 15
PY 2006
VL 9
IS 2
BP 194
EP 203
DI 10.1079/PHN2005855
PG 10
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 027AZ
UT WOS:000236386700005
PM 16571173
DA 2025-04-28
ER

PT J
AU Atanasov, AG
   Dzyakanchuk, AA
   Schweizer, RAS
   Nashev, LG
   Maurer, EM
   Odermatt, A
AF Atanasov, Atanas G.
   Dzyakanchuk, Anna A.
   Schweizer, Roberto A. S.
   Nashev, Lyubomir G.
   Maurer, Evelyne M.
   Odermatt, Alex
TI Coffee inhibits the reactivation of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1:: A glucocorticoid connection in the anti-diabetic action of coffee?
SO FEBS LETTERS
LA English
DT Article
DE 11 beta-hydroxysteroid dehydrogenase; glucocorticoid; coffee; cortisol; diabetes
ID hepatic insulin sensitivity; metabolic syndrome; adipose-tissue; selective-inhibition; hyperglycemic mice; obesity; 11-beta-hsd1; consumption; risk; amplification
AB Recent epidemiological studies demonstrated a beneficial effect of coffee consumption for the prevention of type 2 diabetes, however, the underlying mechanisms remained unknown. We demonstrate that coffee extract, corresponding to an Italian Espresso, inhibits recombinant and endogenous 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) activity. The inhibitory component is heat-stable with considerable polarity. Coffee extract blocked 11 beta-HSD1-dependent cortisol formation, prevented the subsequent nuclear translocation of the glueocorticoid receptor and abolished glucocorticoid-induced expression of the key gluconeogenic enzyme phosphoenolpyruvate carboxykinase. We suggest that at least part of the anti-diabetic effects of coffee consumption is due to inhibition of 11 beta-HSD1-dependent glucocorticoid reactivation. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland.
C3 University of Bern
RP Odermatt, A (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.
EM alex.odermatt@dkf.unibe.ch
CR Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344
   Alberts P, 2002, DIABETOLOGIA, V45, P1528, DOI 10.1007/s00125-002-0959-6
   Apostolova G, 2005, AM J PHYSIOL-ENDOC M, V288, PE957, DOI 10.1152/ajpendo.00442.2004
   Arampatzis S, 2005, J MOL ENDOCRINOL, V35, P89, DOI 10.1677/jme.1.01736
   Asensio C, 2004, INT J OBESITY, V28, PS45, DOI 10.1038/sj.ijo.0802856
   Atanasov AG, 2004, FEBS LETT, V571, P129, DOI 10.1016/j.febslet.2004.06.065
   Battram DS, 2006, J NUTR, V136, P1276, DOI 10.1093/jn/136.5.1276
   Bhathena SJ, 2002, AM J CLIN NUTR, V76, P1191, DOI 10.1093/ajcn/76.6.1191
   Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985
   Dórea JG, 2005, BRIT J NUTR, V93, P773, DOI 10.1079/BJN20051370
   Greenberg JA, 2005, INT J OBESITY, V29, P1121, DOI 10.1038/sj.ijo.0802999
   Hermanowski-Vosatka A, 2005, J EXP MED, V202, P517, DOI 10.1084/jem.20050119
   Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924
   Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI200317845
   Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285
   McCarty MF, 2005, MED HYPOTHESES, V64, P848, DOI 10.1016/j.mehy.2004.03.037
   Miguet L, 2006, J COMPUT AID MOL DES, V20, P67, DOI 10.1007/s10822-006-9037-3
   Morton NM, 2001, J BIOL CHEM, V276, P41293, DOI 10.1074/jbc.M103676200
   Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762
   ODERMATT A, 2005, CURR ENZYME INHIB, V1, P97
   Paterson JM, 2004, P NATL ACAD SCI USA, V101, P7088, DOI 10.1073/pnas.0305524101
   Paterson JM, 2005, AM J PHYSIOL-REG I, V289, PR642, DOI 10.1152/ajpregu.00017.2005
   Rosmond R, 2005, PSYCHONEUROENDOCRINO, V30, P1, DOI 10.1016/j.psyneuen.2004.05.007
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Schuster D, 2006, J MED CHEM, V49, P3454, DOI 10.1021/jm0600794
   Schweizer RAS, 2003, MOL CELL ENDOCRINOL, V212, P41, DOI 10.1016/j.mce.2003.09.027
   Seckl JR, 2004, RECENT PROG HORM RES, V59, P359, DOI 10.1210/rp.59.1.359
   Stewart PM, 2005, CLIN MED, V5, P142, DOI 10.7861/clinmedicine.5-2-142
   Tomlinson J W, 2005, MINERVA ENDOCRINOL, V30, P37
   van Dam RM, 2006, NUTR METAB CARDIOVAS, V16, P69, DOI 10.1016/j.numecd.2005.10.003
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   Wang MH, 2006, CURR OPIN INVEST DR, V7, P319
   Yanagimoto K, 2004, J AGR FOOD CHEM, V52, P592, DOI 10.1021/jf030317t
NR 33
TC 28
Z9 33
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
EI 
J9 FEBS LETT
JI FEBS Lett.
PD JUL 24
PY 2006
VL 580
IS 17
BP 4081
EP 4085
DI 10.1016/j.febslet.2006.06.046
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 067EK
UT WOS:000239284300011
PM 16814782
DA 2025-04-28
ER

PT J
AU Hu, G
   Jousilahti, P
   Peltonen, M
   Bidel, S
   Tuomilehto, J
AF Hu, G.
   Jousilahti, P.
   Peltonen, M.
   Bidel, S.
   Tuomilehto, J.
TI Joint association of coffee consumption and other factors to the risk of type 2 diabetes: a prospective study in Finland
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE coffee consumption; physical activity; joint association; type 2 diabetes
ID aged finnish men; body-mass index; gastric-inhibitory polypeptide; time physical-activity; leisure-time; cardiovascular-disease; magnesium intake; mortality; mellitus; weight
AB Objective: To examine joint associations of coffee consumption and other factors ( including physical activity, obesity and alcohol consumption) with the risk of type 2 diabetes. Design: Prospective follow-up study. Subjects: In all, 10188 Finnish men and 11197 women aged 35-74 years without a history of stroke, coronary heart disease or diabetes at baseline. Measurement: A self-administered questionnaire data on coffee, tea, alcohol and other food consumption, physical activity, smoking, socio-economic factors and medical history, together with measured height, weight and blood pressure using standardized protocol. Results: During a mean follow-up of 13.4 years, there were 964 incident cases of type 2 diabetes. Multivariate-adjusted (age, study year, systolic blood pressure, education, smoking, physical activity, body mass index (BMI) and fruit, vegetable, sausage, bread, alcohol and tea consumption) hazard ratio of type 2 diabetes in participants who drank 0-2, 3-6 and >= 7 cups of coffee were 1.00, 0.77 and 0.66 (P = 0.022 for trend) in men, 1.00, 0.71 and 0.52 (P = 0.001 for trend) in women, and 1.00, 0.75 and 0.61 (P < 0.001 for trend) in men and women combined (adjusted also for sex), respectively. This inverse association was consistent in subjects with any joint levels of physical activity and BMI, and in alcohol drinkers and non-drinkers. Among obese and inactive people, coffee drinking of seven cups or more daily reduced the risk of type 2 diabetes to half. Conclusions: Coffee drinking was associated with a reduced risk of type 2 diabetes in both men and women, and this association was observed regardless of the levels of physical activity, BMI and alcohol consumption.
C1 Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Dept Epidemiol & Hlth Promot, FIN-00300 Helsinki, Finland.
   Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
   Inst Biomed, Helsinki, Finland.
   S Ostrobothnia Cent Hosp, Seinajoki, Finland.
C3 Finland National Institute for Health & Welfare; University of Helsinki
RP Hu, G (corresponding author), Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Dept Epidemiol & Hlth Promot, Mannerheimintie 166, FIN-00300 Helsinki, Finland.
EM hu.gang@ktl.fi
CR Albanes D, 1990, EPIDEMIOLOGY, V1, P65, DOI 10.1097/00001648-199001000-00014
   Barengo NC, 2005, J HYPERTENS, V23, P293, DOI 10.1097/00004872-200502000-00011
   Barengo NC, 2004, EUR HEART J, V25, P2204, DOI 10.1016/j.ehj.2004.10.009
   Carlsson S, 2004, INT J EPIDEMIOL, V33, P616, DOI 10.1093/ije/dyh185
   COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001
   Ford ES, 1997, AM J EPIDEMIOL, V146, P214, DOI 10.1093/oxfordjournals.aje.a009256
   HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302
   Howard AA, 2004, ANN INTERN MED, V140, P211, DOI 10.7326/0003-4819-140-6-200403160-00011
   Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433
   Hu FB, 2001, ARCH INTERN MED, V161, P1542, DOI 10.1001/archinte.161.12.1542
   Hu G, 2005, DIABETOLOGIA, V48, P1477, DOI 10.1007/s00125-005-1824-1
   Hu G, 2004, ARCH INTERN MED, V164, P892, DOI 10.1001/archinte.164.8.892
   Hu G, 2005, DIABETES CARE, V28, P799, DOI 10.2337/diacare.28.4.799
   Hu G, 2004, EUR HEART J, V25, P2212, DOI 10.1016/j.ehj.2004.10.020
   Hu G, 2004, HYPERTENSION, V43, P25, DOI 10.1161/01.HYP.0000107400.72456.19
   Hu G, 2005, INT J OBESITY, V29, P894, DOI 10.1038/sj.ijo.0802870
   Hu G, 2003, DIABETOLOGIA, V46, P322, DOI 10.1007/s00125-003-1031-x
   Hu G, 2004, CIRCULATION, V110, P666, DOI 10.1161/01.CIR.0000138102.23783.94
   Hu G, 2005, STROKE, V36, P1994, DOI 10.1161/01.STR.0000177868.89946.0c
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   Koh-Banerjee P, 2004, AM J EPIDEMIOL, V159, P1150, DOI 10.1093/aje/kwh167
   Lahti-Koski M, 2002, AM J CLIN NUTR, V75, P809, DOI 10.1093/ajcn/75.5.809
   Lopez-Ridaura R, 2004, DIABETES CARE, V27, P134, DOI 10.2337/diacare.27.1.134
   Matsui T, 2001, J AGR FOOD CHEM, V49, P1948, DOI 10.1021/jf001251u
   Meier JJ, 2001, DIABETES, V50, P2497, DOI 10.2337/diabetes.50.11.2497
   NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186
   PAJAK A, 1988, WORLD HEALTH STATISTICS QUARTERLY, V41, P115
   Patja K, 2005, J INTERN MED, V258, P356, DOI 10.1111/j.1365-2796.2005.01545.x
   Reunanen A, 2003, LANCET, V361, P702, DOI 10.1016/S0140-6736(03)12583-4
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Saremi A, 2003, DIABETES CARE, V26, P2211, DOI 10.2337/diacare.26.7.2211
   Song YQ, 2004, DIABETES CARE, V27, P59, DOI 10.2337/diacare.27.1.59
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49
   Wannamethee SG, 2000, ARCH INTERN MED, V160, P2108, DOI 10.1001/archinte.160.14.2108
   *WHO, 1985, WHO TECHNICAL REPORT, V727, P0
   WHO Consultation, 1999, DEF DIAGN CLASS DIAB, V0, P0
   Yoshioka K, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12585-8
   ,, 1988, JOURNAL OF CLINICAL EPIDEMIOLOGY, V41, P105, DOI 10.1016/0895-4356(88)90084-4
NR 42
TC 54
Z9 59
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD DEC 15
PY 2006
VL 30
IS 12
BP 1742
EP 1749
DI 10.1038/sj.ijo.0803341
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 109VO
UT WOS:000242337400008
PM 16652136
DA 2025-04-28
ER

PT J
AU Pereira, MA
   Parker, ED
   Folsom, AR
AF Pereira, MA
   Parker, ED
   Folsom, AR
TI Coffee consumption and risk of type 2 diabetes mellitus - An 11-year prospective study of 28 812 postmenopausal women
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID gastric-inhibitory polypeptide; food frequency questionnaire; glucose-tolerance; magnesium intake; older women; caffeine; humans; reproducibility; polyphenols; tea
AB Background: Coffee intake may be associated with reduced risk of type 2 diabetes mellitus because of minerals, phytochemicals, and antioxidants in coffee, but the role of caffeine is unclear. Our objective was to examine the association between total, caffeinated, and decaffeinated coffee intake, as assessed by food frequency questionnaire at baseline, and risk of incident type 2 diabetes mellitus. Methods: This prospective analysis of the Iowa Women's Health Study (1986-1997) included 28 812 postmenopausal women free of diabetes and cardiovascular disease in the general community. The main outcome measure was incident type 2 diabetes mellitus as determined by mailed questionnaire. Results: Coffee intake was categorized as 0, less than 1, 1 to 3, 4 to 5, and 6 or more cups per day. During 11 years of follow-up, there were 1418 incident cases of diabetes. Relative risks (RRs) were adjusted for a variety of demographic, adiposity, and lifestyle measures. Compared with women who reported 0 cups of coffee per day, women who consumed 6 or more cups per day had a 22% lower risk (RR = 0.78; 95% confidence interval [CI], 0.61-1.01) of diabetes (P for linear trend across categories, .06). This association appeared to be largely explained by decaffeinated coffee (RR = 0.67; 95% CI, 0.42-1.08; P for trend, .006) rather than regular coffee (RR = 0.79; 95% CI, 0.59-1.05; P for trend, .90). Intake of magnesium and phytate did not explain these associations. Intakes of caffeine from all sources was not associated with risk of diabetes. Conclusion: Coffee intake, especially decaffeinated, was inversely associated with risk of type 2 diabetes mellitus in this cohort of postmenopausal women.
C1 Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Med, Minneapolis, MN 55454 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Pereira, MA (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Med, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.
EM pereira@epi.umn.edu
FU NCI NIH HHS [CA 3974, R01 CA039742] Funding Source: Medline
CR Andrade-Cetto A, 2001, J ETHNOPHARMACOL, V78, P145, DOI 10.1016/S0378-8741(01)00335-X
   Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874
   Barbagallo Mario, 2003, MOLECULAR ASPECTS OF MEDICINE, V24, P39, DOI 10.1016/S0098-2997(02)00090-0
   Carlsson S, 2004, INT J EPIDEMIOL, V33, P616, DOI 10.1093/ije/dyh185
   Folsom AR, 2000, AM J PUBLIC HEALTH, V90, P134, DOI 10.2105/AJPH.90.1.134
   FOLSOM AR, 1989, INT J EPIDEMIOL, V18, P361, DOI 10.1093/ije/18.2.361
   Graham TE, 2001, CAN J PHYSIOL PHARM, V79, P559, DOI 10.1139/cjpp-79-7-559
   Greenberg JA, 2005, INT J OBESITY, V29, P1121, DOI 10.1038/sj.ijo.0802999
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Isogawa A, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12586-X
   KAYE SA, 1991, J CLIN EPIDEMIOL, V44, P329, DOI 10.1016/0895-4356(91)90044-A
   Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832
   KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027
   Lane JD, 2004, DIABETES CARE, V27, P2047, DOI 10.2337/diacare.27.8.2047
   Lopez-Ridaura R, 2004, DIABETES CARE, V27, P134, DOI 10.2337/diacare.27.1.134
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Meier JJ, 2001, DIABETES, V50, P2497, DOI 10.2337/diabetes.50.11.2497
   MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485
   Natella F, 2002, J AGR FOOD CHEM, V50, P6211, DOI 10.1021/jf025768c
   NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186
   Reunanen A, 2003, LANCET, V361, P702, DOI 10.1016/S0140-6736(03)12583-4
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Saremi A, 2003, DIABETES CARE, V26, P2211, DOI 10.2337/diacare.26.7.2211
   Song YQ, 2004, DIABETES CARE, V27, P59, DOI 10.2337/diacare.27.1.59
   Svilaas A, 2004, J NUTR, V134, P562, DOI 10.1093/jn/134.3.562
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   van Dam RM, 2004, DIABETOLOGIA, V47, P2152, DOI 10.1007/s00125-004-1573-6
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Yokota K, 2004, J AM COLL NUTR, V23, P506S, DOI 10.1080/07315724.2004.10719390
NR 32
TC 129
Z9 140
U1 1
U2 34
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
EI 
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JUN 26
PY 2006
VL 166
IS 12
BP 1311
EP 1316
DI 10.1001/archinte.166.12.1311
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 056YI
UT WOS:000238560600010
PM 16801515
DA 2025-04-28
ER

